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QUILL ON SCALPEL
This section provides a medium through which Canadian surgeons can declare themselves, briefly 
and informally, on the day-to day affairs of surgery.
The Journal Comes of Age
The Canadian Journal of Surgery com­
mences its 21st year with a new and 
enlarged format.
Not only has the Journal increased 
its size to the more popular 814 x 1114, 
but because of smaller type size there 
is a substantial increase in the amount 
of editorial content even though the 
number of pages has not increased.
More editorial material was received 
during 1977 than at any time in the 
Journal’s past. While the rejection rate 
has increased, the number of accepted 
manuscripts, panel discussions, sym­
posia, review articles and other sub­
missions requires far more space than 
was available in the “old journal”. The 
result has been that there is almost 
a year between acceptance of a man- 
script and its publication.
There is concern among medical edu­
cators and health-care organizers that 
Canada may soon have an excess of 
physicians. A planning document pre­
pared by the health economics and 
statistics division of Health and Wel­
fare Canada provides data to support 
these concerns.1 When the requirements 
committee of the physicians manpower 
planning committee submitted its final 
report in April 1976, it contained rec­
ommendations for optimal 1981 physi­
cian requirements based on the reports 
of 32 working parties representing the 
medical specialties in Canada.2 Al­
though the possibility of maldistribu­
tion is obvious, the requirements com­
This issue presents subjects of in­
terest to general surgeons, the panels 
and symposia of the inaugural meeting 
of the Canadian Association of General 
Surgeons. Short papers by experts on 
peptic ulcer disease, carcinoma of the 
colon and rectum, pancreatitis and in­
tensive care are all followed by a panel 
discussion recorded at the time of the 
meeting. These presentations are de­
signed to meet the needs of the sur­
geons in practice who were not able 
to attend the meeting, but those who 
did attend may wish to organize their 
thoughts on management in these four 
important areas. The panel discussions 
are valuable additions to the papers and 
help to place each topic in perspective.
The objectives of the Journal are: 
a) to serve in the effective continuing
mittee suggested an overall physician/ 
population ratio of 1:665. In June 1977, 
the federal/provincial advisory commit­
tee on health manpower planning ac­
cepted this ratio. However, since the 
graduating class of 1980 had already 
been enrolled, the Department of 
Health and Welfare projected physician 
requirements based on the anticipated 
situation for the period 1982 to 1986.
The current physician/population ra­
tio in Canada is 1:679 (excluding in­
terns and residents) — rich, in the light 
of world requirements. The medical 
schools of Canada will produce 1717 
physicians in 1978; the number will 
increase from 1839 students in 1984
education of Canadian surgical fellows, 
b) to provide an effective vehicle 
for documentation of their clinical and 
scientific observations and c) to up­
grade the international image of Cana­
dian surgery. This issue serves a and b 
and, while designed for the readership 
rather than the author, we think will 
gain international approval as well.
If the receipt of editorial material is 
a measure of interest in this form of 
continuing medical education, the Jour­
nal appeals to general surgeons, cardio­
vascular and thoracic surgeons, and 
orthopedists. We hope other surgical 
specialists will also use the Journal to 
record their efforts in continuing med­
ical education.
Lloyd D. MacLean, md, frcs[c]
C. Barber Mueller, md, frcs[c]
Urgent Problem
to 1869 students in 1986. If our pres­
ent immigration policies maintain the 
number of immigrating physicians at 
400/yr, in 1981 there will be 915 
physicians too many; this figure will 
increase to 2096 in 1984, and the ex­
cess by 1986 will be 2807 (a ratio of 
1:621). These projections assume an 
intermediate growth rate in population 
and that the number of intern and 
resident positions remains at 6500/yr.
An alternative proposal is that if 
the immigration of physicians be lim­
ited to 1 for every 665 immigrants, and 
immigration remain at about 100 000/ 
yr, then 150 more physicians would 
enter Canada each year than would
Physician Manpower Planning: An
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leave the country. If medical school 
output reached the goal of 1869 stu­
dents, there would be, by 1986, 807 
too many physicians.
The planning document is admittedly 
a statistician’s concept. However, it is 
based on realistic estimates and its im­
plications must be seriously considered. 
If immigration is not controlled, then 
medical schools should produce fewer 
physicians if we are to avoid the pre­
dicted excess. There are some obvious 
difficulties to this policy. While some 
“have-not” provincial governments 
might accept this as an excuse to reduce 
the amount of money spent on health 
education, to reduce the number of 
available positions in the local medical 
school might not be politically palatable 
at the constituency level. Further, there 
is the problem of reducing the size of 
medical school staff, and who is to 
decide which schools should, in fact, 
reduce their student intake? Controlled 
immigration seems the most feasible 
step. If one were assured that the 150 
immigrating physicians would be se­
lected to restore our current defi­
ciencies, that is, to fill positions where 
there is immediate need but in which 
we are not yet sufficiently productive 
(e.g., anesthesiologists, radiation ther­
apists and microbiologists), medicine 
might be in a healthy and vigorous 
state in 1984. This solution, however, 
is unlikely to happen since many coun­
tries have shortages similar to our own. 
However, these calculations ignore the 
problem of distribution. Politicians are 
concerned with the availability of pri­
mary physicians in remote areas, but 
postgraduate teachers are concerned 
with the inappropriate overproduction 
of specialists. To have completed one’s 
medical course at the age of 25 and 
find oneself redundant is a problem, 
but to have accepted the challenge of 
another 4 or 5 years of study to become 
a specialist only to find that there are 
no openings in one’s field is a catas­
trophe! True, general surgeons may 
locate in smaller towns to provide a 
first-class service to their community, 
but if an ophthalmologist or neurosur­
geon cannot locate in a community of 
adequate size in Canada, the only op­
tion would be to emigrate or practise 
in circumstances that limit the potential 
as well as the quality of practice.
The class of 1982 is already becom­
ing acquainted with the rigours of 1st 
year medicine. Some forthright plan­
ning is therefore necessary and accurate 
statistics are required. The physician 
requirements committee recommended 
that a registry be established to docu­
ment the major areas of practice of 
each physician in Canada. It is under­
stood that federal and provincial gov­
ernments are instituting a “national
grid” to document disparities in dis­
tribution (Lang OE: Personal com­
munication, 1977). This is encouraging, 
but such data must be available to 
directors of residency programs so that 
they can advise postgraduate students 
of the potential openings in their spe­
cialty when they complete their train­
ing. Admittedly, some of the data may 
be “soft”, but surely they constitute a 
more sensible guide than the current 
“market-place pressures”, which influ­
ence many residents when they select 
their specialties.
Some training programs should be 
reduced and others increased within the 
limits of the 6500 resident/intern posi­
tions per year. These decisions should 
be made by responsible medical educa­
tors rather than imposed by provincial 
governments (on the basis of fiscal ex­
pediency), lest we find, once again, 
that the government solution to a prob­
lem has itself become the problem!
We must note the concern of the 
Association of Canadian Medical Col­
leges of Canada3 at the “possible bal­
kanization of the country, creating in­
ternal restrictions on the movement of 
physicians from province to province, 
even though they may be graduates 
of Canadian schools. Self-sufficiency 
should be considered in the national 
context, not in provincial aspirations.” 
Parochial interests, therefore, must be 
made subservient to national needs by 
responsible cooperation between educa­
tors and government so that residency 
programs are modified nationally rather 
than provincially to meet the predicted 
needs in each specialty. Eventually 
Canadian graduates from whatever 
province may locate with the assurance 
that their newly acquired expertise will 
be a valuable contribution to the med­
ical needs of their communities.
F.G. INGLIS, M D , FRCS[c]
Professor and chairman,
Department of surgery,
University of Saskatchewan,
Saskatoon, Sask.
References
1. Preliminary Physician Manpower Plan­
ning Document, Health, economics 
and statistics division, Health and 
Welfare Canada, Ottawa, 1977, p 6
2. McK endry JBR, McPhedr/VN NT, 
D elisle CJ, et al: Report of the Re­
quirements Committee on Physician 
Manpower to the National Committee 
on Physician Manpower 1975, Part 
111, Health and Welfare Canada, Ot­
tawa, Supply and Services Canada, 
1976, p 100
3. Association of Canadian Medical Col­
leges: Response to: report of the re­
quirements committee of the National 
Committee on Physician Manpower. 
5. Canadian self-sufficiency: immigra­
tion: training of foreign physicians. 
ACMC Forum 10: 42, 1977
meiamuciL
Prescribing Information
INDICATIONS: For the relief of chronic, atonic, 
spastic and rectal constipation and for the 
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Comfortable relief. Naturally
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Many geriatric patients require a 
laxative to encourage relief from 
constipation. Trust Metamucil to 
provide just that for some very 
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• Metamucil is made from grain, 
not chemical stimulants, o ils or 
salines to provide soft, fully 
formed stools
• Metamucil promotes regular 
bowel function, physiologically, 
without straining, cramping
or irritation
• Metamucil will not cause 
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lacking in many diets
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bowel management, 
trust Metamucil for all 
kinds of patients.
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recommended by 
physicians.
>
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Visualizing the Spectrum of Parameters
The standard of medical writing and speaking must have improved over the last generation, because so many books 
and courses have been made available to remedy the ineffective usage of Eng­lish by educated people. Then why is 
sloppy, incorrect and cliche-ridden 
prose still a conspicuous feature of 
medical communication? Doctors often are hurt and resentful if authorities on 
speaking and writing group them in a 
class of educated illiterates; the individ­
ual doctor’s response is that it may apply to many, but certainly not to 
him. Many are unaware that hackneyed expressions and barbarisms can be just 
as distracting as any other unpleasant 
mannerism of speech or writing. Words and phrases have their times of fashion, 
and doctors can be as trendy as poli­ticians.
I would like to cite a few examples of effete fashions in medical writing.
“Parameter” is defined in various dictionaries as an arbitrary constant 
or an independent variable through functions of which other functions may 
be expressed. “Dorland’s Illustrated 
Medical Dictionary” describes it as “a variable whose measure is indicative of a quantity or function that cannot itself 
be precisely determined by direct meth­ods”. Wilson Follett, in “Modern 
American Usage”, says, “parameter, 
in mathematics, is a quantity that varies 
with the conditions under which it occurs. Hence in ordinary life a pedan­
tic substitute for the task before us, 
the limits of our problems.” In medical 
communication it is most often used 
as a fashionable word to mean vari­ables, dimensions, factors, size, scope, measurement, features, findings, but 
the vogue seems to be to put it into the text somewhere, and it scarcely matters where it is inserted.
“Spectrum” originally meant the dis­tribution of a physical system or phe­nomenon, and came from the Latin spectere, to look at. In medical usage it has now almost entirely replaced range, distribution, variation, gamut, extent.
“Emergent”, the adjective, has two meanings defined in dictionaries: a) coming to attention or into existence; b) demanding prompt action. The dif­ficulty in medical communication is in
understanding which of the two defini­tions is meant by the writer at all times. Every emergent condition does not necessarily require prompt action, and 
some emergent situations have been in 
existence and recognized for some time. It would be helpful if writers would 
reserve the word for its original pur­pose, to mean “appearing”, or “coming 
out of”, or “coming to one’s attention”, 
and use the noun emergency to denote 
anything demanding immediate atten­tion.
The radiologists have gradually cor­rupted a large segment of the profes­
sion into preferring “visualize” to see, demonstrate, define, observe. Now 
when we form a mental image we can­
not use visualize to express the idea lest our meaning be mistaken. Similarly 
they have persuaded many of us that “image” used as a verb is superior to copy, portray, or record.
We are often told by a speaker that there was no “mortality” in a series 
he is presenting, when really he means that there were no deaths, or that the 
mortality was zero. In expressing re­sults in medical reporting the term 
mortality should be used to express the death rate. One cannot expect immortal 
prose from those who use “mortality” to mean “death”.
Most surgeons would never think of 
using an osteotome as a screwdriver, yet some see no incongruity in blunting 
our tools of communication and think it pedantry to be concerned with pre­
cision in speech or writing. We must 
look to editors of professional journals to give us guidance and insist upon better standards. Would it really matter 
if some articles were rejected because the authors refused to have their manu­scripts edited?
In addition to knowing and insisting upon good English usage, editors also could help us eliminate the tiresome cliches that were once colourful or expressive of ideas but have become distracting repetitions.
“A high index of suspicion” has become one of the most jaded phrases in medical literature, when all the 
writer is trying to say is “keep this condition in mind”. We should compile an index of suspicion to include the names of all writers found associating with this jade.
“Meticulous attention to detail” is another favourite banality. The speaker merely recommends conscientious or precise care, or exacting measures, or punctilious attention, or scrupulous 
care, or just close attention. Better still, 
the phrase could be left out entirely; 
it is gratuitous as it suggests, obliquely, that “most of you clods had better 
watch out, this has to be done care­fully”.
When a medical author reports a series of instances of some unusual con­
dition that he has collected from an 
intensive search of the medical litera­ture and added a case or two of his 
own, he often becomes impressed with 
the number he has collected and warns us “this condition is commoner than 
usually acknowledged”. When one con­
siders the number of items that have borne this saturnine message, we can 
count ourselves lucky that we have not been afflicted with more strange mal­
adies that few can recognize.
One can expect some bias in the 
reports of results of treatment. An author has a point to make, and it is 
difficult to be completely detached in 
reporting one’s own work. None the less, to state that “there were only two 
deaths in the series” does beg the 
question. At best this is not being ob­jective and at worst presumptuous.
There are many other faults in med­
ical writing, so many indeed that we 
are delighted when we encounter an author who chooses his words with an understanding of their meaning and 
only uses clever words or phrases when 
he has coined them himself, before they have become tedious. But such authors are uncommon, and as com­pensation one can still obtain enjoy­ment from some of the most pedestrian presentations by keeping count of re­dundancies, cliches and solecisms. I have mentioned here a few of the common irritants, but each of us has his own anathemas with respect to speaking and writing, and keeping a tally of them during an uninspiring paper can be pleasantly diverting.
J.E. M ullens, md, ms, frcs[c] Department of surgery,Ottawa Civic Hospital,Ottawa, Ont.
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SELF -  ASSESSMENT
SESAP II Question
600. Fatalities in intensive care units resulting from pseudomonas infections are most often associated with the use of
(A) central venous pressure catheters
(B) urethral catheters
(C) intravenous hyperalimentation
(D) mechanical ventilators for respiratory assistance
For this incomplete statement select the one completion that is BEST from those noted above.
For the critique of Item 600 see page 74 of this issue.
(Reproduced by permission of the American College of Surgeons from SESAP II Syllabus: Surgical Education and Self- 
assessment Program No. 2. For enrolment in the Surgical Education and Self-assessment Program No. 2 please apply 
to the American College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
Kidney Foundation 
Research Fellowships- 
Alberta,
Canada 1978-79
Applicants invited for two 
pos t  D o c t o r a l  Med i c a l  
Fellowships in Nephrology or 
Urology to run concurrently 
from July 1, 1978 at University 
of Alberta, in Edmonton or 
University of Calgary (Faculty of 
Medicine).
Salary concordant with the 
qualifications and prior training 
to maximum of $20,000. p.a. 
Each Fellowship is for one year 
but application for second year 
anticipated.
Application forms available 
from Kidney Foundation of 
Canada (Alberta Branch), No. 
301 - 836 — 5th Avenue S.W., 
Calgary, Alta., Can. T2P ON5.
No application accepted after 
February 28, 1978.
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CORRESPONDENCE
Carcinoma of the Esophagus
To the coeditors: I have read with in­
terest Dr. Mulder’s editorial comment 
on carcinoma of the esophagus (Can J 
Sitrg 20: 400, 1977). I believe that it is 
of great importance that some centres 
adopt an individual approach to this 
problem although the weight of evi­
dence favours another direction. After 
all, the rest of us may be totally wrong. 
Certainly I will await with' interest the 
final presentation of the figures from 
McGill University teaching hospitals; 
however, though I appreciate that the 
figures quoted by Dr. Mulder are pre­
liminary and incomplete, it looks as if 
those for 5-year survival will be little 
different from the figures in other pub­
lished series. Of greater interest is the 
outcome for the remaining 50 patients 
who did not complete the “curative” 
phase of his protocol. It is my con­
tention that the answer to this question 
is extremely important and can only be
obtained through a prospective grading 
system as I outlined in my paper (Can 
J Surg 20: 454, 1977). Dr. Mulder is, 
of course, absolutely correct in pointing 
out that the grading score is time- 
related and changes quickly with recur­
rence of disease. This is as I would 
have expected since I believe that this 
disease has an inexorable course and 
one’s palliative efforts can be expected 
to fail sooner or later.
J u l i u s  L. St o l l e r , m b , f r c s , f r c s [c ] 
Laurel Medical Centre,
316 - 888 West 8th Ave.,
Vancouver, BC
To the coeditors: Dr. Stoller has cor­
rectly pointed out that the final results 
of carcinoma of the esophagus protocol 
at McGill University are very prelimin­
ary, and at the present time it is im­
possible to predict a 5-year survival 
figure. The most striking finding to 
date in the small group of patients is 
that it is possible to use radical surgical 
treatment in selected patients with an 
acceptable operative mortality. This is 
in contrast with the experience of the 
previous 10 years when the operative 
mortality was high and case selection 
was poor.
The patients who did not complete 
the curative phase of the protocol usu­
ally received a course of radiotherapy 
if their general condition warranted it. 
The preliminary results would suggest 
that their mean survival was under 
5 months, the same as reported in the 
surgical literature for cases in which 
celiac axis or supraclavicular lymph 
nodes are involved by tumour.
I cannot comment on the degree of 
palliation provided for this group of 
patients. We are at present in the pro­
cess of re-evaluating this group and it 
would be interesting to apply Dr. 
Stoller’s grading system.
It is only through a prospective treat­
ment protocol, whether palliative or 
curative, that our effectiveness in man­
aging this difficult disease can be as­
sessed.
D.S. M u l d e r , m d , f r c s [c ] 
Surgeon-in-chief,
The Montreal General Hospital,
1650 Cedar Ave.,
Montreal, PQ
Trasylol
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hemorrhage
Indications and Dosage 
Hyperfibrinolytic Hemorrhage 
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sary by slow infusion. Administra­
tion should be continued up to 
1,000,000 K.I.U. per day until the 
hemorrhage has been arrested. 
Pancreatitis
Initial dosage: 100,000 — 200,000 
K.I.U. to be followed by 100,000 
K.I.U. every six hours for a period 
of 4-5 days. The drug is adminis­
tered either by intravenous injec­
tion (at a rate not to exceed 5 ml 
per minute) or by slow infusion. 
Warnings and Precautions 
Trasylol is a polypeptide and thus 
may act as an antigen. Although 
adverse reactions due to hyper­
sensitivity have been described 
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In patients with a history of hyper­
sensitivity, the usual precautions 
for the prevention and arrest of 
a lle rg ic  reactions should be 
observed prior to the administra­
tion of Trasylol.
Availability
Trasylol (aprotinin) is available in 
10 ml ampuls containing 100,000 
K.I.U. in boxes of 5 ampuls. 
Trasylol® Product Monograph is 
available on request.
The object of
Trasylol:
Control of proteolytic enzymes.
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CAGS PAPERS
Symposium on Peptic Ulcer Disease 
1. Medical Treatment of Peptic Ulcer*
K.N. Jeejeebhoy, m b, bs, ph d, frcp( edin), frcp[c]
The conventional treatment of peptic 
ulcer disease with special dietary 
regimens, antacids or anticholinergics 
has been found wanting. Recently 
introduced agents show considerable 
promise in the benefit they can render. 
Carbenoxolone accelerates the healing 
of gastric ulcers by increasing gastric 
mucosal resistance. Cimetidine, a 
histamine H2-receptor antagonist, is an 
effective suppressant of acid secretion 
and therefore promotes healing of 
duodenal ulcers. Metoclopramide 
hastens gastric emptying and increases 
the tone of the gastroesophageal 
sphincter, and is valuable in cases of 
reflux esophagitis and gastric ulcer.
Le traitement classique de I'ulcere 
gastrique a I’aide de regimes alimentaires 
speciaux, d'anti-acides ou d'anti- 
cholinergiques s'est avere insatisfaisant. 
Certains medicaments nouvellement 
lances se montrent fort prometteurs 
en ce qui a trait aux benefices 
escomptes. La carbenoxolone accelere 
la cicatrisation des ulceres gastriques 
par augmentation de la resistance de la 
muqueuse gastrique. La cimetidine, 
un antagoniste des recepteurs hista- 
miniques H2, est un inhibiteur efficace 
de la secretion d'acide et, de la sorte, 
favorise la cicatrisation des ulceres 
duodenaux. Le metoclopramide accelere 
la vidange gastrique et augmente le 
tonus du sphincter gastro-oesophagien; 
il est utile dans les cas d’oesophagite 
de reflux et d'ulcere gastrique.
The conventional treatment of peptic 
ulcer disease has consisted of diet and 
antacids. Traditionally the diet has been 
a so-called “low residue bland diet” and
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the patient has been instructed to take 
antacids usually before or with meals. 
During episodes of acute pain frequent 
small feeds have been advocated. Milk 
has been considered especially useful 
in treating ulcers. However, none of 
these regimens has received critical 
study until recently. In addition to these 
measures new drugs have appeared on 
the market that can alter profoundly 
the metabolism of gastric mucosal 
cells, reducing acid secretion and affect­
ing gastric motility. These drugs have 
shown greater promise for healing pep­
tic ulcer than the plethora of antacid 
or antacid-anticholinergic compounds. 
Their efficacy has been demonstrated 
by rigorously controlled trials.
The average physician has now to 
choose from a variety of different regi­
mens claimed to cure ulcer disease. This 
paper will attempt to place the role of 
such regimens in proper perspective 
on the basis of currently available 
evidence.
Diet
Doll, Friedlander and Pygott1 showed 
that the healing of gastric ulcers was 
unaffected by the administration of so- 
called gastric diets. Likewise, the use 
of belladonna and antacids, while per­
haps relieving pain, did not influence 
the rate of healing of gastric ulcers.
Other investigators2-5 showed that fre­
quent feedings with milk and cream did 
not reduce gastric acidity and might 
even increase the mean acidity above 
values obtained with three meals a day. 
Various diets such as “gastric II diets” 
did not reduce acid below the value 
observed while taking three normal 
meals. More recently Ippoliti, Maxwell 
and Isenberg6 have shown that milk 
actually increases acid output in pa­
tients with duodenal ulcer and that the 
calcium in the milk appears to be re­
sponsible for stimulating acid secretion.
Antacids
Antacids in vitro will neutralize 
gastric acid, but when given according
to a random schedule they do not aid 
the healing of peptic ulcers.7 In the 
studies from which these conclusions 
were drawn, the effect of buffers in a 
meal, to aid and prolong the effect of 
antacids, was not investigated.
Fordtran, Morawski and Richardson8 
showed that antacids have to be given 
in doses of 80 meq (e.g., Maalox, 30 
mL) 1 and 3 hours after a meal and 
at bedtime to suppress acid secretion 
continuously. When given in this dos­
age antacids have improved significant­
ly the rate of ulcer healing.9 However, 
to attain this objective the patient must 
ingest the equivalent of 240 to 300 mL 
of Maalox daily. Such a dose often 
causes diarrhea and is inconvenient for 
ambulatory patients.
Anticholinergic Medications
These agents are effective in reduc­
ing acid secretion, but the doses re­
quired often result in side effects such 
as dry mouth, cycloplegia and urinary 
retention, which may be intolerable to 
the patient. It has been claimed that 
Robinul (glycopyrrolate) may suppress 
acid secretion preferentially10 and may 
improve the rate of healing of gastric 
ulcer.11 Other studies have not shown 
unequivocally that anticholinergic drugs 
aid the healing of duodenal ulcers.12,13
It is quite clear from the above evid­
ence that peptic ulcer disease has not 
been favourably influenced by conven­
tional medical means unless the drugs 
are used in such a way as to be incon­
venient or associated with side effects.
New Therapeutic Agents
Recently there have become avail­
able three new agents (carbenoxolone 
sodium, cimetidine and metoclopra­
mide), which are clearly effective in the 
healing of peptic ulcers.
C arbenoxolone Sodium
This drug is a derivative of glycyr- 
rhizic acid, itself a derivative of lico­
rice.14 It reduces the turnover of gastric
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mucosal cells,15 increases mucous secre­
tions,16 protects the gastric mucosa 
from the injurious effects of bile salts17 
and seems in general to act by increas­
ing gastric mucosal resistance. In clin­
ical trials it has been shown to ac­
celerate the healing of gastric and duo­
denal ulcer.18'19 Its effect is especially 
evident in ambulatory patients. It is of 
interest that this drug requires the pres­
ence of aldosterone to be effective so 
that the use of aldosterone antagonists, 
such as spironolactone, will inhibit its 
healing action on gastric ulcers.20
The main side effects are related to 
the retention of sodium, which causes 
edema, weight gain and congestive fail­
ure in patients with cardiac disease. 
These effects can be avoided by care­
ful monitoring of the patient, using 
lower doses of the drug (e.g., 50 mg 
tid), avoiding its use in patients with 
cardiac disease and by using thiazide 
diuretics.
The regimen recommended is 100 
mg tid for 1 week and then 50 mg tid 
for 6 to 8 weeks. After that period it 
is not clear if maintenance doses will 
prevent recurrence. Should there be a 
relapse after discontinuing the drug, 
the recurrent ulcer will heal at the same 
rate as the initial ulcer.
Cimetidine
Cimetidine21 is the latest compound 
in a series of agents called histamine 
H2-receptor antagonists, developed to 
block the stimulating effect of hista­
mine on gastric acid secretion. The first 
in the series of drugs, burimamide and 
metiamide, were not satisfactory, espe­
cially since metiamide caused agranulo­
cytosis.
Cimetidine in a single 300-mg dose 
will completely suppress acid secretion 
in response to  food and pentagastrin 
for a 3-hour period; the gastric pH 
tends to remain high for up to 6 hours 
after ingestion of the drug. This effect 
is noted when the agent is given either 
orally or intravenously. Its use is not 
associated with serious side effects. 
A slight rise in serum creatinine is 
noted, not due to any demonstrable 
kidney damage. A few instances of 
gynecomastia have been reported.
Given in doses of 300 mg qid (after 
meals and at bedtime), it significantly 
accelerates the healing of duodenal 
ulcers,22 and by continuing to admin­
ister one dose at night the physician 
may reduce the incidence of recurrence. 
Cimetidine is likely to be of value also 
in the treatment of bleeding stress ul­
cers and the bleeding duodenal ulcers 
seen in patients following renal trans­
plantation.
Metoclopramide
This drug hastens gastric emptying 
and reduces the flow of bile into the
duodenum. It also increases the tone 
of the gastroesophageal sphincter23 and 
reduces bile reflux significantly. Clin­
ical trials have indicated that it also 
helps reflux esophagitis appreciably24 
and hence is of value in treating peptic 
ulceration of the esophagus. It favour­
ably influences the course of gastric 
ulcer disease25 and gastritis. Uncon­
trolled observations suggest that it is 
useful in the management of postsur- 
gical bile reflux gastritis with gastric 
ulceration (by contrast with its effect 
on stomal ulcers involving the anastom­
osed intestine). Possible side effects are 
depression, lethargy and parkinsonism, 
which may be unacceptable to some 
patients. The dose recommended is 10 
mg after meals and at bedtime, but 
in thin subjects it is not advisable to 
exceed a total dose of 0.5 mg/kg*d.
In conclusion the drug of choice for 
gastric ulcer is carbenoxolone sodium 
and for duodenal ulcer, cimetidine. An­
tacids should be given in large doses if 
they are used in an attempt to heal 
ulcers. A dose of 30 mL, 1 and 3 hours 
after food and at bedtime, is the only 
logical way to use these agents.
While the results of controlled trials 
are not yet available, it may be prac­
tical in some situations to combine 
drugs to treat special situations. For 
example, where esophageal reflux is a 
major problem or where there is gas­
tric retention, as with pyloric channel 
ulcer, as well as hypersecretion, a com­
bination of cimetidine and metoclo­
pramide will afford symptomatic relief.
Finally, it should be recognized that 
there is no place for restricted and 
unpalatable diets in the treatment of 
peptic ulcer disease. These are more 
therapeutic for the psyche of the physi­
cian (? surgeon) than for the patient.
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2. Vagotomy and Its Variations*
P e t e r  J. D o r is, m d , m  sc, f r c s [c]
All the forms of vagotomy that are used 
in the treatment of peptic ulcer disease 
lower the acid secretion by the gastric 
parietal ceils. The preferred operation 
is the proximal selective vagotomy in 
which the innervation to the antrum 
and pylorus is undisturbed. Therefore 
the necessity for any type of drainage 
procedure is obviated. The results of a 
number of clinical trials can be 
considered highly satisfactory. The 
undue rate of ulcer recurrence 
sometimes reported after the operation 
is possibly attributable to its incorrect 
performance.
Toutes les formes de vagotomie qui 
sont utiiisees dans le traitement de 
I’ulcere de I'estomac abaissent la 
secretion d'acide par les cellules 
parietales de I'estomac. L'operation de 
choix est la vagotomie proximale 
selective qui permet de conserver 
I'innervation de I'antre et du pylore. On 
evite de la sorte la necessity de toute 
forme de drainage. Les resultats d'un 
bon nombre d'etudes peuvent etre 
consideres comme tres satisfaisants.
Le taux indu de recidives ulcereuses 
parfois signale apres l'operation est 
possiblement attribuable a son execution 
imparfaite.
Currently there are three forms of 
vagotomy that are recommended for 
the surgical treatment of peptic ulcera­
tion. 1-4 The rationale for each type is 
the lowering of acid secretion by the 
gastric parietal cells subsequent to their 
denervation, thereby allowing ulcers to 
heal and preventing their recurrence. 
The various forms of vagotomy differ 
from each other only in the extent of 
the denervation of the other abdominal 
organs.
A truncal vagotomy (TV) involves a 
denervation of all intra-abdominal
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structures innervated by the vagus 
nerve, whereas a selective vagotomy 
(SV) denervates only the stomach. A 
new type of vagotomy introduced by 
Holle, Johnston and Amdrup brings 
about denervation of only the proximal 
portion of the stomach, so that the 
innervation to the antrum and pylorus 
as well as the other abdominal organs 
is preserved.2 This last operation is 
variously referred to as highly selective 
vagotomy, parietal cell vagotomy, prox­
imal gastric vagotomy or, the term I 
propose to use, proximal selective vago­
tomy (PSV) . 3
Acid Secretion
All three forms of vagotomy, TV, SV 
and PSV, reduce acid secretion to an 
equivalent degree provided a technically 
adequate operation has been per­
formed. 6 The retention of innervation 
to the antrum by PSV might be thought 
to be associated with vagal release of 
gastrin and higher acid production, but 
this has not been borne out in clinical 
studies and must be considered only a 
theoretical objection to PSV. 7' 8
Motility
The major differences between the 
forms of vagotomy are to be found in 
the alterations caused in motor function 
of the abdominal viscera.
Proximal Stomach
Denervation of the proximal portion 
of the stomach, produced by TV, SV 
and PSV, results in a failure of recep­
tive relaxation of this part of the organ 
leading to higher intragastric pressures9 
and causing a more rapid emptying of 
liquids from the stomach. 10 In addition, 
the decreased distensibility may result 
in the symptom of early satiety.
Distal Stomach
Denervation of the distal portion of 
the stomach, brought about by SV and 
TV, impairs the antral mill leading to 
incomplete mixing of solids and by its 
effect on the pylorus retards the empty­
ing from the stomach of solid foods. 10 
As a consequence a drainage procedure 
is necessary, which is not the case 
when PSV is performed since it pre­
serves innervation to the distal stomach. 6
Intestine
The motor activity of the small in­
testine is disturbed following vagal de­
nervation in experimental animals. The 
characteristic normal wave of motor 
activity beginning in the antrum and 
sweeping down the whole of the small 
intestine has been demonstrated to be 
disorganized by vagotomy of the small 
intestine. 1112 The role of this interdi­
gestive myoelectrical complex has yet 
to be determined in man. It is pre­
served by SV and PSV and altered by 
TV.
Clinical Trials
In clinical practice it would be ex­
pected from consideration of the func­
tional effects of the various types of 
vagotomy that PSV would cause the 
least number of postoperative side ef­
fects. There are now several reports of 
randomized clinical trials comparing 
the various operations that have justi­
fied this premise. 7,13 Sawyers, 14 in a 
study comparing PSV with SV com­
bined with pyloroplasty, found a sig­
nificantly decreased incidence of the 
early dumping syndrome following 
PSV. Devries and colleagues13 recently 
reported on a randomized clinical trial 
comparing PSV with TV plus antrec­
tomy; in the PSV group there was a 
significant increase in the number of 
patients in the “excellent to good” 
category postoperatively.
In summary, all forms of vagotomy 
lower acid secretion and, in the short 
term, control duodenal ulceration to an 
equal degree if the operation is tech­
nically adequate. Likewise all forms of 
vagotomy lead to loss of receptive re­
laxation in the proximal stomach and 
more rapid emptying of liquids from 
the stomach. The operations that de- 
nervate the antrum and pylorus must 
be accompanied by either a drainage 
procedure or a pyloroplasty. PSV is 
associated with the lowest incidence of 
postvagotomy side effects and avoids 
the complications that may be asso­
ciated with pyloroplasty or gastroen­
terostomy.
Discussion
Proximal selective vagotomy appears
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to have many advantages in its favour. 
Nevertheless this is not the most com­
mon operation for peptic ulcer disease 
in Canada or in North America. The 
main argument against its adoption is 
the relatively short duration of follow­
up in the studies that compare it with 
other forms of vagotomy, so that there 
is a possibility that the true incidence 
of ulcer recurrence may be unaccept­
ably high. The high rates of recurrence 
after PSV in some reports have led to 
scepticism concerning the value of this 
type of vagotomy.13 Since the main 
reason for recurrence is related to tech­
nical aspects of the operation, it is 
obvious that if the operation is not 
performed correctly, the initial rate of 
recurrence will be unacceptably high. 
At the moment, the incidence of de­
layed recurrence appears not to differ 
from that for other forms of vagotomy 
although it may be slightly higher than 
for vagotomy and antrectomy.6
Another concern regarding PSV 
(without pyloroplasty) relates to gastric 
emptying. Although inadequate gastric 
emptying occasionally may be present 
after PSV and either gastric retention 
or gastric ulceration may develop, if 
the innervation to the antrum has been 
preserved, the distal stomach in most
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patients retains the normal mechanism 
of emptying,16 a drainage procedure is 
not required and tests for gastric empty­
ing show normal indices.17
A specific complication of PSV has 
been lesser curve necrosis with per­
foration, presumably due to the ex­
tensive devascularization of this area 
of the stomach.1,4 Although it is un­
common, this possibility must receive 
attention in the postoperative period 
and the complication recognized so that 
reoperation may be performed as soon 
as it is suspected.
The final objection to PSV has refer­
ence to the technical aspects of the 
operation and in particular the length 
of time required for its performance. 
On average a PSV takes longer than a 
truncal vagotomy and antrectomy and 
certainly much longer than TV plus 
drainage.18 When done as an elective 
procedure a longer operative time is 
not an important consideration, but if 
required as an emergency operation or 
when done for a poor-risk patient, then 
an alternative operation to PSV should 
be considered.
On the other hand there are cogent 
arguments in favour of PSV, particu­
larly that this operation has the lowest 
operative mortality to date.7'19 In 
randomized clinical trials, as well as 
in numerous reports of retrospective 
analyses, it has been found that PSV 
is effective in preventing recurrence of 
duodenal ulceration and is associated 
with a significantly lower incidence of 
postoperative side effects than the al­
ternatives,1,2'6'7 Continued investigation 
into the role of the vagus nerve in af­
fecting motility, endocrine activity and 
extragastric secretion may reveal un­
expected benefits from reducing the 
extent of intra-abdominal vagal de­
nervation.
Recommendations
Proximal selective vagotomy has ad­
vantages over other forms of vagotomy 
and should be introduced as routine 
surgical practice in Canada. However, 
unless this operation is performed to 
adequate technical standards an unac­
ceptably high rate of ulcer recurrence 
will follow. Therefore PSV should be 
performed only by surgeons who have 
received instruction in its performance, 
and some form of either intraoperative 
or postoperative testing is required.
Vagotomy and drainage retains an 
important role in the treatment of ulcer 
disease in that the operation can be 
performed quickly and it is the safest 
operation in the hands of a surgeon not 
trained in the performance of PSV.
Vagotomy and antrectomy should be 
performed when the rate of recurrence 
must be kept as low as possible. Of 
the various operations that have been
devised, it has the highest potential 
mortality. Also it has a higher post­
operative morbidity than PSV.
For any individual patient the data 
are still insufficient to indicate in ob­
jective terms which operation is most 
appropriate. The continued process of 
randomized clinical trials is required to 
determine the answer to the question, 
“Which operation for which patient?”
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3. Practical Management of Recurrent Peptic Ulcer*
Max M. Cohen, mb, frcs(edin), frcs[c], facs
Recurrent peptic ulcer usually develops 
as the result of an ill-advised or 
poorly executed operation. The 
commonest surgical error is an 
incomplete vagotomy. Diagnosis is 
made best by endoscopy. Mandatory 
investigation includes determination 
of serum gastrin and calcium, and 
measurement of basal and maximal acid 
output. Management is surgical and 
depends on the initial ulcer operation. 
Decision-making is aided by the 
Hollander insulin test, the secretin 
infusion test and occasionally by a 
technetium scan. There is no place 
for procedures that do not reduce 
acid output. Emergency treatment of a 
complication should be followed by 
full investigation and the appropriate 
operation. Recurrent gastric ulcer 
should be treated by gastrectomy and 
excision of the ulcer.
La recidive d’un ulcere de I'estomac 
est souvent le resultat d'une operation 
peu judicieuse ou mal executee.
L'erreur chirurgicale la plus frequente 
est une vagotomie incomplete. 
L'endoscopie est le meilleur moyen de 
diagnostic. Les examens obligatoires 
comprennent la determination de la 
gastrine et du calcium seriques, et la 
mesure du debit basal et maximal 
d'acidite. Le traitement est chirurgical 
et depend de I'operation initiate. La 
prise de decision est aidee par le test a 
I'insuline de Hollander, le test de 
perfusion a la secretine et, 
occasionnellement, par une scintigraphie 
au technetium. Toute intervention 
qui ne vise pas a reduire la secretion 
d'acide est a proscrire. Le traitement 
d'urgence d’une complication doit 
etre suivi d’un examen complet et de 
I'operation appropriee. L'ulcere gastrique 
recidivant doit etre traite par la 
gastrectomie et I'excision de l'ulcere.
*From the department of surgery, 
University of British Columbia, Vancouver 
General Hospital, Vancouver, BC
Presented at the inaugural meeting of 
the Canadian Association of General 
Surgeons, Toronto, Ont., May 11 and 
12, 1977
Reprint requests to: Dr. M.M. Cohen, 
Associate professor, Department of 
surgery, University of British Columbia, 
Vancouver General Hospital, Vancouver, 
BC V5Z 1L5
Recurrent peptic ulcer is probably the 
best term to describe the development 
of an ulcer following primary peptic 
ulcer surgery and is preferable to the 
common synonyms, stomal, anastomotic 
and marginal ulcer. It is a serious con­
dition, carrying a much greater com­
plication rate and mortality than the 
primary ulcer. While the incidence 
appears to be declining it still poses 
a difficult problem in management. 
This review focuses on recurrence after 
treatment of duodenal ulcer with the 
intention of offering the surgeon a 
practical guide to the management of 
what is often a complex problem.
The incidence and timing of recur­
rent ulcer varies considerably depend­
ing on the initial surgical procedure 
(Fig. 1). Unquestionably the most suc­
cessful operation in terms of the pre­
vention of recurrence is vagotomy and 
antrectomy. There is no single correct 
treatment for recurrent ulcer. This will 
depend on the etiology of the lesion, 
which in turn is usually determined by 
the nature of surgery for the primary 
ulcer.
E tiologic F ac to rs
Responsibility for the development
of a recurrent ulcer can almost always 
be attributed to the surgeon who per­
formed the initial operation. Either the 
decision to operate was ill-advised be­
cause the patient was, for example, 
drug dependent or severely neurotic, 
and an “albatross” results,' or because 
the operation was badly executed (Ta­
ble I). Gastroenterostomy alone has 
now been overtaken by incomplete 
vagotomy as the commonest cause of 
recurrent ulcer. Gastroenterostomy is 
unsatisfactory because it does not re­
duce gastric acid secretion. An inade­
quate vagotomy means there is con­
tinued vagal stimulation of acid 
secretion, continued potentiation of 
gastrin release and unimpaired parietal 
cell responsiveness.
Less than a two-thirds gastrectomy 
without vagotomy is inadequate and 
was once a common cause of recurrent 
ulcer. This is becoming an increasingly 
rare cause as this operation gradually 
disappears from the surgical scene. Re­
current ulcer is rare after vagotomy 
and antrectomy and then is usually due 
to incomplete vagotomy, since even a 
40% resection will successfully remove 
the antrum.
Poor gastric drainage is another con-
VAGOTOMY 
& ANTRECTOMY
0.5 %
3 years
FIG . 1— Incidence of recurrent ulcer following each of four main ulcer operations 
and mean time interval between first and second operation.
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Table I— Recurrent Ulcer: Etiologic Factors
Inadequate operation 
Gastroenterostomy 
Incomplete vagotomy 
Inadequate gastric resection 
Inadequate gastric drainage 
Retained antrum  
Nonabsorbable sutures
Endocrine factors
Zollinger-Ellison syndrome 
Hyperparathyroidism  
Pitu itary-adrenal tumours
Ulcerogenicdrugs
tributory factor since gastric retention 
stimulates acid secretion. It is more 
likely to follow pyloroplasty than gas­
troenterostomy and probably explains 
the slightly higher rate of recurrent ul­
cer after the former.2
While antrum retained in continuity 
with the duodenum after a Billroth I 
gastrectomy is not hazardous, the 
arrangement effected by Billroth II 
gastrectomy is highly ulcerogenic.3 The 
continuous bathing of the antral mu­
cosa in alkaline duodenal juice produces 
a continuous gastrin hypersecretion 
and a clinical situation resembling the 
Zollinger-Ellison syndrome (ZES).4 For­
tunately, there appears to be a decline 
in the prevalence of this complication 
of Billroth II gastrectomy.
Extruded nonabsorbable suture ma­
terial at the anastomosis is a rarely 
reported but important cause of recur­
rent ulceration and can be readily 
dealt with by endoscopic removal of 
the suture material.
Although endocrine abnormalities 
are rarely the cause of recurrent ulcer5 
it is essential that this possibility be 
considered in every case and actively 
ruled out. Gastrinomas (ZES) are usual­
ly not recognized until recurrent ul­
ceration occurs and such ulceration is 
classically of a fulminating variety.6 
Less than 2% of recurrent ulcers are 
due to gastrinomas.7
There is a well-established relation 
between hypercalcemia and peptic ul­
cer.8 Treatment of an underlying hyper­
parathyroidism will often cure the 
ulcer.9 There is also an association be­
tween multiglandular endocrine adeno­
matosis and recurrent ulcer.10
Diagnosis
The diagnosis of recurrent ulcer is 
made from the history, by roentgeno­
graphy and especially by endoscopy. 
While secretory and other studies are 
of enormous value in the management 
of individual proven cases, the opinion 
that these investigations are of diag­
nostic value should be abandoned. Re­
currence of epigastric or left upper
quadrant pain relieved by antacid is 
highly suggestive of recurrent ulcera­
tion. However, many patients with 
proven recurrence deny pain11 and 
present with frank hemorrhage or, 
more usually, chronic anemia due to 
occult blood loss.12 Weight loss, diar­
rhea and feculent vomiting should sug­
gest the diagnosis of gastrojejunocolic 
fistula.13
Roentgenography after ingestion of 
barium is usually the initial investiga­
tion and will provide the diagnosis in 
rather more than half the cases.14 How­
ever, it is notoriously difficult to inter­
pret the findings in the region of the 
anastomosis, and endoscopy must be 
performed on all patients in whom the 
findings are negative or equivocal. In 
our experience an ulcer previously 
suspected but missed will often then 
be clearly visualized.
It has recently been suggested that 
it may be possible to diagnose recurrent 
ulceration by detecting an increase in 
serum pepsinogen group I values in 
response to betazole,15 but this is a 
difficult determination, and the ob­
servation requires confirmation.
Management
In every case of proven recurrent 
ulcer it is essential to exclude the use 
of ulcerogenic drugs and an underlying 
endocrine abnormality. A meticulous 
inquiry should be made into the use 
of drugs such as acetylsalicylic acid, 
indomethacin, phenylbutazone and ste­
roids. These agents must be scrupulous­
ly avoided while the remainder of the 
investigation is completed and if the 
ulcer heals nothing further need be 
done. The 1-hour basal acid output 
(BAO) and pentagastrin-stimulated 
maximal acid output (MAO) are meas­
ured. If the patient is achlorhydric the 
diagnosis of recurrent ulcer is almost 
certainly incorrect and alkaline reflux 
gastritis should be considered. If the 
BAO is more than 5 mmol/h and the 
ratio BAO/MAO is greater than 0.6, 
ZES is suspected.16 In any event, in all 
cases of recurrent ulcer, fasting serum 
gastrin should be determined on 3 con­
secutive days. If the values for acid 
secretion and serum gastrin are equivo­
cal the diagnosis can be established by 
means of the secretin infusion test.17 
In ZES there is an immediate increase 
in serum gastrin in response to intra­
venous secretin whereas in other pa­
tients with recurrent ulcer, including 
those with retained antrum, there will 
be the expected fall in gastrin concen­
tration.18
Serum calcium is measured in all 
patients with recurrent ulcer to rule 
out the rare parathyroid adenoma.
If the ulcer is not drug-induced, 
medical treatment is usually unsatis­
factory7 and should be reserved for 
patients in whom the risk of operation 
is too great. If ZES is proved, the cor­
rect treatment is total gastrectomy. A 
retained antrum should be excised. Hy­
perparathyroidism should be treated 
surgically before surgical treatment of 
recurrent ulcer is considered.
An excellent review of the literature7 
from 1950 to 1974 yielded reports of 
over 3400 surgically treated cases of 
recurrent ulcer; the important results 
are summarized in Table II. The authors 
make the valuable observation that any 
operation that does not reduce acid out­
put will fail in an unacceptably high 
proportion of cases.
There is, however, no single correct 
surgical treatment of recurrent ulcer. 
Surgical management depends entirely 
on the nature of the initial operation 
(Table III).
Recurrent Ulcer after
Gastroenterostomy
No additional investigation is re­
quired. While the logical treatment is 
vagotomy alone — and indeed this has 
a very low mortality — the rate of 
second recurrence is prohibitive (24%). 
The combination of vagotomy and 
antrectomy has been performed very 
infrequently and carries an unaccept­
able operative mortality (9%). The 
operation of choice therefore is partial 
(two thirds) gastrectomy, after which 
the recurrence rate is 11%. Vagotomy 
alone should be reserved for patients
Table I I—Overall Results of Surgical Treatm ent for Recurrent U lcer
Operation
No. of 
patients
Operative 
m ortality, %
Second
recurrence, %
Vagotomy or repeat vagotomy 888 1.1 15
Resection 957 2.9 12
Repeat resection 387 6.5 21
Vagotomy or repeat vagotomy and 
resection 76 7.9 8
Vagotomy or repeat vagotomy and 
repeat resection 241 5.4 8
2549 3.2 14
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who are poor risks or hyposecretors 
and in whom the ulcer is uncompli­
cated.
Recurrent Ulcer after Partial
Gastrectomy
The first step is to exclude the pos­
sibility of retained antrum if the 
anastomosis is of a Billroth II type. 
This will usually have been achieved 
by the essential investigations noted 
above. In addition, it may be useful to 
obtain a technetium pertechnate scan, 
which will identify a “hot spot” to the 
right of the main stomach uptake if as 
little as 1 cm of antrum is present.19 
Direct proof is theoretically possible 
by endoscopic visualization and biopsy 
of antral mucosa by way of the af­
ferent limb of the stoma. If retained 
antrum is identified it should be ex­
cised, but if it can be ruled out then 
vagotomy alone is sufficient. Vagotomy 
carries a low mortality (1.0%) and an 
acceptable recurrence rate (12%). Re­
peat resection is accompanied by a 
prohibitive mortality (7%) and is much 
less likely to provide a permanent 
cure.20
Recurrent Ulcer after Vagotomy
and Drainage
The underlying cause is always an 
incomplete vagotomy (if ZES has been 
excluded). There are only three case 
reports in the literature of properly 
performed insulin tests giving persist­
ently negative results and it is not 
known if these patients with recurrent 
ulcer after vagotomy were using ul­
cerogenic agents.21'22 It can therefore be 
argued that an insulin test is unneces­
sary as its result can be predicted. Most 
investigators nevertheless continue to 
use the insulin test to assess complete­
ness of vagotomy in this situation. 
Certainly, if the MAO data obtained 
before the initial operation are avail­
able, a repeat MAO study is simpler 
and quite adequate — a reduction in 
acid output of less than 50% and a 
BAO of more than 2 mmol/h are in­
dicative of incomplete vagotomy.23 The 
converse does not follow. It cannot be
assumed that in the patient with an 
incomplete vagotomy as determined by 
tests of acid secretion a recurrent ulcer 
has developed, or inevitably will de­
velop. It is quite wrong to reoperate 
on an asymptomatic patient to com­
plete a vagotomy.
The approach we have adopted in 
recurrences following vagotomy is to 
explore the hiatus abdominally. If a 
substantial vagal trunk is found (and 
there is usually a large posterior trunk) 
we perform vagotomy alone, provided 
there is no stomal stenosis. If no vagal 
trunk can be identified we employ 
antrectomy. There is insufficient re­
ported experience of this approach to 
provide data on its results. It must 
carry a lower morbidity and mortality 
than the alternative of antrectomy in 
all cases.
Recurrent Ulcer after Vagotomy
and Antrectomy
As this occurs much less frequently 
than recurrence after vagotomy and 
drainage the reported experience is 
even more limited. Again, the cause is 
almost always incomplete vagotomy, 
and the insulin test will be positive. In 
this event the patient should be man­
aged in the same way as after vagotomy 
and drainage. The hiatus should be 
explored and if a vagal trunk is found 
vagotomy alone is performed; if no 
significant nerve is identified, repeat 
resection should be undertaken. In the 
rare event of the insulin test being 
negative on two occasions (and assum­
ing that drug and hormonal factors 
have been excluded) there is little al­
ternative but to perform subtotal gas­
trectomy.
Emergency Management of
Recurrent Ulcer
Hemorrhage
This is a common presenting symp­
tom of recurrent ulcer, and massive 
bleeding is more likely to require sur­
gical control than bleeding from a 
primary duodenal ulcer. If at laparo­
tomy the surgeon is astute enough to
recognize an ulcerogenic tumour of the 
pancreas then unquestionably the cor­
rect treatment is immediate total gas­
trectomy.24 Fortunately, this lesion is 
rare.
Under normal circumstances the first 
step will be to obtain control of the 
bleeding vessel by direct suture using 
a large needle mounted with nonab­
sorbable material. If the patient’s con­
dition is still unstable, a pause at this 
stage while blood is replaced often pays 
dividends. In the very poor-risk patient 
the operation can be terminated at this 
point with a view to elective reopera­
tion. Otherwise, the next step is deter­
mined by the nature of the previous 
operation. If vagotomy has not pre­
viously been performed, or is found 
to be incomplete, vagotomy alone is 
added. If there has been what appears 
to be a complete vagotomy, resection 
or repeat resection is performed.
Perforation
Unlike hemorrhage this is quite rare, 
representing only 1% of all perfora­
tions.25 Experience is meagre and sug­
gests that this complication should be 
handled like any other perforation, 
namely by simple patching. If the pa­
tient is young and otherwise healthy, 
if it is less than 8 hours from the time 
of perforation, and if contamination is 
minimal, definitive surgery can he con­
sidered. Rarely, a large perforation will 
demand immediate gastrectomy. If 
there is concern about gastric emptying 
it is advisable to fashion a gastrostomy 
for long-term gastric suction, and a 
jejunostomy for enteral feeding. Pa­
tients who have been treated by patch­
ing should be fully investigated in the 
convalescent period and managed sur­
gically, exactly as any other case of 
recurrent ulcer.
Gastrojejunocolic Fistula
This condition should be suspected 
in any patient who presents with diar­
rhea, steatorrhea and weight loss after 
gastric surgery,13 and especially after a 
gastroenterostomy. The diagnosis is 
confirmed by barium enema and by 
endoscopy. With the advent of safe 
total parenteral nutrition there should 
be no need for the former staged pro­
cedures. Once the metabolic disorders 
have been resolved and the bowel pre­
pared, the surgeon should proceed to 
a one-stage resection of the fistula and 
en-bloc revision gastrectomy.26
Recurrent Gastric Ulcer
This is quite uncommon unless the 
initial gastric ulcer was treated by vago­
tomy and drainage.27 As with a recur­
rence after surgery for duodenal ulcer,
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it is first mandatory to exclude ulcero­
genic agents, retained antrum and hor­
monal causes such as hyperparathyroid­
ism and ZES. The surgical treatment 
will then depend on the initial opera­
tive procedure. If the first operation 
was vagotomy and drainage, partial 
gastrectomy should be performed; if 
it was vagotomy and antrectomy, then 
repeat vagotomy and revision gastrec­
tomy are undertaken; and if the initial 
operation was partial gastrectomy, the 
operation of choice is vagotomy and 
subtotal gastrectomy. In every instance 
the gastric ulcer should be excised 
along with the gastrectomy specimen.
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at this time. Therefore, such usage of Amino Acid Injection 5% 
in children is not recommended.
2 . Adjunctive for total parenteral nutrition
For long-term total nutrition, or if a patient has inadequate fat 
stores, it is essential to provide adequate exogenous calories 
concurrently, if parenterally administered amino acids are to be 
retained by the body and utilized for protein synthesis. Concen­
trated dextrose solutions are an effective source of such calories. 
Special care must be taken when giving hypertonic glucose to 
diabetic or pre-diabetic patients. In such cases crystalline insulin 
should be added to the solution8. Such strongly hypertonic nu­
trient solutions should be administered through an indwelling in­
travenous catheter with the tip located in the superior vena cava.
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See WARNINGS and DOSAGE AND ADMINISTRATION 
Peripheral Infusions
Local reactions consisting of a warm sensation, erythema, 
phlebitis and thrombosis at the infusion site have occurred with 
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_ DOSAGE AND ADMINISTRATION
1 . Protein-sparing (peripheral vein)
This preparation (without dextrose) can be administered by the 
peripheral intravenous route. It should not be infused via a central 
vein, unless it is admixed with sufficient dextrose to provide full 
caloric energy requirements in patients who require prolonged 
total parenteral nutrition.
For peripheral intravenous infusion, 1 to 1.5 g/kg/day of total 
amino acids will achieve optimal fat mobilization and spare protein 
catabolism if no carbohydrate is infused or ingested.
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Given an amino acid solution of specified total concentration, the 
volume required to meet amino acid requirements per 24 hours 
can be calculated. Then, after making an estimate of the total daily 
fluid (water) requirement, the balance of fluid needed beyond the 
volume of amino acid solution required, can be provided as a 
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electrolytes (except bicarbonate) as needed to correct imbalances 
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the presence and amount of acetonuria Amino acid dosage may 
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peripheral vein can be continued as long as oral nutrition is im­
paired. However, if a patient is unable to take oral nourishment at 
the end of 5 to 7 days, institution of total parenteral nutrition with 
exogenous calories should be considered.
2 . Adjunctive for total parenteral nutrition
For central vein infusion with concentrated dextrose solution, the 
total daily dose of the amino acid solution depends on daily pro­
tein requirements and on the patient’s metabolic and clinical re­
sponse. The determination of nitrogen balance and accurate daily 
body weights, corrected for fluid balance, are probably the best 
means of assessing individual protein requirements. For patients 
in a stable metabolic condition the provision of amino acids as a 
3.5% concentration with 20 to 25% dextrose is usually considered 
adequate. Vitamins, minerals and electrolytes should be added as 
indicated.
DOSAGE FORMS
Aminosyn 5% Injection is supplied in 1000-ml ABBO-VAC* 
containers.
A 1000-ml unit provides a total equivalent of 50 g of protein and 
7.86 g of nitrogen. Each 100 ml contains crystalline amino acids 
5 g and potassium metabisulfite not more than 60 mg (equivalent 
to 5.4 mEq K*/litre); pH 5.25 (approx ), adjusted with acetic acid 
30 mEq/litre (approx.).
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4. Panel Discussion on Peptic Ulcer Disease*
Chairman: B.J. Perey, md, FRCs[c]f 
Panelists: M.M. Cohen, P.J. Doris, J.C. Goligher and K.N. J eejeebhoy
Dr. Perey: I would like to welcome 
Professor Goligher of Leeds, who has 
agreed to join our panel. Professor 
Goligher, we have always been inter­
ested in the results of various prospec­
tive randomized studies that you have 
conducted over the years in the field 
of gastrointestinal surgery. Have you 
conducted or are you currently con­
ducting such a study of this new opera­
tion of proximal selective vagotomy, 
which allows you to decide how good 
an operation it is?
Prof. Goligher: Although we are
very attracted to controlled trials in 
gastric surgery, we did not conduct 
such a trial of proximal selective vago­
tomy. When we began, we couldn’t get 
enough surgeons to participate in a 
controlled trial of this rather peculiar 
operation, but when the trial got under­
way and the results seemed so good, 
surgeons were so happy with it that 
they wouldn’t agree to do any other 
operation. So a controlled trial was out 
of the question and though we have 
performed this operation now in nearly 
600 patients (about 400 of them with 
duodenal ulcer), we have no properly 
controlled data. We have to make re­
trospective comparisons with the results 
of other operations. Of course we have 
been interested in the trials carried out 
by other surgeons, like Kennedy. He 
has recently found a 10% recurrence 
rate following this operation, which is 
rather daunting, and I think that’s the 
only question that remains. It is safer 
than most operations, it has fewer side 
effects and gives wonderful functional 
results. How often does it prevent re­
currences? That’s the thing we want to 
know.
Dr. Perey: I would ask Dr. Jeejeebhoy 
what he foresees as happening to the
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role of surgery in duodenal ulcer in 
years to come in view of the new 
drugs now available?
Dr. Jeejeebhoy: I can only guess. I 
think that there will continue to be a 
place for surgery in the foreseeable 
future. There will continue to be ulcer 
complications, and patients who do not 
tolerate the medication for long periods 
of time. Also, we do not know what 
are the long-term effects of cimetidine. 
Recent reports suggest that low-dosage 
prophylaxis with cimetidine probably 
is not very effective.
Prof. Goligher: I don’t know to what 
extent cimetidine is used in Canada. It 
is certainly used a great deal in Britain 
at the moment. Many surgeons find 
that fewer patients are now referred for 
surgery because internists and general 
practitioners are now treating ulcers 
with cimetidine, so that there has been 
a considerable diminution in the num­
ber of surgical cases. I have a feeling 
that this medical treatment cannot go 
on for ever and that persons with 
chronic ulcers will eventually require 
surgery.
Dr. Perey: Dr. Cohen, would you also 
comment on the influence of cimetidine 
on the role of surgery?
Dr. Cohen: I think it is irrational to 
expect that cimetidine will be the an­
swer to the treatment of peptic ulcer 
because the patient has to continue 
taking the drug for the rest of his 
life. Walmsley has reported on seven 
patients who were maintained for 1 
year on metiamide, which acts like 
cimetidine. One of them had bleeding 
while taking the drug metiamide. As 
soon as treatment was stopped, the 
ulcer recurred dramatically in two other 
patients and an asymptomatic recur­
rence developed in the other four. I 
think the only way to cure an ulcer 
permanently is by surgery.
Dr. Perey: Dr. Jeejeebhoy, is there any 
place for cimetidine in the management 
of the Zollinger-Ellison syndrome? 
Should it be tried first before resorting 
to surgery, and does it work?
Dr. Jeejeebhoy: Reports have suggested 
that patients with the Zollinger-Ellison 
syndrome will benefit from cimetidine,
but with time there is a fairly high 
incidence of breakthrough. I think that 
breakthroughs have occurred because 
of the presence of significant meta- 
stases. The drug would probably be 
useful in cases where preservation of 
the stomach is particularly desirable, 
as in patients who have difficulty in 
gaining weight. However, if a break­
through occurs, the necessity for sur­
gery is obvious. We have two patients 
with proven Zollinger-Ellison syndrome 
who currently are taking cimetidine 
and they are doing quite well. One of 
them had an inadequate operation in 
the past and he doesn’t want to have 
another one.
Dr. Perey: Let us now go on to some­
thing else. Is there any test of gastric 
secretion that helps in deciding whether 
an operation is indicated, or in choos­
ing the best type of procedure? Let us 
hear from Dr. Doris.
Dr. Doris: In general terms, secretory 
tests do not provide sufficient informa­
tion that allows me to select the type 
of operation. However, I do use secre­
tory tests to detect the rare patients 
with the Zollinger-Ellison tumour, al­
though serum gastrin determinations 
make these tests less necessary. Also, 
marked acid hypersecretion is signifi­
cant in the case of patients who have 
typical ulcer symptoms but no ulcer 
visible on roentgenographic or endo­
scopic examination. In routine practice, 
gastric analysis is of little practical 
consequence.
Dr. Perey: So you’re telling us that 
secretory tests are important to estab­
lish whether or not we are dealing with 
a common garden variety of duodenal 
ulcer, but beyond that they don’t help 
much. Professor Goligher, would you 
like to express your view?
Prof. Goligher: I would go along with 
Dr. Doris. We’ve done hundreds or 
even thousands of these secretory tests 
in my department over the last 25 
years and they’ve had some academic 
interest but they haven’t really helped 
us in deciding on the type of operation 
to perform or whether operation was 
necessary, because we haven’t tried to 
tailor the operation to the patient. 
We’ve always chosen the smallest
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possible and the safest operation that 
would be reasonably effective. So even 
if we knew the patient had high acid 
secretion we would still do a relatively 
limited operation. I haven’t been very 
impressed with the efforts of groups 
who have tried to select the patients 
for different types of operations. I 
would also add that it is almost easier 
to perform a satisfactory gastric opera­
tion than a satisfactory secretory test. 
You need a good organization for doing 
a satisfactory test.
Dr. Perey: So in these days of financial 
and budget constraints, you two gentle­
men are suggesting that perhaps we are 
wasting the taxpayers’ money on these 
tests. But there may be other view­
points. I understand, Dr. Cohen, that 
you may consider this matter differ­
ently.
Dr. Cohen: Yes, in part. I do not be­
lieve that you can specifically tailor 
the operation on the basis of the acid 
secretory data, but I do believe that it 
is mandatory to obtain acid secretory 
data, in particular the maximal acid 
output (MAO), before operating on a 
patient with duodenal ulcer. As Dr. 
Doris has said, this can prevent you 
from doing the wrong operation on a 
patient with the Zollinger-Ellison syn­
drome. Also, you do not want to oper­
ate on a patient who is achlorhydric. 
Finally, by measuring the maximal acid 
output both pre- and postoperatively, 
you can avoid having to do the insulin 
test, which is more hazardous. When 
vagotomy produces a 70% reduction 
in the MAO, it is complete and the 
insulin test is not needed. I also think 
that the most restricted operation 
should be done, and as far as I ’m con­
cerned, that is truncal vagotomy and 
drainage. If, however, the patient is 
a really massive hypersecretor — by 
that I mean putting out 50 mmol/h 
or more — then I think that an antrec­
tomy should be done as well.
Dr. Perey: On what basis do you hold 
that opinion?
Dr. Cohen: Because the data provided 
by Kronborg show that patients who 
have acid secretion of more than 45 to 
50 mmol/h do badly with vagotomy 
and drainage.
Dr. Perey: Are the other members of 
the panel aware of studies such as 
Kronborg’s that would support Dr. 
Cohen’s approach?
Prof. Goligher: I’m well aware of this 
work. We recently analysed our cases 
that were treated by proximal gastric 
vagotomy (parietal cell vagotomy). 
Using Kronborg’s criteria we did not 
find that there was a higher incidence 
of recurrence in the patients with very 
high acid secretion or a lower incidence
in the patients with low acid secretion, 
so we regard the verdict as unproven. 
I have a high regard for this Danish 
surgeon’s work, but I must say our 
results haven’t been in agreement with 
his.
Dr. Perey: But Professor Goligher, do 
I understand that you have recurrences?
Prof. Goligher: Naturally, we do have 
recurrences. But most of our recur­
rences after proximal gastric vagotomy 
have occurred in the last year. Among 
300 male patients we now have 7 
proven recurrences and about 10 others 
that are dubious. We do not know what 
the number will be when our follow-up 
period reaches 5 years as for other 
operations. I can’t see why the recur­
rence rate with this operation should 
be any less than after truncal vagotomy 
and drainage.
Dr. Perey: We all probably agree on 
this. Before we leave the subject of 
gastric analysis I would like to ask Dr. 
Jeejeebhoy, as a gastroenterologist, 
what he thinks about the value of this 
test?
Dr. Jeejeebhoy: From what I have 
heard from the panel members, I would 
say that much of the evidence on which 
we have estimated the worth of gastric 
analysis is anecdotal. Whether there is 
any advantage in modifying the opera­
tion according to gastric acid output 
remains to be shown by well-controlled 
randomized studies. Without that kind 
of data it remains unproven at this 
time. I would like to enlist surgeons 
who would be prepared to cooperate 
with me in carrying out clinical trials.
Dr. Perey: Should we select the best 
operation and employ it in almost all 
patients or is it your opinion that we 
should choose from a number of pos­
sible procedures the one most appropri­
ate for each patient? May we put this 
question first to you, Professor Gol­
igher?
Prof. Goligher: I have already declared 
that I am a believer in the most limited 
Operation that is likely to be reasonably 
effective, for if this fails you can al­
ways reoperate and perform a more 
major one. I think that for practical 
purposes this is a good doctrine, but 
it is not one that is popular in the 
United States. You can do 400 of 
these new operations with no deaths, 
but you cannot do 100 vagotomies and 
antrectomies as a rule without at least 
one death and perhaps more. It’s a 
much more dangerous operation. You 
can always operate on a patient again 
for recurrent ulcer. That is my philo­
sophy, stated quite boldly and un­
equivocally.
Dr. Perey: So you’re in favour of the
minimal operation, whichever it may 
be, for everybody. Dr. Doris?
Dr. Doris: I agree with Professor 
Goligher’s statement. This is a matter 
of philosophy. I feel that there is a 
specific place for each of proximal 
selective vagotomy, vagotomy and py­
loroplasty, and vagotomy and antrec­
tomy in duodenal ulcer disease. But I 
know of no way to decide which pa­
tient should get which operation. 
Therefore, my philosophy is to start off 
with a proximal selective vagotomy.
Dr. Perey: But does this mean you are 
going to use all the others afterwards 
on the same patient?
Dr. Doris: Quite possibly. I have not 
had to reoperate on any patient after 
my very short follow-up.
Dr. Perey: Dr. Jeejeebhoy, would you 
like to venture some comments on this 
topic?
Dr. Jeejeebhoy: I think that in the pres­
ence of a duodenal ulcer one could first 
try cimetidine. You would have no 
morbidity and no deaths with that! 
If you examine Walmsley’s data, the 
recurrence occurred after an interval 
of about 7V2 months and I would say 
that if it were my ulcer, I would be 
prepared to take cimetidine for 6 weeks 
every TV?, months. Many diseases re­
quire more medication than that, and 
I do not consider this to be a major 
imposition on most patients. I think 
that recurrent ulcer disease can also be 
managed with cimetidine —  we have 
done this in four patients —  although 
controlled trials will be required in 
this regard.
Dr. Perey: Dr. Cohen?
Dr. Cohen: The important point is, can 
you keep them healed?
Dr. Perey: If we had eight panelists we 
would probably have eight different 
opinions. Before closing, I have a few 
short questions from the audience. Dr. 
Jeejeebhoy, is there any acid rebound 
after stopping cimetidine?
Dr. Jeejeebhoy: It is difficult to give 
an answer because there are no good 
data on which to base it.
Dr. Perey: Are there uses for cime­
tidine in other acid peptic conditions 
such as reflux esophagitis?
Dr. Jeejeebhoy: Oh yes! We are in the
process of carrying out a controlled 
trial ourselves and there is now increas­
ing evidence that it is significantly 
useful.
Dr. Perey: Thank you gentlemen. On 
behalf of the Canadian Association of 
General Surgeons, I would like to thank 
the panelists for their excellent pre­
sentations.
VOLUME 21, NO. 1, JANUARY 1978 / THE CANADIAN JOURNAL OF SURGERY 27
Current Status of Surgical Treatment for Ulcerative 
Colitis and Crohn’s Disease of the Large Bowel*
J . c .  G O L IG H E R , CH M ( E D 1 N ) ,  FR C S,  F R C S ( E D I N ) ,  HON FRCSI, HON F A C S f
In ulcerative colitis surgery is most 
often indicated because of frequent 
relapses when there is evidence of 
total or subtotal colitis. It may be 
performed as prophylaxis against the 
development of carcinoma of the large 
bowel, especially when rectal biopsies 
show epithelial dysplasia. The preferred 
operation would seem to be colectomy 
with ileorectal anastomosis, but the 
results obtained by most surgeons 
have been unsatisfactory. Therefore 
the procedure most favoured is 
ileostomy with proctocolectomy. 
Ileostomy is now more accepted by 
patients because of modern improve­
ments in its management. To obviate 
the necessity of an external appliance, 
a continent or reservoir ileostomy 
with a valve mechanism has been 
devised, but this requires a highly 
intricate operation which should be 
performed only when the disease is 
in remission.
When surgery is required during a 
severe attack that has not responded 
to intensive medical treatment, the 
mortality rate is much higher than after 
an elective procedure.
In Crohn's disease the type of 
operation necessary depends on the 
extent of the disease. Often an 
ileorectal or ileosigmoid anastomosis 
is possible, even when the possibility 
of a recurrence is recognized, since 
the recurrence may be long delayed.
La colite ulcereuse est tres souvent 
une indication de chirurgie a cause des 
rechutes frequentes lorsqu’il y a signe 
de colite totale ou quasi totale. 
L’intervention chirurgicale peut etre 
effectuee prophylactiquement contre 
le carcinome du gros intestin,
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specialement lorsque la biopsie du 
rectum revele une dysplasie epitheliale. 
L’operation de choix semble etre une 
colectomie avec anastomose ileorectale, 
mais les resultats obtenus par la 
plupart des chirurgiens ont ete peu 
satisfaisants. Done, I'intervention qui 
Iui est preferee est I’ileostomie avec 
rectocolectomie. L'ileostomie est 
maintenant mieux acceptee par les 
patients grace aux ameliorations 
recentes apportees a son maniement. 
Pour parer a la necessity d’un dispositif 
externe, une ileostomie avec controle 
de continence, ou ileostomie avec 
reservoir et systeme de soupape, a 
ete mise au point; toutefois, celle-ci 
exige une operation tres compliquee 
qui ne devrait etre effectuee que 
lorsque la maladie est en remission.
Ouand on doit recourir a la chirurgie 
pendant une crise grave qui n’a pas 
cede a un traitement medical intensif, 
le taux de mortality est beaucoup 
plus eleve qu'apres une intervention 
elective.
Dans la maladie de Crohn, le type 
d'operation necessaire depend de 
I'etendue de la maladie. Souvent, une 
anastomose ileorectale ou ileosigmoi'de 
est possible, meme lorsque I’on 
reconnait la possibility d'une recidive, 
puisque celle-ci peut etre longuement 
retardee.
In this survey of the contemporary role 
of surgery in the treatment of ulcerative 
colitis and Crohn’s disease of the large 
bowel I should like to devote particu­
lar attention to a few of the outstand­
ing controversial issues.
Ulcerative Colitis
Choice of Operation
One controversial question concern­
ing ulcerative colitis, at least in the 
United Kingdom, is, What is the place 
of colectomy with ileorectal anastomosis 
in the management of this disease? It 
should be emphasized that the term 
“ulcerative colitis” is a misnomer; 
the condition ought to be called “ulcer­
ative proctocolitis”, for the rectum 
also is almost always involved. Con­
sequently, to preserve the rectum and
its function by means of an ileorectal 
anastomosis would seem an invitation 
to further trouble. But what matters 
in medicine is not so much what should 
happen as what actually does happen, 
and it must be admitted that the results 
reported by Aylett,1'3 the leading ad­
vocate of this operation for ulcerative 
colitis, are remarkably good. At one 
stage almost 90% of about 300 patients 
treated by this method were highly 
satisfied with the results of the pro­
cedure. No one else seems to have been 
able to obtain results quite as good 
as these, although Turnbull4 and Watts 
and Hughes5 have had up to 60% and 
70% rates of success, respectively. On 
the other hand Muir,6 Ault,7 Anderson,8 
Griffen, Lillehei and Wangensteen,9 
Baker,10 Adson, Cooperman and Far­
row" and I12 have been much less im­
pressed by the results of ileorectal 
anastomosis — about half the patients 
eventually needed rectal excision and 
ileostomy. However, there has been a 
revival of interest in this procedure in 
Britain recently (Parks AG: Personal 
communication, 1975; Hawley PR: 
Personal communication, 1975).
One of the difficulties concerning the 
controversy over the use of colectomy 
with ileorectal anastomosis is the ab­
sence in published reports of any clear 
guidance as to which patients may do 
particularly well after this operation 
and which will do badly.10 It seems 
reasonable to restrict the use of this 
method of treatment to patients with 
relatively mild changes in the rectum. 
The ileorectal anastomosis should be 
located at the upper end of the rectum 
and, because of the considerable risk 
of subsequent anastomotic dehiscence, 
it would appear wise to follow Aylett’s3 
advice to establish a temporary covering 
loop ileostomy until the suture line has 
healed (Fig. 1).
The operation favoured by most 
surgeons is ileostomy with proctocolec­
tomy or subtotal colectomy. To those 
familiar with the synchronous combined 
abdominoperineal technique for rectal 
excision, as is widely practised in Brit­
ain and many countries of the British 
Commonwealth, it is simple to extend 
this operation upwards to include a
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FIG. 1—Diagrammatic representation 
of ileorectal anastomosis with proximal 
loop ileostomy to protect anastomosis. 
Note projecting active opening and reced­
ing inactive opening of loop ileostomy.
colectomy and ileostomy. But if the 
surgeon lacks this familiarity or is in­
experienced in treating patients with 
colitis, he should restrict the initial in­
tervention to a subtotal colectomy and 
ileostomy. In this case the sigmoido­
rectal stump is brought out in the 
suprapubic region as a mucous fistula 
or, if the tissues are considered strong 
enough to hold sutures, it is closed 
and dropped back into the pelvis. It is 
preferable to suture the stump to either 
the anterior or posterior abdominal 
wall to keep it readily available in case 
a secondary ileorectal anastomosis is 
ever required. But in most cases, al­
though the patient makes a good recov­
ery of general health, the persistent 
inflammation in the rectal wall makes 
an anastomosis unwise. Indeed, the 
continued discharge of blood, mucus 
and pus from the rectum may cause so 
much inconvenience as to necessitate 
its excision within a few months. Be­
cause of the risk of malignant change, 
the likelihood of eventual rectal excision 
should always be considered, although 
regular sigmoidoscopic review with rec­
tal biopsy to confirm the absence of 
epithelial dysplasia may permit a more 
conservative attitude to this problem 
(see below).
What is so daunting to the patient 
about a proctocolectomy is the ileo­
stomy, which initially impresses the 
lay person, particularly a young woman 
or teenager, as repulsive and unnatural. 
Unquestionably the best way to over­
come the patient’s apprehension is to 
arrange for a confidential talk with an 
ileostomist of similar age and social 
background. This plan seldom fails to 
secure the patient’s consent for opera­
tion.
Ileostomy
The success of the operation depends 
mainly on the ability of the surgeon to 
provide a good ileostomy and to en­
sure that the patient receives proper 
instruction on its management.
Operative technique.—The siting of 
the stoma is extremely important 
because the patient will subsequently 
wear an appliance adherent to the skin 
immediately surrounding it. The sur­
geon should make a separate circular 
wound for the ileostomy away from 
the main incision and not too close to 
the umbilicus, the anterior superior 
iliac spine, or the groin in order to 
ensure a smooth flat skin surface to 
which the bag can be affixed. Popular 
sites for this wound are shown in Fig. 
2, the lower one being preferable be­
cause it is not at the waistline. The 
surgeon should choose a tentative site 
for the ileostomy before operation, 
while the patient is both lying and 
standing, and mark this point for his 
guidance at the operation.
For ileostomy most surgeons now 
use the technique of eversion and 
primary mucocutaneous suture, first 
described by Brooke13 (Fig. 3), which
FIG. 2—Common sites for circular or 
trephine wound for terminal ileostomy in 
relation to main laparotomy wound and 
anatomical structures of anterior abdom­
inal wall. Site A is inconvenient because 
it lies on waistline; site B is preferable.
FIG. 3—Ileostomy technique. Ileal
stump is fixed by circumferential row of 
3-0 silk sutures between anterior rectus 
sheath and superficial layers of ileal wall 
and leaf of mesentery, about 7.0 cm from 
cut distal edge. End of bowel is then 
everted by sutures between it and edges 
of skin wound to produce ileal spout 
about 3 cm long.
provides a soft, supple, projecting 
ileostomy spout that shows no tendency 
to stenose. It is probably wise to aim 
for a completed ileostomy protrusion 
of 2.5 to 3 cm; therefore the ileal 
stump should extend 5 to 7.5 cm beyond 
the skin before it is everted.
Appliances and care of the stoma.— 
One of the great innovations in regard 
to ileostomy was the introduction of 
the adherent bag by Koenig and 
Rutzen.14 The original bag was made 
of rubber and was stuck to the skin by 
a double-sided adhesive plaster or a 
cement, similar to that used for re­
pairing bicycle tires. The ileostomy 
appliances fashionable today are made 
of a plastic, odour-resistant, rustle- 
proof material that is disposable; they 
are often fixed to the skin in part by 
washers of karaya gum. Many patterns 
are available — two of the more popu­
lar ones are illustrated in Figs. 4 and 5.
Of the complications that may occur 
after an ileostomy, the most common 
and troublesome is that of the soreness 
of the skin around the stoma. This may 
be due to sensitivity to the material 
of the appliance or adhesive, or to 
leakage of ileal contents with resulting 
digestion of the skin. Factors predis­
posing to leakage are a poor standard 
of care in the fixation of the appliance, 
loose watery motions and, occasion­
ally, a poorly constructed stoma, for 
example, one that does not project 
adequately, or protrudes too much, or 
is associated with a depressed scar in 
the immediate peristomal skin or with 
some other structural defect. Whatever 
the initial cause of skin soreness, the 
difficulty in keeping the appliance 
stuck to a raw oozing surface predis­
poses to leakage and a vicious circle 
is established. The best way to break 
this circle is for the patient to wear 
karaya gum washers, or Stomahesive 
(Squibb) or Reliaseal (Davol Interna­
tional) squares between the flange of 
the appliance and the abdominal skin. 
These are good adhesive agents and at 
the same time are nonirritating and 
soothing to the raw cutaneous surface. 
If the feces are particularly loose, anti- 
diarrheal drugs such as codeine phos­
phate (60 to 120 mg qid) or diphe­
noxylate hydrochloride and atropine 
(Lomotil) (2 tab, qid), may give them 
a firmer consistency. Occasionally 
severe structural abnormalities of the 
stoma may necessitate refashioning or 
resiting of the ileostomy.15,16
Although transient skin soreness oc­
curs in 10% to 20% of ileostomy pa­
tients, it can be eliminated or greatly 
reduced with the aid of the measures 
mentioned above in all but a  small 
proportion of the patients. A notable 
advance in colorectal surgery in recent 
years has been the evolution of ente­
rostomal therapy as a recognized aux-
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Fig. 4b
FIG. 4—(a) Rear view of Hollister 
draining bag. (b) Frilled cloth covering 
bag worn by some patients over Hollister 
bag to conceal feces.
iliary service for ileostomy and colos­
tomy patients. We owe this advance 
mainly to the foresight and energy of 
Turnbull4 and Gill17 of Cleveland, Ohio. 
The availability of a keen enterostomal 
therapist can undoubtedly improve the 
recognition of stomal difficulties and 
help to bring them more quickly under 
control.
Reservoir or continent ileostomy.— 
Kock (personal communication,
30
FIG. 5— Coloplast patterned draining ileostomy bag.
1976)18'20 of Gothenburg has devised 
the method of the continent or reser­
voir ileostomy, in which a length of 
ileum (40 to 50 cm) immediately 
proximal to the stoma is folded on 
itself, opened and anastomosed to make 
a pouch or sump in which the feces 
can accumulate and from which they 
can be evacuated three or four times 
a day by the passage of a tube 
through the stoma into the reservoir. 
Between intubations, if the operation 
has been successful, there is no leak­
age from the stoma and no need for 
an external appliance, merely a piece 
of gauze held in place with strapping. 
This is naturally an attractive method 
to many patients. Originally Kock18 
thought that by constructing such a 
reservoir an aperistaltic intestinal bag 
would be produced, which would ex­
hibit no tendency to expel feces spon­
taneously. Experience soon showed 
that this was not so, and that to 
achieve anything like complete con­
tinence, a nipple valve mechanism, in 
the form of an intussusception of the 
base of the exit conduit into the re­
servoir (Figs. 6 and 7) producing a 
sort of “unspillable inkwell” effect was 
necessary. Then it was discovered that 
prolapse of the intussusception valve 
could take place (Fig. 8) resulting in 
loss of continence and inability to pass 
the tube into the reservoir (Kock NG: 
Personal communication, 1976).20,21 In 
his explanation for this prolapse Kock 
(personal communication, 1976)20 drew 
attention to the existence of a gap in 
Ihe circumferential row of sutures at 
the base of the valve, corresponding to 
the coinciding mesenteries of the in-
FIG. 6—Diagram of reservoir ileostomy 
with 4- to 5-cm nipple valve on exit con­
duit projecting into interior.
FIG. 7—Completed reservoir fixed to 
anterior abdominal wall.
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FIG. 8—Radiograph showing reservoir 
ileostomies, (a) Well-formed nipple valve, 
indicated by clear area around tube on 
upper part of reservoir, (b) Displaced 
nipple valve producing sharp kink in exit 
conduit.
going and outgoing portions of bowel 
(Fig. 9). He believed that the valve 
might extrude through this weak spot. 
To counter this weakness he proposed 
a modified technique for constructing 
the nipple valve: as the bowel is in- 
tussuscepted into the reservoir it is 
rotated 60° to 90° to separate the 
mesenteries of the entering and leav­
ing segments. In this new technique the 
mesentery of the 8- to 10-cm length of 
ileum earmarked for making the nipple 
valve is split exactly at its middle (Fig. 
10). One or two silk sutures are then 
inserted on one side of the bowel 
proximally and passed through the 
mesenteric gap to be inserted on the 
other side distally. Then, as the ileum 
of the exit conduit is drawn into the 
lumen of the reservoir, these sutures
VOLUME 21, NO. 1, JANUARY 1978 /
FIG. 9—Diagrammatic drawing of completed nipple valve demonstrating potential 
gap at site of ingoing (A) and outgoing (B) mesentery, through which prolapse of 
valve is thought to take place.
FIG. 10—Preparation of nipple valve 
by technique designed to rotate bowel as 
it is intussuscepted and to separate ingoing 
and outgoing mesentery. Mesentery cor­
responding to 8- to 10-cm segment of 
bowel that will be used for manufacturing 
valve is divided at its middle. Fine silk 
sutures are then inserted in one side of 
bowel, proximally, they are passed through 
mesenteric gap and are then inserted in 
opposite side of bowel, distally.
are tied, the effect being to rotate the 
bowel and separate the two portions of 
mesentery. Further Lembert sutures of 
silk are inserted around the basal part 
of the intussuscepted bowel (Fig. 11).
Before the ileum is intussuscepted, 
its peritoneal and muscle coats are 
scarified by diathermy to encourage 
the development of adhesions between 
the apposed serosal surfaces after in­
tussusception. Kock (personal com­
munication, 1976) has recently aban­
doned his technique'9 of suturing the 
tissues of the nipple valve together 
with two or three longitudinal rows of 
silk stitches inserted through both 
layers of bowel from within the lumen 
of the reservoir, because it sometimes 
led to the development of a fistula 
through the substance of the valve with 
nullification of its valvular effect.
Certainly the major difficulty with 
the reservoir ileostomy is to provide 
an effective valve mechanism that will 
endure. It remains to be seen whether 
this new technique for manufacture 
of the nipple valve will prevent it 
prolapsing later, but the experience 
with this innovation so far reported by 
Kock (personal communication, 1976) 
is encouraging, and this method has 
given improved results in my own 
smaller group of patients, although sub­
sequent extrusion of the valve has still 
occurred in a few cases.
In this connection it is appropriate 
to discuss the legitimate role of the 
reservoir ileostomy in the surgical man­
agement of colitis. Obviously this pro­
cedure, which involves extensive and 
complex intestinal suturing, carries 
risks of contamination, dehiscence, 
leakage and sepsis that do not apply 
to a conventional ileostomy operation. 
These risks are greatly increased in 
patients seriously ill during severe 
acute phases of ulcerative colitis; 
therefore a reservoir ileostomy is con­
traindicated at the time of the initial 
excisional surgery unless the disease is 
temporarily in full remission. The ideal 
candidate for a reservoir ileostomy is, 
in my view, one who has already un­
dergone proctocolectomy and conven­
tional ileostomy but who wishes the 
latter to be converted to a reservoir 
ileostomy because of persistent prob­
lems in the management of the stoma, 
or for various deeply felt psychologic 
or social reasons. It is certainly im­
portant that the patient who wants a 
reservoir ileostomy should be firmly 
dedicated to this idea, for complications 
after this operation are common; even 
in very experienced hands at least half 
the patients need one or more addition­
al operations before a satisfactory con-
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BFIG. 11—Preparation of nipple valve by rotation technique. As exit conduit is 
drawn into lumen of reservoir, sutures are tied and produce rotation of bowel and 
separation of ingoing (A) and outgoing (B) mesentery, best seen in diagrammatic 
cross-section.
tinent ileostomy is obtained. A reservoir 
ileostomy is generally considered inad­
visable in patients undergoing colectomy 
for Crohn’s colitis because if the dis­
ease recurs the recurrence is most 
likely to be located just above the 
stoma. In a patient with a reservoir 
ileostomy that would mean in the re­
servoir itself, and its removal would 
thus necessitate sacrifice of a con­
siderable segment of precious lower 
ileum. Finally the construction of an 
efficient reservoir ileostomy is tech­
nically a highly demanding operation 
and unless the surgeon is engaged in 
the exercise fairly frequently, he is un­
likely to master its intricacies.
Indications for Surgery
Elective operation.—The common­
est indication for elective surgery is 
chronic invalidism and the occurrence 
of frequent relapses, generally in 
patients with radiologic evidence of a 
total or subtotal colitis. However, 
especially in older patients, a more 
limited distal proctocolitis confined to 
the rectum and sigmoid colon may 
produce enough recurrent problems to 
require operation.
A debatable issue is the use of 
surgery as a measure of prophylaxis 
against the well-recognized risk of car­
cinoma of the large bowel in patients 
with long-standing and extensive colitis. 
Certainly in the past we have advised 
ileostomy and complete proctocolec­
tomy to patients who have had total 
colitis for 10 or more years,16,22 but, 
as Svartz and Ernberg23 pointed out, 
many of these patients have learned to 
handle their disease satisfactorily and 
to lead a reasonably normal existence 
with relatively few symptoms. Conse­
quently it is often difficult, as I have 
found, to induce them to accept an 
operation involving an ileostomy, and 
I have had the mortifying experience 
of seeing several such patients, who 
refused operation, return a few years 
later with established and sometimes 
incurable “colitis carcinoma”. More 
recently some clinicians24 have con­
sidered the presence of epithelial dys­
plasia in rectal biopsy specimens as an 
indication for prophylactic operation 
in patients with a long history of ex­
tensive colitis or, more correctly, the 
absence of dysplasia as an indication 
that it is safe, so far as risk of devel­
opment of a carcinoma is concerned, 
to continue with conservative manage­
ment for a further period of 6 to 12 
months. Just how reliable this plan 
may be is questionable,25 but Lennard- 
Jones and colleagues26 have given an 
encouraging account of the conserva­
tive management of patients with 
ulcerative colitis monitored by rectal 
biopsy in this way.
Physical retardation in children with 
severe extensive ulcerative colitis is 
possibly another indication for resort­
ing to elective surgery, which should 
always be borne in mind in managing
these young patients. Contrary to ex­
pectation, proctocolectomy and ileo­
stomy are usually well tolerated by 
children.
Arthritis, eye complications and skin 
manifestations in association with co­
litis often respond well to adequate 
medical treatment of the underlying 
bowel condition, but troublesome sys­
temic and local anorectal complica­
tions may necessitate proctocolectomy.
Urgent and emergency operations.—  
These are life-saving operations un­
dertaken at the height of severe attacks 
that have not responded to medical 
treatment. Unfortunately they are not 
always successful in their objective, for 
some of these patients are extremely 
ill at the time they undergo operation 
and the operative mortality may be 
four or five times greater than that 
after elective operations (Table I). In 
most patients admitted with a severe 
attack of colitis it is usual to give a 
short course of intensive medical treat­
ment with high doses of steroids. If at 
any stage during this treatment there 
is toxic dilatation or perforation of the 
colon, immediate operation is required. 
If no such complications occur, the 
medical treatment is continued, but if 
by the end of about 1 week there are 
no unequivocal signs of commencing 
remission of the attack, urgent laparo­
tomy is advised.
A procedure that has attracted much 
attention in recent years for the man­
agement of such cases, is that of loop 
ileostomy with decompressing trans­
verse or sigmoid colostomy, recom­
mended by Turnbull and associates27 
specifically for patients with toxic me­
gacolon. It is particularly suitable for 
the management of megacolon when 
there is an associated sealed perfora­
tion, for, if a colectomy is performed, 
the perforation is unsealed and inevi­
tably there is a contamination of the 
peritoneum by feces. But if there is no 
colonic dilatation (and in my experi­
ence more than half the patients re­
quiring urgent surgery for colitis have 
no megacolon), or if there is megacolon 
but no sealed perforation is present. 
I prefer to perform an ileostomy and 
subtotal colectomy or complete procto­
colectomy, as I do also for patients with 
free perforation into the peritoneal
T a b le  1— O p e ra tiv e  M o r ta lity  in U lc e r a t iv e  C o lit is  A cc o rd in g  to  U rg en cy  o f O p e ra tio n ,
1952 to  1977
N o . o f O p e ra tiv e
p a tie n ts m o r ta lity  (a n d  % )
E le c tiv e  o p e ra tio n 420 13 (  3 )
U rg e n t and e m e rg e n c y  o p e ra tio n s 135 22 (1 6 )
A ll  o p e ra tio n s 555 35 (  6 )
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T a b le  I I — R e c u rre n c e  a f te r  L a rg e  B o w e l E xc is io n  a n d  I le o s to m y  o r  C o lo s to m y  A c c o rd in g
to  V a r io u s  A u th o rs
C ases In c id e n c e  o f
A u th o r fo llo w e d r e c u r re n c e , %
N u g e n t and  a s s o c ia tes , B o s to n , M A , 197339 
R itc h ie  an d  L o c k h a r t-M u m m e ry , Lond on ,
28 3 .6
U K , 197331 80 6.2
S te in b e rg  and  a s s o c ia te s , B irm in g h a m , U K , 197430 70 33 .0
K o re litz  an d  a s s o c ia tes , N e w  Y o rk , 197240 67 46 .0
G o lig h e r , L eeds , U K , 197633 167 10 .2
cavity. But the results reported by 
Turnbull, Weakley and Hawk*8 for 
ileostomy with decompressing colos­
tomy are challengingly good; there was 
only one operative death in 57 patients 
so treated.
Crohn’s Disease
Crohn’s disease has a wide distribu­
tion in the alimentary tract and occa­
sionally occurs elsewhere, but in most 
cases the lesions are found in the lower 
portion of the small bowel or, increas­
ingly in the last 10 to 15 years, in the 
large bowel.16 I shall consider only 
Crohn’s disease confined mainly or 
entirely to the colon and rectum (Fig. 
12). Medical measures, as for ulcerative 
colitis, with steroids and salicylozosul- 
fapyridine are, in my experience, often 
effective in securing a remission of 
exacerbations of symptoms, but often 
surgical treatment is required eventual­
ly. Occasionally, in patients with 
localized lesions, this may entail 
a restricted colonic resection with 
colocolonic or ileocolonic anastomosis, 
or an abdominoperineal excision of the 
rectum with terminal iliac colostomy, 
but far more frequently one of the 
standard operations for colitis is needed 
— colectomy with ileosigmoid or ileo- 
rectal anastomosis, or ileostomy with 
subtotal colectomy or complete procto­
colectomy. Often these operations must 
be combined with resection of a vari­
able amount of terminal ileum if there 
is associated ileal involvement. One 
consequence of this ileal resection is 
that the ileostomy tends to be more 
active, and antidiarrheal agents such as 
codeine phosphate are often required 
to make it manageable. The other con­
sequence is that owing to disturbance of
FIG. 12—Subtotal colectomy specimen 
showing typical gross appearance of 
Crohn’s disease.
the enterohepatic circulation of bile 
salts these patients are predisposed to 
the development of gallstones.29 The 
fact that the rectum (or rectum and 
sigmoid) is spared in about 30% of 
patients with Crohn’s disease of the 
large bowel makes a colectomy with 
ileorectal or ileosigmoid anastomosis 
fairly frequently a logical and attractive 
means of treating this condition. Al­
though recurrence, usually just above 
the anastomosis or in the rectal stump, 
is not uncommon after this opera­
tion,11-30'33 a reasonable argument can 
be advanced for its use, where feasible, 
at any rate as a temporary measure. It 
has generally been considered, how­
ever, that ileostomy and complete proc­
tocolectomy yield superior results with 
respect to recurrence in Crohn’s disease 
of the rectum and colon. 34 35 Indeed, 
soon after the pathological and clinical 
features of Crohn’s disease affecting 
chiefly the large bowel were first clear­
ly defined by Lockhart-Mummery and 
Morson,38-37 many gastroenterologists 
formed the impression that the results 
of its surgical treatment, particularly by 
ileostomy and complete proctocolec­
tomy, would be much better than the 
50% 5-year recurrence rate after re­
section for Crohn’s disease affecting 
mainly the small bowel.34-38 But during 
the 15 years that have elapsed several 
careful follow-up studies have been 
published of the outcome after ileos­
tomy and proctocolectomy for Crohn’s 
disease, with widely varying findings 
(Table II30’31-33-39'40). It is not clear
FIG. 13—Graph showing cumulative 
risk of recurrence after large bowel ex­
cision and ileostomy (or colostomy) for 
Crohn’s disease.
why there should be such variations in 
the recurrence rate, especially since the 
lowest incidence of recurrent disease 
was in the study of Nugent and col­
leagues,39 which had the longest follow­
up (every patient had been operated 
on at least 10 years previously). Cer­
tainly in my own series the striking 
feature was the increasing recurrence 
rate as the length of follow-up increased 
(Fig. 13). Unfortunately, because the 
number of cases available for follow-up 
of more than 12 years is small, the 
validity of the curve beyond this period 
is extremely dubious. By far the most 
frequent site for recurrence was imme­
diately above the ileostomy (Fig. 14). 
It is emphasized, however, that a large 
number of patients enjoy freedom from 
recurrence for many years, or indef­
initely, after ileostomy and proctoco­
lectomy and that when recurrence does 
take place a second resection and es­
tablishment of a new ileostomy can be 
followed by further relief of symptoms 
for quite long periods.33
While the results of surgical treat­
ment for Crohn’s disease of the large 
intestine appear to be better than those 
of surgery for this condition in the 
small intestine, they do not provide any 
grounds for complacency. But until 
more effective medical treatment is de­
veloped the surgeon will continue to
i f  '
FIG. 14— Appearance of recurrent 
Crohn’s disease just proximal to site of 
ileostomy.
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play a major role in the management 
of this disease.
Figs. 2, 4, 5 and 6 are reproduced by 
permission from Goligher JC: Surgical 
treatment, in Colitis Ulcerosa, Kremer 
K, Kivelitz H (eds), Stuttgart, Georg 
Thieme, 1977, p 87. Fig. 3 is reproduced 
by permission from Goligher JC: The 
ostomy reconstruction. Br J Surg 50: 259, 
1962. Fig. 13 is reproduced by permission 
from Goligher JC: Results of resection 
for Crohn’s disease. Dis Colon Rectum 
19: 584, 1976. Fig. 14 is reproduced by 
permission from Goligher JC: Ileal re­
currence after ileostomy and excision of 
large bowel for Crohn’s disease. Br J Surg 
50: 253, 1972.
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Symposium on Carcinoma of Colon and Rectum
1. Results of Standard Surgical Treatment of 
Colon and Rectal Carcinomas*
Andre B. Peloquin, md, frcs[c], FAesf
A review is presented of 1550 cases 
of cancer, 545 of the rectum and 1005 
of the colon, treated at Hopital 
Notre-Dame, Montreal.
A survey of the patients with rectal 
cancer treated during successive periods 
shows that over the years there has 
been no improvement in survival 
after standard surgical treatment.
On the contrary, in patients with colonic 
cancer there has been a significant 
improvement in the crude survival rate, 
from 32.5% to 63.2%. Over the 28-year 
period studied, we noted also an 
increase in the resectability rate (from 
71.8% to 90.4%) and a decline in the 
operative mortality rate (from 12.1% 
to 2.9%). Moreover, the number of 
patients over 70 years of age tended 
to increase. These three factors 
combined can explain, at least partly, 
the rise in the crude survival rate.
The corrected survival rate excludes 
these factors since it is based on only 
the resected cases and excludes 
postoperative deaths and deaths from 
intercurrent disease. Nevertheless we 
found an evident improvement in this 
survival rate as well, which rose from 
46.2% to 75.4%. These gratifying 
results can therefore be attributed to 
an improvement in surgical technique: 
more extensive resection with high 
ligation of the pedicle thereby preventing 
dissemination of cancer cells.
On presente une revue de 1550 cas 
de cancer, dont 545 du rectum et 1005 
du colon, qui ont ete traites a I’Hopital 
Notre-Dame de Montreal.
Une etude des patients atteints du 
cancer du rectum et traites pendant
*Presented at the inaugural meeting of 
the Canadian Association of General 
Surgeons, Toronto, Ont., May 11 and 
12, 1977
t Attending surgeon, Hopital Notre-Dame, 
Montreal, and associate professor of 
surgery, University of Montreal, Montreal,
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diverses periodes successives, montre 
que, au cours des annees, il n’y a eu 
aucune amelioration des taux de survie, 
suite a la chirurgie conventionnelle.
Au contraire, dans le cas du cancer 
du colon, il y a eu une amelioration 
significative du taux de survie brut, 
celui-ci passant de 32.5% a 63.2%. Au 
cours de la periode de 28 ans etudiee, 
on a aussi observe une augmentation 
de la possibility de resection (le taux 
passant de 71.8% a 90.4%) et une 
baisse du taux de mortality operatoire 
(de 12.1% a 2.9%). De plus, le nombre 
de patients de plus de 70 ans a montre 
une tendance a augmenter. L'association 
de ces trois facteurs peut expliquer, 
au moins en partie, ['amelioration du 
taux de survie brut.
Le taux de survie corrige exclut ces 
trois facteurs puisqu'il ne tient compte 
que des cas ou il y a eu resection 
et qu'il elimine les deces postoperatoires 
et les morts dues a une maladie 
intercurrente. On a neanmoins trouve 
une amelioration evidente de ce taux 
de survie qui a augmente de 46.2% 
a 75.4%. Ces resultats encourageants 
peuvent done etre attribues a une 
amelioration des techniques 
chirurgicales: une resection plus etendue 
avec ligature haute du pedicule, 
prevenant de la sorte la dissemination 
des cellules cancereuses.
From 1942 to 1969 inclusive, carci­
noma of the colon or rectum, or both, 
was diagnosed and treated in 1550 
patients at Hopital Notre-Dame, Mont­
real. The author has reviewed person­
ally all their records. Only three pa­
tients (0.19%) were lost to 5-year 
follow-up. The location of the carci­
nomas in the large bowel is shown in 
Fig. 1. In eight cases it was impossible 
to fix the exact location of the tumour 
because advanced carcinomatosis was 
present; these patients are included in 
the group of cancer of the colon. Can­
cers of the rectosigmoid treated by 
anterior resection are included in the 
group of sigmoid cancers.
Staging was by Dukes’ classification, 
established on pathological findings.1 
Patients who were not operated upon
all had advanced disease with distant 
metastases proved either by biopsy or 
at autopsy.
Operability refers to the percentage 
of patients operated upon, whether the 
operation was laparotomy, a bypass 
procedure, colostomy or resection. Re­
sectability refers to the percentage of 
patients operated upon who had a resec­
tion. The crude survival rate is based 
on the total number of cases. The 
corrected survival rate is calculated 
from the number of patients in whom 
resection was performed. Therefore the 
operative deaths, the deaths from inter­
current disease and the three patients 
lost to 5-year follow-up are excluded 
from this figure, as suggested by 
Bacon.2 Operative mortality includes ail 
deaths occurring before the 30th post­
operative day. By obstruction we mean 
complete obstruction, and by perfora­
tion, those patients with symptomatic 
abscess formation or generalized peri­
tonitis.3
Global Results
There were 545 patients with cancer 
of the rectum. The operability was 
94.3% and the resectability of stages 
A, B and C was 85.3%. The operative
FIG. 1— Location of tumour in 1550 
cases of colorectal carcinoma.
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Table I—Cancer of the Rectum: Crude Survival Rate by Stage for Patients Treated in Each Time Period
Dukes’ stage 1942-1946 (n = 48)* 1947-1951 (n = 102) 1952-1956 (n = 111) 1957-1961 (n =  99) 1962-1966 (n = 119) 1967-1969 (n = 66) X2 P valuesff
A 7 (50.0)f 12 (75.0) 20 (71.4) 14 (48.3) 16 (66.7) 14 (82.3) 8.42 <  0.2 (NS)
B 3 (33.3) 10 (30.3) 12 (44.4) 10 (47.6) 11 (30.5) 3 (14.3) 7.119 <  0.3 (NS)
C 0 7 (25.9) 4 (16.7) 2(24.1) 2(19-3) 2(23.1) 4.984 <  0.5 (NS)
Total 10 (26.3) 29 (38.1) 36 (45.6) 31 (39.2) 33 (36.3) 20 (39.2) 4.278 <  0.7 (NS)
'Numbers (n) include patients with stage D cancer (distant metastases) not considered in this table. fNo. (and %) surviving. ffNS = not significant.
Table II—Cancer of the Rectum: Corrected Survival Rate by Stage For Each Time Period
Dukes' stage 1942-1946 1947-1951 1952-1956 1957-1961 1962-1966 1967-1969 X2 P values
A 7 (63.6)* 12 (92.3) 20 (90.9) 12 (63.1) 16 (80.0) 14 (87.5) 8.701 <  0.2 (NS)
B 1 (33.3) 10 (50.0) 12 (57.1) 9 (56.2) 11 (40.7) 3 (23.1) 5.1 <  0.5 (NS)
C 0 J_ (41-2) 4 (36.4) 7 (31.8) 6 (21.4) 2_(33.3) 3.118 <  0.7 (NS)
Total 8 (50.0) 29 (58.0) 36 (66.6) 28 (49.1) 33 (44.0) 20 (52.6) 7.394 <  0.2 (NS)
*No. (and %) surviving.
mortality for resection was 10.6%. The 
corrected survival rates for stages A, 
B and C were 80.2%, 46% and 30.3%, 
respectively. For patients with a stage 
A, B or C lesion considered as a group, 
the corrected survival rate was 53.1%.There were 1005 patients with cancer 
of the colon. The operability was 97% and the resectability for stages A, B 
and C was 85.1%. The operative mor­
tality for resection was 6.5%. The cor­
rected survival rates for stages A, B and C were 83.1%, 65% and 37.7%, 
respectively. The corrected survival rate 
for all patients with stage A, B or C 
lesions was 61.7%.These results of what is termed stand­
ard surgical treatment of colorectal car­
cinomas are similar to those reported in the literature.4'8 As in other series, 
they apply to a large number of pa­tients treated over a considerable pe­riod.
It is logical to study the outcome in patients treated at different periods: accordingly the total period of 28 years was subdivided into five 5-year periods and a final one of 3 years. Many fac­tors can influence survival after stand­ard surgical treatment, and in each period of the study one can notice a variation in the number of cases, the age of the patients, the proportion of cases in each Dukes’ stage, the inci­dence of complications (obstruction or free perforation), the operability, the resectability, the operative mortality, 
and possibly the surgical technique.
Cancer of the Rectum
The crude survival rate on the six time periods for patients grouped ac­
cording to Dukes’ classification is 
shown in Table I. The percentage of lesions belonging to each stage is shown 
in Fig. 2. Most of the patients were aged between 60 and 70 years; in suc­
cessive periods we noted a small rise in the number of patients aged over 
70 years.The operability varied between 
90.9% and 95.8% and did not change
%
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FIG. 2— Carcinoma of rectum: percen­tage of lesions in each stage for each time period.
significantly over the years (x2 =  2.703, 
P >  0.7).The resectability for stages A, B and C rose significantly; in successive pe­
riods it was 50%, 84.2%, 88.6%, 
87.2%, 94.4% and 87.7% (x2 =  42.98, P <  0.001).A considerable decrease in the oper­
ative mortality was noted as the series accumulated. For the various periods 
it was 10.5%, 18.3%, 18.9%, 6.8%, 4.5% and 2.2%. This improvement is 
statistically significant (y2 =  18.334, 
P <  0.01).In cases of rectal carcinoma the in­
cidence of complete obstruction and of obstruction associated with perforation 
has always been low. For the former it 
ranged between 4.2% and 0% (x2 ~  4.096, P >  0.5) and for the latter be­
tween 2.1% and 0% (x2 =  3.013, P >  0.5). These variations are not 
statistically significant.At first sight, the crude survival rate seems to improve with the years, but neither the variations for the individual stages nor for the group as a whole are 
significant (Table I).
The corrected survival rates for re­sected rectal cancer are set forth in Table II. Again, the differences in suc­cessive periods were not statistically significant, whether one considers the 
various stages individually or the group as a whole. We noted for cases of stages A, B and C a corrected sur­
vival rate varying from 63.6% to 87.5%, from 33.3% to 23.1% and
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Table III—Cancer of the Colon: Crude Survival Rate by Stage for Patients Treated in Each Time Period
Dukes' stage
1942-1946 
(n = 63)*
1947-1951 
(n = 139)
1952-1956 
(n = 176)
1957-1961 
(n = 183)
1962-1966 
(n = 267)
1967-1969 
(n = 177) X2 Pvalues
A 5 (62.5)f 11 (55.0) 13 (86.6) 17 (56.7) 28 (78.4) 34 (79.1) 9.932 > 0.05 (NS)
B 7 (38.9) 20 (38.5) 34 (58.6) 17 (41.5) 33 (45.8) 36 (66.6) 13.07 < 0.05
C 1  (7.2) _4 (14.3) 2 (6.9) 8 (20.0) 24 (36.9) 16 (41.0) 19.62 < 0.01
Total 13 (32.5) 35 (35.0) 49 (48.0) 42 (37.8) 86 (49.4) 86 (63.2) 27.747 < 0.001
*Numbers (n) include patients with stage D cancer (distant metastases) not considered in this table. 
fNo. (and % )  surviving.
Table IV—Cancer of the Colon: Corrected Survival Rate by Stage for Each Time Period
Dukes' stage 1942-1946 1947-1951 1952-1956 1957-1961 1962-1966 1967-1969 X2 P values
A 4 (66.6)* 11 (68.7) 13 (100.0) 17 (G8.0) 29 (96.6) 34 (85.0) 14.22 < 0.02
B 7 (58.3) ’0 (52.6) 34 (69.4) 17 (56.7) 33 (63.5) 36 (80.0) 8.63 < 0.2 (NS)
C _1_(12.5) 4 (36.4) 2 (14.3) 8 (25.0) 24 (46.2) 16 (55.2) 12.99 < 0.05
Total 12 (46.2) 35 (52.8) 49 (64.5) 42 (48.3) 86 (64.2); 86 (75.4) 20.72 < 0.001
*No. (and % )  surviving.
from 0% to 33.3%, in the first and 
final time periods respectively. These 
differences also are not significant. To­
tally for carcinomas of stages A, B and 
C the corrected survival rate, which 
was 50% in the first period, was only 
52.6% in the last one, a variation that 
is not significant.
Even if, over the years, we noted an 
improvement in the resectability and 
the operative mortality, there was no 
change in the duration of survival after 
the standard surgical treatment of rectal 
cancer. The treatment, namely Miles’ 
abdominoperineal resection, was the 
same throughout the 28 years of our 
study.
4-
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FIG. 3—Carcinoma of colon: percen­
tage of lesions in each stage for each 
time period.
Cancer of the Colon
The numbers of patients treated in 
the six periods of the study are set forth 
in Table III where they are grouped 
according to the stage of disease. In 
each period the distribution of patients 
according to age decade was the same. 
The incidence was highest in persons 
in the seventh decade, but in the latter 
years of the study more patients were 
aged over 70 years. The percentage of 
patients in each stage is indicated in 
Fig. 3.
The operability remained fairly con­
stant over the years, varying only be­
tween 96.6% and 97.3% (y2 =  0.179, 
P >  0.8). The resectability, regardless 
of stage of disease (A, B or C) changed 
significantly. For successive periods it 
was 71.8%, 72%, 86.1%, 88.2%, 
88.9% and 90.4% (y2 =  24.972,
P <  0.001). We noted also a decrease 
in operative mortality after resection of 
cancers of the colon, from 12.1% in 
the first period to 2.9% in the final 
one (y2 =  5.375, P >  0.3).
In cases of colonic carcinoma the in­
cidence of complications (complete ob­
struction or free perforation, or both) 
has always been high. Successively for 
each period it was 22.2%, 21.6%, 
19.3%, 15.8%, 18.7% and 17.4%; 
these variations are not statistically sig­
nificant (y2 =  2.461, P >  0.8).
The crude survival rate showed an 
increase in all three stages (Table III). 
These improvements are statistically 
significant for stages B and C cases. 
For the group as a whole the crude 
survival rate increased from 32.5% in
the first period to 63.2% in the final 
one. This improvement is highly signi­
ficant. The corrected survival rate also 
increased (Table IV) significantly for 
cases belonging to stages A and C. The 
increase in the corrected survival rate 
for the group as a whole, from 46.2% 
to 75.4%, is also significant.
Discussion
Our study of results obtained over a 
28-year period demonstrates that, in 
the case of rectal cancer, even if we 
noted an increase in the resectability 
and in the operative mortality, there 
was no increase of duration of survival 
after standard surgical treatment.
However, when we take account of 
the results in our study of cancer of 
the colon, we can conclude that both 
crude and corrected survival rates have 
improved significantly. During the 28 
years the resectability improved sig­
nificantly (from 71.8% to 90.4%) and 
the operative mortality dropped from 
12.1% to 2.9%. Both factors can in­
fluence the survival rate.
The corrected survival rate, as de­
fined by Bacon,2 evaluates more ac­
curately than the crude rate the form 
of surgical treatment. The former ex­
cludes the nonresected cases, and thus 
avoids the influence of the resectability 
rate. Operative deaths are also excluded 
and thus the effect of the variation in 
operative mortality rate is eliminated. 
The corrected rate also excludes deaths 
from intercurrent disease during the
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5-year follow-up and thus it is not in­
fluenced by (he age of the patients.9A definite improvement is evident over the years. For stages A, B and C cancers the corrected survival rate rose from 46.2% to 75.4%. During the 
entire 28-year period neither radiation therapy, nor chemotherapy nor immu­notherapy were ever used as an adjunct to surgical treatment. None of our sur­geons ever utilized the Turnbull’s no­touch isolation technique. Nevertheless over the years the surgical technique was gradually modified. In the final 
period covered by our study all sur­geons concerned were performing more 
extensive resections with high ligation of the pedicle. All were following the 
practice of Cole intended to prevent dissemination of cancer cells.10
Our latest results for 5-year survival 
in cancer of the colon in stages A, B and C of 85%, 80% and 55.2%, re­
spectively, are comparable to those ob­tained in other centres.11'14 A high 
resectability rate, extended resections 
and the use of Cole’s measures to pre­vent cancer cell dissemination are, we 
believe, common to all series from which superior results are reported.
We finally suggest that, grosso modo, the survival figures for standard sur­gical treatment for stages A, B and C should be 75%, 50% and 25% for
At St. Mark's Hospital in London, 
England there has been a steady 
improvement over 20 years in the results 
of treatment of rectal cancer. The 
resectability rate has reached 95% and 
the overall operative mortality rate has 
declined to 2%. The corrected 5-year 
survival rate is about 70% for all who 
recover from the operation. It is 
unlikely that these figures can be
*Presented at the inaugural meeting of the Canadian Association of General Surgeons, Toronto, Out., May 11 and 12, 1977
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rectal carcinomas, and 90%. 80% and 
55% for colonic carcinomas. These re­sults should be the base from which improvement of survival should be cal­culated in any further investigation or experiment.
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totale est descendue a 2%. Le taux 
corrige de survie a 5 ans est d'environ 
70% pour ceux qui survivent a 
I'operation. Comme il est quasi 
impossible que ces statistiques puissent 
etre ameliorees, I’attention s'est 
portee vers I’emploi de la radiotherapie 
et des agents cytotoxiques d'appoint 
mais, jusqu'a maintenant, aucune 
conclusion definitive n’est possible 
sur les benefices de ces deux modes 
de traitement. Dans le but d’eviter 
une colostomie, on peut envisager une 
excision locale de la tumeur ou le 
recours a une voie d'abord a travers 
le sphincter, mais peu de cas se 
pretent a ces modes operatoires ou 
a leurs alternatives plus radicales.
2. Sphincter-Preserving Operations for Rectal
I a n  P. T odd, m s, m d (tor), frcs
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The management of carcinoma of the 
rectum has altered slowly but conti­
nuously since Dukes1 made the impor­
tant observation that spread occurred 
primarily upwards towards the inferior 
mesenteric pedicle and only later in a 
retrograde or lateral direction. This 
observation was confirmed by Gilchrist 
and David2 and is the basis of surgical 
practice today. As a direct outcome of 
this teaching, anterior resection and the 
modifications of pull-through, sleeve 
resection and peranal anastomoses have 
evolved. Local operations, such as 
peranal and transsphincteric (York 
Mason) excisions,3 have gained ground 
even more recently, again largely 
through application of the original 
Dukes’ classification,1 stages A and B, 
to clinical practice.
To put into focus the place of the 
newer conservative excisions and sphinc­
ter-saving procedures in the manage­
ment of rectal cancer it is essential to 
have some idea of resectability, opera­
tive mortality and 5-year survival rates 
for routine procedures such as com­
bined excision of the rectum and an­
terior resection. At St. Mark’s Hospital, 
London, England, the resectability rate 
for all rectal cancer is around 95%. 
The overall operative mortality for 
rectal cancer is 2%; it is less than 1% 
for combined excision and about 4% 
for anterior resection, the principal sur­
gical techniques used at this hospital. 
The figures for these procedures have 
improved steadily over the past 20 
years and any further improvement 
seems unlikely. Our corrected 5-year 
survival rate for patients with cancer 
of the rectum is around 70% for all 
who recover from the operation. It is 
64% when combined excision is per­
formed and 80% when anterior resec­
tion is selected. To obtain some idea 
of the chances for an individual patient 
one can break down these figures to 
apply to every computation of grade 
of malignancy, Dukes’ staging, degree 
of local spread and presence or ab­
sence of venous involvement.
Since operative mortality and re­
sectability figures are unlikely to 
change, treatment regimens must be 
reconsidered. Can more be done and 
can the quality of life be improved? 
All major centres in the world are now 
concentrating on these issues. Should 
preoperative or postoperative radio­
therapy be given and in what dosage? 
Toronto has been foremost in conduct­
ing one of these trials, but there is still 
no definite answer. At St. Mark’s we 
abandoned, halfway through its course, 
a trial of postoperative radical radio­
therapy, mainly because of the mor­
bidity induced. We still use radio­
therapy for young patients when there 
is a high grade of malignancy but have
no figures in its support. At present 
the British Medical Research Council 
is conducting a multicentre controlled 
trial of preoperative radiotherapy, but 
as yet no figures are available. Three 
regimens are being studied: no treat­
ment; 850 rads immediately preoper- 
atively (as, I believe, was the practice 
in Toronto); and up to 2200 rads over 
a 10-day period immediately preoper- 
atively.
Many trials are being conducted of 
early cytotoxic adjuvant therapy, but 
the results of those reported so far 
have been unimpressive. At St. Mark’s 
Hospital the trial proposed is con­
cerned with the use of neuraminidase- 
treated cells, but the results will not be 
available for several years.
We have therefore to consider im­
proving the quality of life. It is un­
likely that dramatic changes will be 
made in the techniques of combined 
excision and anterior resection. We 
firmly believe in attention to detail: 
careful and early ligation of the pedicle, 
gentleness of dissection, painstaking 
control of bleeding and, above all, 
irrigation of the perineal cavity in the 
case of excisions or of the lumen of 
the bowel when resection has been 
performed. Eighty percent of perineal 
wounds are now completely healed in 
2 weeks through use of the Shirley 
drain and a sump suction apparatus. 
We have thus been able to reduce hos­
pital stay, expense and morbidity. But 
because every patient wants to avoid 
having a colostomy we are trying other 
restorative procedures.
Certain other operations can be per­
formed for tumours very low in the 
rectum and for those at that difficult 
location, 6 to 8 cm from the anus. 
Physical factors have to be taken into 
account: size of the patient and whether 
he or she is obese, sex, breadth of the 
pelvis, size and grading of the tumour, 
condition of the blood vessels, presence 
of other diseases such as diabetes and 
so forth. These are fairly obvious fac­
tors that may militate against some 
operative procedures.
Local excision is now being done 
more often, but figures to some extent 
reflect the recent increase in colono­
scopic removal of malignant polyps. 
We surgeons still take a fairly serious 
view of the surgical local excision pro­
cedure, even though our peranal tech­
niques have improved greatly. Of our 
143 patients with colorectal cancer 
only 24 had a local excision of a sessile 
lesion. In two less than 5 years have 
passed since the operations, so they can­
not be included in a report. In 6 of the 
other 22 the local excision was thought 
to be incomplete, so immediate radical 
reoperation was undertaken. Two had 
a late reoperation (combined excision)
for recurrence and both are well. Only 
14 of the 22 have survived 5 years 
without further procedures. Our method 
of local excision was mainly removal 
per anum of a full-thickness wedge 
with at least 1 cm clearance, and 
closure by direct suture. We have 
treated only four patients using the 
transsphincteric approach, rediscovered 
and popularized by York Mason.3 We 
think this operation has little place in 
the surgical management of rectal can­
cer, though certainly it is useful for 
other problems. The selection of pa­
tients for local excision depends upon 
the presence of certain obvious fea­
tures: the tumour must be small (dia­
meter, <  2.5 cm), proliferative and 
protuberant, not ulcerated, mobile over 
the deeper layers and accessible. It 
must not be of high grade as determined 
from a biopsy. Hence it is not a 
common lesion. Clinical selection and 
staging can be difficult and mistakes 
must be expected.
There are a number of more radical 
alternatives: pull-through procedures, 
sleeve resection and abdominoperanal 
resections where the anastomosis is done 
per anum. We have abandoned the old 
Bacon-Babcock-Black type of pull- 
through procedure and also the Maun- 
sell-Weir or Swenson type of abdomino- 
anal anastomosis. The Kraske proce­
dure has been done only once in the 
last 10 years but perhaps it has a larger 
place. Our own experience with pull- 
through operations for rectal cancer is 
small, comprising only 32 patients up 
to 1967. Of the 23 patients who under­
went a radical procedure 15 survived 
for 5 years. Only six more procedures 
have been done since 1967, of which 
five were considered radical and one 
palliative. In this small series totalling
Table 1— Selection of Operative Procedure for 
Rectal Carcinoma
Height of tumour 
from anal margin, 
cm Preferred operation
13-15 High anterior resection
9-12 Low anterior resection
6-8 Abdominoperineal exci­
sion
Anterior resection and 
peranal anastomosis 
Pull-through 
Local excision 
Peranal
Transsphincteric
Kraske
Fulguration
3-5 Abdominoperineal exci­
sion
Local excision
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38 patients there were three postoper­
ative deaths. Since 1972 there has been 
a tendency to treat the smaller rectal 
tumours at 6 to 8 cm from the anus 
by an abdominoperanal operation. This 
is preferred to the abdominotranssphinc- 
teric operation or the abdomino-Kraske 
procedure or even the Localio opera­
tion as being somewhat less dangerous, 
less traumatic and providing a more 
satisfactory anastomosis. Obviously it 
is too early to report results, but we are 
reasonably pleased with the procedure.
Table I summarizes our position. Re­
member that the grade of malignancy 
and the size and type of tumour must 
be taken into account whenever a 
sphincter-saving operation is undertaken 
for cancer of the rectum. At St. Mark’s 
Hospital we do not yet feel completely 
confident about these newer procedures, 
although we are using them to an in­
creasing extent. We shall wait until a 
larger series provides-us with statistical­
ly sound figures before advocating 
their general use.
References
1. Dukes CE: Cancer of the Rectum, 
Edinburgh, Livingstone, 1960
2. Gilchrist RK, David VC: Considera­
tion of pathological factors influencing 
5 year survival in radical resection of 
the large bowel and rectum for carci­
noma. Ann Surg 126: 421, 1947
3. Mason AY: Trans-sphincteric resec­
tion, in Colon, Rectum and Anus 
fOperative Surgery Series), Rob C, 
Smith R (eds), London, Butterworth, 
1977, p 178
3. Radiation Therapy in Rectal Cancer*
B J . Cummings, m b , ch b, frcp[c] frcr, mracr|
In a number of studies preoperative 
irradiation of cancer of the rectum has 
procured 5-year survival rates higher 
than those obtained with conventional 
surgical techniques, whether or not 
the tumour has spread to lymph nodes. 
There appears, as well, to be a lower 
rate of local recurrence and possibly 
of the development of distant 
metastases. Also, some tumours of 
questionable operability are reduced 
in size to make resection possible.
The effectiveness of postoperative 
radiation therapy is not yet firmly 
established.
Radiation therapy as the primary 
method of treatment of rectal 
carcinoma has been used at the Princess 
Margaret Hospital in Toronto in 79 
patients over a period of 18 years.
The overall 5-year survival rate is 28%; 
this rises to 38% when the tumour 
is not fixed but falls to half this figure 
when fixity of the growth is evident. 
These results offer grounds for
*Presented at the inaugural meeting of 
the Canadian Association of General 
Surgeons, Toronto, Out., May 11 and 
12, 1977
t Radiation oncologist, The Princess 
Margaret Hospital, Toronto
Reprint requests to: Dr. B.J. Cummings, 
The Princess Margaret Hospital, 500 
Sherhourne St., Toronto, Out.
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investigating radical radiation therapy 
as an alternative to surgical methods 
of dealing with low-lying carcinomas 
of the rectum.
Dans un certain nombre d'etudes, 
I’irradiation preoperatoire dans le cancer 
du rectum a procure une survie a 
5 ans superieure a celle qui est obtenue 
avec les techniques chirurgicales 
conventionnelles, qu'il y ait 
envahissement des ganglions 
lymphatiques ou pas. Egalement, il 
semble y avoir un plus faible taux de 
recidives locales et une moins grande 
possibility d’apparition de metastases 
a distance. De plus, quelques tumeurs 
difficilement operables sont reduites 
de taille, rendant la resection possible. 
L'efficacite de la radiotherapie 
postoperatoire n'a pas encore ete 
parfaitement etablie.
La radiotherapie a ete utilisee au 
Princess Margaret Hospital de Toronto 
comme traitement primaire du 
carcinome rectal chez 79 patients, en 
18 ans. La survie a 5 ans a ete de 
28%; ce nombre augmente a 38% 
lorsque la tumeur n’est pas adherente, 
mais il diminue de moitie lorsqu'il y 
a fixation evidente de la neoplasie.
Ces resultats offrent des raisons pour 
examiner la radiotherapie radicale 
comme alternative aux methodes 
chirurgicales pour traiter les carcinomes 
bas du rectum.
Survival rates for patients presenting 
with carcinoma of the rectum and 
treated by surgery alone have not im­
proved substantially over the past 20 
years.1
Patients rarely present early in the 
course of their disease when preserva­
tion of the rectum and anal canal by 
local excision of the growth might be 
possible. Most patients with cancer of 
the lower part of the rectum must still 
undergo a surgical procedure that re­
quires a colostomy. Spread of the 
tumour to lymph nodes or through the 
bowel wall means that more than half 
the patients will die because of their 
cancer, and in many a local recurrence 
will develop.2 For many years it has 
been apparent that better methods of 
treatment are needed, not only to im­
prove survival rates but also to save 
the rectum and anus and thus spare the 
patient a colostomy. There is evidence 
that radiation therapy may achieve 
these aims.
Morson and Bussey3 reported that 
80% of local recurrences followed the 
removal of tumours of the lower two 
thirds of the rectum that had penetrated 
the bowel wall or spread to the local 
lymph nodes. Their 9.7% overall in­
cidence of local recurrence with clin­
ical examination is a minimum figure. 
This is well below the incidence re­
ported in autopsy and surgical series. 
For example, Gunderson and Sosin4 
found local recurrences in 65% of pa-
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tients undergoing a “second-look” op­
eration. The range of these figures 
reflects the difficulty of assessing the 
pelvic contents by clinical means and 
the lack of an accepted definition of 
local recurrence.
Radiation therapy has been added to 
conventional surgical techniques and 
has also been used as the sole treat­
ment for rectal carcinoma.
Preoperative Irradiation
The rationale of preoperative irra­
diation is based on experimental 
evidence that suggests that such treat­
ment will reduce the risk of implanta­
tion of cells dislodged at surgery, 
sterilize unrecognized local tumour ex­
tension and reduce the bulk of large 
tumours to make resection technically 
easier. Comparison between patients 
who receive preoperative irradiation 
and those who are treated by surgery 
alone is made difficult by the lack of 
a clinical staging system for carcinoma 
of the rectum.
However, all trials of preoperative 
irradiation for cancer of the rectum, 
with only a single exception, have 
brought about improvement in survival, 
although not always in the same sub­
groups of patients (Table I5’8). A 
variety of radiation doses and field 
arrangements have been used. In the 
retrospective Memorial Hospital study6 
a dose of 1000 to 1500 rads was given 
to the pelvis, and increased survival 
rates were reported at 5 and 10 years 
for patients who had involved lymph 
nodes. A later nonrandomized study 
at Memorial Hospital,9 in which a 
dose of 2500 rads was given in 
12 days, showed no apparent difference 
in survival rates at 5 years. The large 
randomized trial conducted by the 
Veterans Administration Group7 em­
ployed a preoperative dose of 2000 to 
2500 rads in 12 days. Their patients 
who had abdominoperineal resection 
after preoperative irradiation had im­
proved 5-year survival. In this trial 
patients with and without lymph-node 
involvement benefited. In a Toronto 
study5 a single dose of 500 rads 
was given on the day of operation, and 
improved survival was demonstrated in 
those who had an abdominoperineal re­
section in the presence of positive 
lymph nodes. Stevens, Allen and 
Fletcher,8 reported increased overall 
survival rates with the use of 5000 rads 
given over 5*/i weeks to the primary 
rectal tumour.
Local recurrence rates after preop­
erative irradiation have been lower, 
although again not all subgroups seem 
to have derived equal benefit. In the 
high-dose study of Stevens and col­
leagues8 not a single local recurrence 
developed in the 40 patients who had 
curative resection after 5000 rads. 
Studies in which a lower radiation dose 
was given suggest a greater benefit 
when lymph nodes are positive. How­
ever, these are the patients in whom 
local recurrence rates are highest, and 
it may simply be easier statistically to 
detect improved results in this group.
The effect of preoperative irradia­
tion on rates of development of distant 
metastases is difficult to assess, because 
occult metastases may be missed at 
surgery. The Veterans Administration 
Trial7 does suggest that such rates are 
lower in irradiated patients. More ef­
fective systemic therapy is needed to 
deal with distant metastases, and also 
to help improve control rates for local 
metastases.
Marginally operable tumours have 
been reduced to resectable size in some 
studies. Higher dose radiation therapy 
in the range 5000 to 6000 rads in 5 to 
6 weeks has been used, sometimes with 
additional chemotherapy. Stevens and 
colleagues8 reported the results of treat­
ment of 35 patients with locally fixed 
tumours; of the 20 who subsequently 
underwent surgery 3 lived longer than 
5 years without tumour and 2 others
died without evidence of tumour activ­
ity. Kligerman and Urdaneta-Lafee10 
treated 15 patients with fixed tumours; 
in 13 the tumour became operable, and 
3 of the 9 who subsequently underwent 
resection survived 5 years.
Postoperative Irradiation
Postoperative irradiation has been 
advocated by those who believe 
adjunctive therapy should be offered 
only to those with a statistically high 
risk of local recurrence. The difficulties 
of selecting such patients on the basis 
of operative and pathology reports have 
been demonstrated.11 Also, on theo­
retical grounds, the disturbance to the 
pelvic blood supply caused by surgery 
might produce areas of local hypoxia 
with reduction in the radiosensitivity of 
malignant cells. Postoperative irradia­
tion cannot affect cells that are not 
within the radiation field, and after 
surgery the whole abdominal cavity and 
perineum become potentially conta­
minated. High-dose, wide-field radia­
tion therapy carries a risk of irradia­
tion-induced small-bowel complications. 
None of the preliminary studies have 
progressed far enough to provide sig­
nificant information as to survival,12 
but on clinical grounds local control 
rates appear to be improved. Current 
trials are also studying combinations 
of radiation therapy and chemotherapy 
following surgery. The irradiation of 
established local recurrences produces 
good palliation but few cures.
Primary Curative Irradiation
The use of radiation therapy as a 
primary curative method for cancer of 
the rectum has been reported in three 
widely differing situations. The first 
of these is one in which patients re­
garded as likely to receive only pallia­
tion of their disease have been irradi­
ated, and a small percentage has been 
cured.13 Also, Papillon14 has demon­
strated that, in carefully selected pa­
tients, contact radiotherapy or the in­
sertion of radioactive implants provides 
local tumour control rates similar to 
those obtained with local excision or 
electrocoagulation.
In the third situation, external su­
pervoltage radiation therapy has been 
employed as curative treatment for 
rectal carcinoma. Results in some series 
have been disappointing, with 5-year 
survival rates of about 5% ,13 but the 
radiation techniques used may have 
been inadequate. Studies at the Princess 
Margaret Hospital, Toronto, show that 
results much better than these can be 
achieved with primary curative radia­
tion therapy. Seventy-nine patients 
were so treated between 1958 and 1975. 
Of these, 60 were over 60 years of age,
Table I— Positive Results at 5 Years in Patients w ith Adenocarcinoma 
of Rectum, some of whom Received Irradiation Preoperatively
Reference
no.
Preoperative irradiation 5-year survival following Group w ith
Dose, rad Tim e, d RT +  surgery Surgery alone results
5 500 1 40 10 AP, LN +
6 1000 - 1500 6 - 1 2 39 25 LN +
7 2000 - 2500 10 41 28 All AP
47 34 Curative AP
32 24 AP, LN +
8 5000 33 53 38 C urative resection,
all stages
RT =  preoperative irradiation; AP =  abdominoperineal resection, combined resection etc ., but 
excluding anterior resection; LN +  =  lymph nodes involved by tumour.
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and 30 were over 70 years. Most of 
these patients had locally advanced 
tumours. Those with smaller tumours 
had refused abdominoperineal resec­
tion or were medically unfit for surgery. 
In general, there was only a clinical 
search for distant metastases. It is now 
recognized that in treating some of 
these patients adequate radiation fields 
and doses were not used. The Princess 
Margaret Hospital techniques for irra­
diating carcinoma of the rectum are 
now standardized as far as possible. 
Most of the pelvic contents are irra- 
dated to a tumour dose of 4500 to 
5000 rads given in 18 to 20 fractions 
over a 4-week period using anterior and 
posterior opposed fields on a 25 MeV 
linear accelerator.
The effect of tumour fixation on 
patient survival is shown in Fig. 1. The 
5-year survival for patients with tu­
mours that were not fixed was 38%. 
The results for a comparable group 
are not reported in the surgical litera­
ture, since tumour spread beyond the 
limits of a curative resection cannot be 
discovered in those patients treated by 
radiation therapy. Those with fixed 
tumours had a 5-year survival of 19%. 
This figure obtained with radiation 
therapy is comparable to published re­
sults for extended pelvic resection for 
locally advanced tumours, and to the
FIG. 1— Princess M argaret Hospital 
1958 to 1975. Effect of tum our fixation 
on actuarial survival of patients with 
primary carcinoma of rectum. Patients 
treated by prim ary radiation therapy.
FIG. 2— Princess M argaret Hospital 
1958 to 1975. Results of treatm ent of 
primary carcinoma of rectum by radiation 
therapy (actuarial survival).
results obtained from planned high- 
dose preoperative irradiation and sur­
gery for marginally operable tumours.
Fig. 2 shows that the overall 5-year 
survival rate was 28% and also the 
results when patients are grouped ac­
cording to the surgical management 
they received. Those who had postra­
diation surgery did not fare unexpected­
ly worse than those who did not; they 
include those patients whose tumours 
were not controlled by radiation 
therapy. They also include a group of 
patients who probably underwent un­
necessary surgery. An important ob­
servation by Rider15 has been that the 
rate of regression of some irradiated 
adenocarcinomas of the rectum is much 
slower than that seen in many other 
irradiated tumours, for example, squa­
mous cell carcinoma. Of those patients 
for whom regression information was 
available, in only about 20% had the 
rectal carcinoma disappeared clinically 
3 months after irradiation, and in 10% 
the tumour was still palpable and 
visible 12 months or more later. 
Neither the slow rate ot regression nor 
the finding of morphologically identi­
fiable carcinoma cells in the irradiated 
areas, is in itself proof of failure of 
irradiation. Those patients who under­
went radical surgical procedures after 
radiation therapy did not appear to 
have an unusual incidence of surgical 
complications.
C onclusion
A practical scheme for the manage­
ment of patients with rectal carcinoma 
may be developed from the reported 
studies. An effective form of systemic 
adjuvant therapy has not yet been dis­
covered. Preoperative irradiation offers 
improved local control and survival 
rates, especially if it should be proved 
that the patient has involved lymph 
nodes or spread of the tumour through 
the bowel wall. Postoperative irradia­
tion cannot be given in high doses over 
a wide abdominal field, and until more 
adequate trials are completed it should 
be reserved for known residual tumour 
or be given only in moderate doses.
The evidence from the Princess 
Margaret Hospital experience is that 
radical radiation therapy should be 
investigated as an alternative to surgical 
techniques for low-lying carcinomas of 
the rectum that require removal of the 
rectum and anal canal. Surgery would 
then be used only for locally uncon­
trolled tumours.
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4. Place des Traitements d’Appoint Complementaires 
de la Chirurgie dans les Cancers du Colon et du Rectum
Louis J. Dionne, md, frcs[c], facs, !  A ntoine K ibrite, m d , frcs[c]| 
et Marcel Martin, md, frcs[c]$
Le traitement chirurgical des cancers 
du colon et du rectum, en depit de 
certains raffinements techniques, semble 
avoir atteint ses limites: le taux de 
survie a 5 ans est d'environ 50%. On 
ne peut guere esperer guerir 
chirurgicalement un patient que si la 
maladie cancereuse est locale. Lorsqu'il 
y a atteinte generate, il y a lieu de 
recourir aux therapies adjuvantes visant 
a augmenter I'efficacite du traitement 
conventionnel par destruction des 
cellules tumorales residuelles et des 
micrometastases.
Les auteurs passent en revue les 
etudes publiees sur (’utilisation 
prophylactique de la chimiotherapie—  
thiotepa, 5-fluorouracil et methyl- 
cyclohexyl-chloroethyl-nitrosurea—  
et de I'immunotherapie— bacille 
Calmette Guerin et Corynebacterium  
parvum— comme adjuvants de la 
chirurgie dans le traitement a visee 
curative des cancers colorectaux. Les 
resultats sont generalement peu 
significatifs et souvent contradictoires, 
mais ils indiquent une tendance qu'il 
y a lieu de confirmer.
Suite a leur experience personnelle 
dans la chirurgie des cancers du tube 
digestif les auteurs se sont engages 
dans des etudes cliniques sous I'egide 
d'organismes reconnus. Ils incitent 
les chirurgiens a participer a de telles 
etudes et ils soulignent le rdle que 
doit jouer (’Association canadienne des 
chirurgiens generaux afin de promouvoir 
les essais therapeutiques canadiens.
Surgical treatment of colon and rectal 
carcinoma, in spite of technical
*Presente sous le titre “Place for 
Chemotherapy and Immunotherapy in 
Colorectal Cancer" au congres inaugural 
de VAssociation canadienne des chirurgiens 
generaux, Toronto, Ont., 11 et 12 mai, 
1977
• Chef du service de chirurgie generate, 
I'Hotel-Dieu de Quebec, Quebec, PQ
tAssistant du service de chirurgie generate, 
VHotel-Dieu de Quebec
Les demandes de tires-a-part doivent 
etre adressees au: Dr LJ. Dionne, Service 
de chirurgie generate, I’Hotel-Dieu de 
Quebec, 11 Cote du Palais, Quebec, PQ 
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improvements, seems to have reached 
its limit; the 5-year survival rate is still 
approximately 50%. There is some 
hope of curing a patient by surgery if 
the cancer is localized. If the condition 
is generalized, one must resort to 
adjunctive therapy with a view to 
improving the effectiveness of 
conventional therapy by destroying 
residual tumour cells and 
micrometastases.
The authors reviewed the literature 
pertaining to the prophylactic use of 
chemotherapy— thiotepa, 5-fluorouracil 
and methylcyclohexyl-chloroethyl- 
nitrosurea— and immunosuppressive 
therapy— bacille Calmette Guerin 
and Corynebacterium parvum— as 
surgical adjuvants in the curative 
treatment of colonic or rectal cancers. 
The results generally are not very 
significant and often are contradictory, 
but they indicate a trend that requires 
confirmation.
Based on their own experience in 
the surgical treatment of gastrointestinal 
cancers, the authors are at present 
engaged in conducting therapeutic 
studies under the aegis of recognized 
research groups. They urge surgeons 
to participate in such studies and 
emphasize that the Canadian Association 
of General Surgeons must play a role 
in promoting Canadian therapeutic trials.
Les traitements chirurgicaux classiques, 
tels que pratiques depuis des annees 
dans le cancer du colon et du rectum, 
semblent avoir atteint leurs limites. Les 
divers types de resection decrits depuis 
quelques decennies pour radicaliser la 
resection colique, n’ont guere ameliore 
le pronostic. II en est ainsi des raffine­
ments de techniques pour prevenir la 
dissemination des cellules cancereuses 
lors des manipulations operatoires.1'6
C’est ainsi que Morson et Bussey7 
ont remarque, a juste titre, que la 
chirurgie ne pouvait apporter plus que 
ce qu’elle avait donne. Le raisonnement 
qui amene ces auteurs a cette conclu­
sion s’appuie sur une revue de plus de 
1500 cas de cancers du rectum, traites 
chirurgicalement au St. Mark’s Hospital 
de Londres.
Une analyse plus approfondie des 
causes de deces apres traitement chi­
rurgical a visee curative, permet de 
poser le probleme et d’illustrer le fon- 
dement des therapies d’appoint qui ont 
ete, depuis quelques 10 ans, mises de 
l’avant pour contrer 1’evolution locale 
et generate de la maladie cancereuse.
En effet, pour 100 cancers du rectum 
traites dans un but curatif, le taux de 
survie a 5 ans est d’environ 50% . 
Cinquante patients decederont de leur 
cancer, dont 10% de dissemination par 
vote lymphatique, 20% de recidive 
perineale et 70% de metastases visce­
rates a distance, principalement hepa- 
tiques.8
L’apparition de metastases a distance 
presuppose la circulation de cellules 
neoplasiques depuis la lesion primaire 
jusqu’au foyer de nidation. L’invasion 
veineuse par les cellules tumorales, 
souvent visible sur les prelevements, 
est un facteur favorisant la presence 
de cellules cancereuses dans la circula­
tion et implique habituellement un 
mauvais pronostic. La presence de cel­
lules tumorales dans la circulation 
veineuse de drainage et dans la circula­
tion peripherique varie selon le temps 
operatoire et la technique employee.9
C’est pour prevenir cette dissemina­
tion peroperatoire des cellules cance­
reuses que Cote, Roberts et Strehl10 ont 
recommande certains gestes preventifs 
et que Turnbull11 a decrit la “ no touch 
isolation technique” . Ackerman19 a re­
commande la ligature precoce de l’ar- 
tere principale et des arteres marginales. 
Bien que le but de ces details de tech­
nique soit mis en doute par certains,13 
il est de bonne pratique de les observer 
en cours d’operation.
Si la maladie est locate au moment 
du traitement a visee curative, la chi­
rurgie seule a d’excellentes chances de 
guerir le patient. Par contre, si la 
maladie est generate au moment du 
traitement primaire, la chirurgie seule 
est vouee a l’echec; elle devrait etre 
completee d’un traitement a portee ge­
nerate, pour prevenir la nidation des 
cellules en circulation et leur develop- 
pement sous forme de micrometastases.
Schabel14 a precise cette notion de
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micrometastases et a demontre l’impor- 
tance des cellules residuelles en post- 
traitement. Pour guerir un cancer, il 
faut theoriquement detruire toutes les 
cellules cancereuses, puisque une seule 
cellule residuelle peut se developper et 
donner naissance a des metastases. Un 
nodule de 1 mm de diametre peut con- 
tenir de 105 a 106 cellules.
Dans les cancers a risque eleve, il 
est logique de croire que de multiples 
llots de cellules tumorales existent un 
pen partout dans l’organisme, sous 
forme de micrometastases tel que l’a 
decrit Schabel chez l’animal.
Par ailleurs, revolution fatale de la 
maladie cancereuse est souvent previ- 
sible au moment du traitement a visee 
curative. En effet, le pronostic et revo­
lution peuvent etre determines par l’exa- 
men anatomopathologique et le degre 
d’extension de la lesion primaire. Quand 
la tumeur penetre les couches de la 
paroi, jusqu’a la sereuse et la graisse 
pericolique (Astler-Coller stage B2),15 la 
survie est d’environ 40%. Quand il 
existe une invasion des ganglions 
(Dukes’ C), la survie a 5 ans est de 
l’ordre de 25%.
Le taux eleve de recidive des cancers 
Bz-C suggere la presence de microme­
tastases deja existantes au moment de 
la chirurgie. C’est dans cette situation, 
c’est a dire, lorsque la masse cellulaire 
residuelle est minime, que la therapie 
d’appoint a de bonnes chances d’etre 
efficace.16 En effet, dans le schema de 
Schabel, plus la tumeur est petite, plus 
la loge A est importante, et plus les 
cellules sont actives et attaquables par 
les inhibiteurs chimiques specifiques du 
cycle cellulaire.
La therapie adjuvante s’appuie sur 
l’hypothese que l’efficacite d’un traite­
ment conventionnel peut etre augmen- 
tee par 1’usage complementaire de sub­
stances chimiques, visant a detruire les 
cellules tumorales residuelles et les mi­
crometastases. Adjuvant se dit d’une 
methode qui renforce l’action d’une 
autre.
Et comme exemple, il est classique 
de mentionner l’experience des tumeurs 
de Wilms, traitees conventionnellement 
par chirurgie et radiotherapie et dont 
le pronostic a ete ameliore par l’usage 
de l’actinomycine D en traitement d’ap­
point.17
Nous allons essayer de situer la place 
de ces methodes, soit la chimiotherapie 
et l’immunotherapie, en revoyant quel- 
ques etudes publiees. Nous voulons ega- 
lement en degager les indications et 
finalement nous voulons preciser le role 
que doit jouer l’Association canadienne 
des chirurgiens generaux dans le do- 
maine des essais therapeutiques.
Chimiotherapie Prophylactique
Pour illustrer le travail fait dans le
domaine de la chimiotherapie prophy­
lactique, l’Union internationale contre 
le cancer18 a publie une liste des essais 
therapeutiques en voie de realisation.
La plupart ne datent que de 5 ans 
et ne sont pas termines; les resultats 
publies ne sont que preliminaires et 
partiels et ne permettent pas de tirer 
de conclusion ferme. Ils illustrent ce- 
pendant une tendance qui remet en 
“question” la place des traitements con- 
ventionnels et celle des traitements 
d’appoint. La chimiotherapie est utilisee 
en phases operatoire et postoperatoire, 
sous forme de monochimiotherapie ou 
de polychimiotherapie.
Le VA Surgical Cancer Chemother­
apy Group19 presente une premiere etu­
de de chimiotherapie per- et postopera­
toire. La drogue utilisee, le thiotepa, a 
ete administree aux patients par di- 
verses voies et la posologie a varie selon 
les phases de l’etude. Cette etude ran­
domisee ne permet pas de conclusion 
positive et il en ressort que le thiotepa, 
a la dose employee (dose totale 0.6 a 
0.8 mg/kg) n’a apporte aucune amelio­
ration du taux de survie a 5 ans.
L’etude de Holden, Dixon et Kuzma20 
regroupant 14 hopitaux americains, 
porte sur l’usage du thiotepa comme 
adjuvant postchirurgical. Sur 693 pa­
tients, 337 ont regu la medication. Les 
resultats sont complexes mais non con- 
cluant: ni le temps de latence ni la 
survie ne sont ameliores.
Rousselot,21,22 de St. Vincent’s Hos­
pital de New York a, depuis 1960, 
utilise la chimiotherapie peroperatoire 
comme adjuvant a la chirurgie colo- 
rectale.
Dans le but de detruire les cellules 
disseminees dans la lumiere colique au 
cours de l’intervention, les cellules cir- 
culant dans le systeme porte et les 
cellules en circulation dans les veines 
peripheriques, le 5-fluorouracil (5-FU) 
a ete utilise en injection intraluminale 
(10 mg/kg) au moment de l’interven- 
tion et par voie intraveineuse durant les 
2 premiers jours postoperatoires (30 
mg/kg).
Il ne s’agit pas d’une etude rando­
misee; le controle est historique, par 
comparaison avec les resultats du traite­
ment chirurgical des cancers du colon 
et du rectum traites au St. Vincent’s 
Hospital pendant la meme periode et 
ceux des statistiques nationales ame- 
ricaines.
Compte tenu de la faible morbidite, 
cette etude parait valable et traduit une 
tendance vers laquelle la therapeutique 
doit s’orienter. Dans les stades III 
(Dukes’ C), le 5-FU semble avoir ete 
plus efficace, la survie a 5 ans etant 
le double de celle de la serie temoin; 
apres 8 ans d’observation la difference 
se maintient.23
Du Medical College of Virginia une 
etude randomisee faite par Lawrence
et collegues24 de 1968 a 1973, portant 
sur une serie de 156 patients dont 80 
regurent du 5-FU comme adjuvant 
postchirurgie, apporte des conclusions 
contraires et negatives. Lawrence utilise 
la chimiotherapie peroperatoire en vue 
de prevenir la dissemination chirurgi- 
cale des cellules cancereuses et com­
plete par une chimiotherapie a long 
terme par voie buccale, pour prevenir 
le developpement des micrometastases 
viscerales.
En conclusion, ni l'intervalle libre, 
c’est a dire, le temps avant recidive, ni 
la survie, n’ont ete ameliores par le 
traitement prophylactique. Il n’y a pas 
de difference significative dans le taux 
de survie a 4 ans, entre le groupe traite 
par chirurgie seule et le groupe traite 
par chirurgie et 5-FU.
Grage2’ du Central Oncology Group 
presente les resultats d’une etude ran­
domisee prospective au cours de la­
quelle 204 patients sur 372 ont regu 
un traitement postoperatoire d’appoint 
au 5-FU par voie intraveineuse. Le 
protocole est le suivant: 12 mg/kg par 
jour, pendant 4 jours, suivi de 6 mg/kg 
a tous les 2 jours pendant 5 jours, et 
finalement 12 mg/kg par semaine pen­
dant 1 annee. La toxicite est rarement 
severe et une leucopenie survient chez 
50% des patients traites. La majorite 
des patients a ete suivie de 6 mois a 
3 ans, et la survie a ce jour est a peu 
pres identique pour les deux groupes, 
soit 68% des patients vivants et sans 
signe de maladie apres un traitement 
d’appoint par comparaison a 63% de 
ceux traites par chirurgie seule.
Li et Ross26 de Californie ont traite 
un groupe de 213 patients porteurs de 
cancer colorectal, dont 183 etaient aux 
stades II et III. La chimiotherapie (5- 
FU) fut administree de la fagon sui- 
vante: 1 g de 5-FU par voie intra­
veineuse le ler jour, 500 mg les 4 
jours suivants, suivi 4 semaines plus 
tard d’un second cycle identique de 
chimiotherapie. L’amelioration du taux 
de survie a 5 ans dans les groupes de 
tumeurs classe C est de l’ordre de 
33.2%, tandis que pour le groupe de 
tumeurs classe B, 1’amelioration du taux 
de survie est de 23.1%. L’augmentation 
globale de la survie a 5 ans est de 
l’ordre de 28.1%. Cette etude n’est pas 
randomisee, le groupe temoin est cons­
titute de patients traites par chirurgie 
seule par l’auteur durant les 5 annees 
qui ont precede l’essai. Une chimio­
therapie de courte duree, a doses non- 
toxiques, semble avoir donne des re­
sultats tres interessants.
Apres avoir essaye, sans resultats, le 
thiotepa et le 5-FU en per- et postope­
ratoire, le Veterans Administration Sur­
gical Adjuvant Group27 a entrepris deux 
autres etudes prospectives, randomisees, 
comparant la chirurgie seule et la chi­
rurgie plus 5-FU.
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Les 1118 patients furent divises en 
trois groupes (A, B et C) selon l’examen 
anatomopathologique du specimen chi- 
rurgical.
Dans une premiere serie, l’injection 
de 5-FU (12 mg/kg'j, iv, pendant 5 
jours) se donne aux 2e et 6” semaines 
apres l’operation; dans la seconde serie, 
le 5-FU se donne en cycles repetes, 
durant 18 mois.
Dans tous les groupes, la survie est 
meilleure pour les patients qui requrent 
du 5-FU, bien que les resultats ne soient 
pas statistiquement significatifs.
L’Eastern Cooperative Oncology 
Group, du Docteur Paul Carbone, a 
propose deux protocoles (2276 et 4276, 
non-publies) pour etablir un traitement 
d’appoint a la suite d’une resection a 
visee curative d’un cancer du colon et 
du rectum de type B2 et C. Le traite­
ment vise a comparer l’effet du 5-FU 
seul (450 mg/m2 iv, id pendant 5 jours 
a toutes les 5 semaines) ou du 5-FU 
(325 mg/m2 iv, les lers et 5e jours et 
375 mg/m2 iv, les 36 et 40 jours) 
plus methylcyclohexyl-chloroethyl-ni- 
trosurea (MeCCNU) (130 mg/m2 per 
os, le ler jour seulement a toutes les
10 semaines) pour les cancers situes 
au-dessus du repli peritoneal (non- 
publie); pour les cancers du rectum la 
radiotherapie (de 4500 a 5100 rads) 
s’ajoute a la chimiotherapie (non- 
publie). Les traitements chimiothera- 
peutiques doivent se poursuivre pour 
un total de 15 cycles avec un intervalle 
de 5 semaines entre chaque cycle, pour 
ceux qui reqoivent du 5-FU seul, et 
pour un total de 8 cycles avec intervalle 
de 10 semaines, pour ceux qui reqoivent 
du 5-FU et du MeCCNU.
Le but de ces etudes vise principale- 
ment I’amelioration du taux de la survie 
et de la periode de latence; elles per- 
mettront egalement de comparer les 
resultats de la monochimiotherapie a 
ceux de la bichimiotherapie. Aucun re- 
sultat n’est disponible a date, puisque 
ces protocoles n’ont pas assez de recul.
Immunotherapie Prophylactique
Le principe de Timmunotherapie s’ap- 
puie sur la capacite immunitaire anti- 
tumorale d’un individu qui, pour une 
raison inconnue, serait inefficace ou 
faible et qui pourrait etre effectivement 
stimulee par des vaccins.28
La maladie cancereuse serait due a 
la presence permanente de cellules neo- 
plasiques dans l’organisme. En effet,
11 semble qu’il y aurait constamment 
dans 1’organisme des cellules tumorales 
en croissance qui seraient regulierement 
eliminees soit par un processus de de­
fense immunologique de l’hote, soit par 
d’autres mecanismes. Le cancer se de- 
veloppe lorsque cette defense vient a 
faire defaut; ce fait peut se verifier 
chez les patients cancereux en phase
avancee, dont la plupart montrent une 
immunocompetence generale diminuee.
Morton et collegues29 ont fait la 
preuve de faction benefique de l’immu- 
notherapie dans les melanomes stade II, 
apres excision locale large et lympha- 
denectomie. Apres deux ans, 70% des 
patients ayant eu une immunotherapie 
adjuvantielle sont libres de toute mala­
die, tandis que 40% seulement du 
groupe controle n’ont pas de signe de 
maladie.
L’experience de Timmunotherapie 
dans le traitement des macrometastases, 
c’est a dire, chez les patients ayant un 
cancer avance, n’a donne pratiquement 
aucun resultat.18 Cependant, Israel30 
pretend que Timmunotherapie ne de- 
vrait pas etre reservee seulement aux 
patients qui n’ont qu’un minimum de 
cellules residuelles.
Dans le tableau suivant, on peut 
constater que les essais therapeutiques 
en immunotherapie31 sont de date re- 
cente, que la quantite de patients traites 
est faible, que la surveillance est de 
courte duree, rendant les resultats dif- 
ficiles d’interpretation. La majorite uti­
lise Timmunotherapie active nonspeci- 
fique ou Tassociation chimioimmuno- 
therapie. Certaines etudes ne sont pas 
randomisees et utilisent, comme te- 
moins, des controles historiques.
Dix-neuf institutions americaines, re- 
groupees dans le Southwest Oncology 
Group,32 ont participe depuis mars 1975 
a une etude randomisee comparant la 
chimiotherapie et la chimioimmunothe- 
rapie dans les cancers localement avan- 
ces du gros intestin (Dukes’ B2 et C), 
recevant un traitement a visee curative. 
Tous les patients ont requ du MeCCNU 
par la voie orale, et du 5-FU en injec­
tion, a toutes les 3 semaines. La moitie 
de ce groupe recevait, en plus, du BCG 
par voie orale (Connaught bacille Cal­
mette Guerin [BCG] 6 x 10s organis- 
mes) a toutes les 2 semaines. L’etude, 
trop recente, quoique comptant 130 
patients, ne nous offre aucune conclu­
sion. Elle vise cependant a juger de 
Tefficacite de la polychimiotherapie et 
de la chimioimmunotherapie.
Mavligit,33,34 du M.D. Anderson Hos­
pital, presente Texperience d’une etude 
prospective nonrandomisee dans les 
cancers colique classe Dukes’ C. Cent 
vingt-et-un patients ont ete admis a 
l’etude; 52 requrent du BCG en scarifi­
cation et 69 une combinaison chimio­
immunotherapie de 5-FU et BCG. Le 
5-FU (150 mg/m2, qid) est administre 
pendant 5 jours a tous les 28 jours pen­
dant 2 ans. Le BCG se donne en scari­
fication une fois par semaine pendant 
3 mois, puis aux 2 semaines par la 
suite.
Utilisant comme temoins des patients 
traites par chirurgie seule, au M.D. 
Anderson Hospital pendant une periode 
de 10 ans, Tauteur rapporte une
difference statistiquement significative 
touchant Tintervalle libre et la survie. 
En effet, le temps de recidive et le 
pourcentage de survie des cancers 
Dukes’ C, traites par chimioimmuno­
therapie, semblent rejoindre ceux des 
cancers Dukes’ B, traites par chirurgie 
seule. D’apres Mavligit, il semble done 
que Timmunotherapie, avec ou sans 
chimiotherapie, puisse ameliorer la sur­
vie des cancers du colon.
Ce groupe du M.D. Anderson Hos­
pital vient de commencer un nouvel 
essai therapeutique combinant Timmu­
notherapie et la chimiotherapie (5-FU, 
Corynebacterium parvum et BCG).
Le BCG seul a ete utilise avec suc- 
ces en instillation intrapleurale dans les 
cancers operables du poumon, par Mc- 
Kneally et Maver35 Falk et collegues35 
de Toronto ont utilise le BCG en instil­
lation intraperitoneale (2 mg) et par 
voie buccale (120 mg) combine avec 
chimiotherapie (5-FU et cyclophospha­
mide) pour les cancers du tube digestif 
en metastase. Les resultats paraissent 
valables et permettraient de faire un 
essai identique pour les cancers du 
colon traites dans un but curatif.
Notre Experience
Bien que nous ayons une experience 
chirurgicale de longue date dans le 
domaine des cancers du tube digestif, 
notre interet aux therapies d’appoint est 
recente, partielle et sans influence sta- 
tistique sur nos resultats a date.
Personnellement, c’est depuis 1970 
que nous appliquons, pour les patients 
subissant une operation dans un but 
curatif, une technique adjuvante selon 
le protocole de Rousselot, c’est a dire, 
le 5-FU en injection intraluminale per- 
operatoire suivi d’injection intravei- 
neuse les 2 premiers jours postopera- 
toires.
Les techniques chirurgicales que nous 
avons toujours utilisees ont ete classi- 
ques et radicales. Pour les adenocarci- 
nomes situes sous le repli peritoneal 
(<  10 cm de la marge de l’anus) 
nous pratiquons la resection de type 
perineoabdominale decrite par Lloyd- 
Davies37 a deux equipes chirurgicales 
qui travaillent simultanement. La phase 
perineale de Toperation est plus radicale 
et plus extensive que celui de la resec­
tion abdominoperineale de Miles.38 
C’est ainsi que Texcision des muscles 
releveurs de l’anus se fait tres laterale- 
ment et que, chez la femme le septum 
rectovaginal est excise.
Les resultats de notre experience 
avec les cancers du rectum traites chi- 
rurgicalement sont comparables aux 
statistiques connues, la survie globale 
est a 51%, la mortalite operatoire est 
de 2.8%, et le taux de recidive locale 
est de 10%. Dans les cancers locale­
ment avances, les resultats sont pau-
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vres, ce qui met en evidence de fagon 
irrefutable l’importance de faire une 
therapie adjuvante des cancers de classe 
Cl et C2.
Voila pourquoi le groupe que nous 
dirigeons a l’Hotel-Dieu de Quebec 
s’est interesse aux essais therapeutiques 
depuis 5 ans. Une centralisation ad­
ministrative a permis d’elargir cette 
sphere d’activite a plusieurs types de 
cancers, a plusieurs hopitaux et a plu­
sieurs participants, sous l’egide d’or- 
ganismes nationaux. C’est ainsi que 
nous participons aux essais therapeu­
tiques du National Surgical Adjuvant 
Breast Project et du Institut National 
du Cancer du Canada.
Depuis 6 mois, nous avons rejoint 
le groupe du Carbone et sommes deve- 
nus membres de l’Eastern Cooperative 
Oncology Group.
Conclusion
Cette revue de la litterature nous a 
permis de faire le point sur les traite- 
ments d’appoint dans les cancers coli- 
ques et de voir se confirmer ce que 
nous avons preconise il y a 10 ans 
pour les cancers dont l’examen patho- 
logique laisse supposer un mauvais 
pronostic.8
Malgre des resultats peu significatifs, 
souvent contradictoires, nous croyons 
qu’il se degage une tendance qu’il faut 
suivre et qui permet de rationaliser 
notre therapeutique.
En effet, pour ameliorer le taux de 
guerison des patients qui vont eventuel- 
lement developper une recidive ou des 
metastases, et chez qui, nous pouvons, 
au moment du traitement chirurgical 
primaire, prevoir cette evolution par 
l’examen anatomopathologique, il nous 
semble que “l’abstention” soit un cons­
tat d’echec. Personnellement, nous ne 
pouvons l’accepter.
Quelle devrait etre l’attitude des chi- 
rurgiens generaux? Maintenir le statu 
quo, c’est a dire, continuer a n’utiliser 
que Fexcision chirurgicale radicale et 
n’accepter aucune amelioration du 
pourcentage de guerison? Connaissant 
les causes d’echec, ne serait-il pas plus 
logique d’essayer de prevenir par des 
methodes connues, peu morbides, la 
nidation des cellules tumorales en cir­
culation et le developpement des micro- 
metastases?
Le stade pathologique de la maladie, 
tel que determine par l’examen mi- 
croscopique du prelevement chirurgical, 
fournit les criteres qui permettent de 
selectionner les patients pour qui un 
traitement d’appoint nous parait s’im- 
poser. En effet, le pronostic des ade- 
nocarcinomes du colon et du rectum 
depend du degre d’extension parietale 
et extracolique, du grade histologique, 
de l’invasion lymphatique et ganglion- 
naire et de l’invasion veineuse.
L’utilisation des marqueurs39 biochi- 
miques (hydroxyproline urinaire, fer- 
ritine) et immunologiques (antigene 
carcino-embryonnaire, a-foetoproteine, 
et antigenes associes a la tumeur) per- 
mettraient de bien diviser les cancers 
selon leur stade et offriraient une plus 
stride selection. En attendant, il faut 
se fier a Fexamen anatomopatholo­
gique.
Chez ces patients a risque eleve, il 
faudrait done completer Fexcision chi­
rurgicale classique radicale par l’une ou 
l’autre des methodes d’appoint.
Pour etre pratique cependant, et pour 
que toutes ces techniques experimen- 
tales d’appoint soient utilisables pour 
la majorite des patients a risque eleve, 
elles doivent etre simples d’application, 
etre faibles en morbidite, sans mortalite 
et etre a la portee de tout centre 
regional.
Pour ce faire, il faut cependant que 
les chirurgiens acceptent de participer 
a des essais therapeutiques stricts, dont 
les indications sont bien specifiques, la 
selection des patients honnete et sous 
la direction immediate d’un responsable 
regional ou d’un organisme provincial 
ou national.
C ’est uniquement dans un tel cadre 
qu’un chirurgien peut s’aventurer dans 
ces types de traitements qui sont avant- 
gardistes et encore experimentaux. 
Ainsi, pourra-t-on accumuler dans un 
temps relativement court, des donnees 
valables statistiquement et fournir des 
reponses a toutes ces questions depuis 
si longtemps debattues.
En 1974, l’lnstitut National du Can­
cer a tente en vain de mettre en branle 
un essai therapeutique pour le cancer 
du colon. Tout recemment, un groupe 
de travail du Cancer Research Co­
ordinating Committee presentait aux 
membres participants de l’lnstitut du 
Cancer du Canada, un projet d ’essai 
therapeutique pour les cancers de classe 
B2, Ci et C2, traites chirurgicalement.
L’Association canadienne des chirur­
giens generaux se doit de faire oeuvre 
de pionnier au Canada dans le domaine 
des cancers du tube digestif et princi- 
palement du colon et du rectum. L’as- 
sociation doit promouvoir les essais 
therapeutiques canadiens de concert 
avec le Conseil medical de la recherche 
du Canada et l’lnstitut du cancer du 
Canada.
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5. Panel Discussion on Carcinoma of the Colon and Rectum
Chairman: E.B. Tovee, md, frcs(edin), frcs[c], facs|
Panelists: B.J. Cummings, L.J. Dionne, A.B. Peloquin and I.P. Todd
Dr. Tovee: How do the members of 
our panel stage carcinoma of the rec­
tum?
Mr. Todd: I think we all recognize that 
it is possible to stage only a proportion 
of rectal malignant growths. As many 
as 50% are not palpable. In addition 
there are those that are obviously very 
advanced. We are left with quite a 
small percentage to which we can as­
sign a stage. One must take into 
account all the physical findings, and 
these include any protuberance as well 
as ulceration and mobility. Very rarely 
can one feel retrorectal glands. If there 
is a palpable retrorectal gland, I know 
the case is an advanced one and that 
more than local treatment is necessary. 
Dr. Tovee: Dr. Cummings, you are at 
a disadvantage because you’re not 
like the surgeon who can use the knife 
to find what the specimen looks like, 
and send it to the pathologist for ex­
amination. You must have some special 
method of staging tumours.
Dr. Cummings: I recognize that it’s im­
portant to know the extent of a tumour, 
but I wonder if in some tumours we 
don’t attach too much importance to 
staging. Certainly in regard to rectal 
tumours, there is no question that 
Dukes’ staging system has been of tre­
mendous help in estimating prognosis. 
It does not, of course, determine treat­
ment. It may affect treatment when we 
consider the field of adjuvant therapy, 
which today means the field of post­
operative adjuvant therapy. Has the 
time not come when we must decide 
on some form of clinical staging? The 
UICC tried to do this some years ago 
and, as you are aware, TNM staging 
was abandoned in 1967. The difficulty 
with clinical staging is that the only 
unequivocal finding is the size of the 
primary growth, which is quite unre­
lated to any other features of the case.
*Conducted at the inaugural meeting of 
the Canadian Association of General 
Surgeons, Toronto, Ont., May 11 and 
12, 1977
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The techniques that we have been 
investigating in a preliminary way at 
the Princess Margaret Hospital include 
perirectal node scanning, which has 
been developed along the same lines 
as internal mammary node scanning 
used in breast carcinoma. We are also 
trying to devise a system similar to 
that advocated by Feinstein who de­
fined certain clinical markers that en­
abled him to venture a vague prognosis 
for the patient. As a radiotherapist, I 
can tell you how I arrive at a clinical 
staging. I can tell whether the tumour 
is mobile or not; if it is not, I cannot 
be sure whether its fixity is due to an 
inflammatory or a malignant process. 
With the patient under anesthesia I can 
determine whether it infiltrates the 
bladder. I can do a liver scan and incur 
all the problems that it may involve. 
I can do lymphangiography, which will 
tell me nothing about the lymph nodes 
below the bifurcation of the aorta in 
this disease. I can do a bone scan, 
which may or may not be useful, al­
though it has been advocated in this 
disease. I can do a carcinoembryonic 
antigen determination which tells me 
nothing whatever about the stage of 
the disease. I can record a lot of 
information, but really we are left 
with a clinical decision — “Is this 
tumour confined within the pelvis or 
not?” And at this stage I don’t think we 
have advanced beyond that. I wish we 
did have a reliable clinical staging sys­
tem because then I could claim that 
our 79 cases are as good as, or are 
better, or are worse than any other 
surgical series, but at the moment I 
cannot do that. Neither can I tell you 
what happens after high-dose preopera­
tive irradiation, because any preopera­
tive treatment must alter the stage. It 
is wrong to talk about operative staging 
without specifying whether the patient 
has had preliminary treatment.
Dr. Tovee: Dr. Dionne, what do you 
do when confronted with carcinoma of 
the rectum in a patient on the operating 
table when that patient has gross hepa­
tic metastases? Would you do a palli­
ative anterior resection, an abdomino­
perineal resection or a proximal colos­
tomy, or would you do nothing and 
treat the patient with chemotherapy?
Dr. Dionne: I recall reading about a 
series of 12 patients who survived 10 
years after an abdominoperineal resec­
tion, at which time the surgeon noticed 
that there were liver secondaries. Mind 
you, these were very good surgeons 
because they were from St. Mark’s Hos­
pital. This report gives me help in an­
swering your question. If you are ab­
solutely sure that there is a metastasis 
in the liver, then the steps you take 
depend on how large it is, what the 
expectation of life is and the effect 
your operation will have on the quality 
of life for that individual. If you are 
not sure, you think there is a metastasis 
but you’re not completely sure, I think 
you should excise the lesion.
Dr. Tovee: Any other comments? Dr. 
Peloquin?
Dr. Peloquin: I agree entirely that all 
the tumours that can be resected must 
be excised even in the presence of hepa­
tic metastases. When the primary tu­
mour either in the rectum or in 
the colon was resected, the survival 
rate at 2 years was as high as five 
times the rate when a resection was 
not done. The reason for this is not 
understood but it is believed by many 
surgeons. Even at the beginning of this 
century some surgeons realized that 
when you resect the primary tumour 
you may arrest or retard the growth of 
hepatic metastases.
Dr. Tovee: Mr. Todd, this next ques­
tion is directed to you. Are there any 
technical problems in performing re­
section and anastomosis if the patient 
has had preoperative irradiation, espe­
cially if this has been administered in 
several doses?
Mr. Todd: With the regimen that has 
been used in the trials in England, no 
problems have arisen from this form 
of management. I’m still slightly wor­
ried, I must admit, about anterior re­
sections, and one of my colleagues at 
St. Mark’s won’t allow preoperative 
irradiation because he claims he can’t 
always decide whether he’s going to 
excise the rectum or do an anterior 
resection until he has opened the ab­
domen and he is worried about break­
down of the anastomosis after the ad­
ministration of 2000 rads. I personally
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don’t think that we’ve had any serious 
problems as a consequence.
Dr. Cummings: May I make a com­
ment? In the recorded series where the 
dose range has been that used in the 
United Kingdom, namely 2000 rads 
given over 2 weeks or a single dose of 
500 rads, there has been no increase 
in the complication rate. One such 
randomized series is the Veterans Ad­
ministration study in which most pa­
tients, it is true, were treated by 
abdominoperineal resection; however, 
in approximately 200 cases other types 
of resection were used and the compli­
cation rate was not increased. If as 
high a dose as 6000 rads is given over 
6 weeks, as reported by Stevens from 
Oregon, anterior resection was deliber­
ately avoided at first because of fear 
about the anastomosis. By now they 
have experience of 4 out of 50 cases 
in which they have safely done an 
anterior resection. In Kligeman’s report 
from the southern United States, 4500 
rads is given and the type of operation 
is left to the discretion of the surgeon; 
no problems are recorded with anterior 
resection in a relatively small number 
of patients. I myself would think that 
the dose could safely reach about 4500 
to 5000 rads. I would be worried about 
levels higher than that.
Dr. Tovee: Mr. Todd, what’s the best 
operation for rectal villous adenoma? 
Mr. Todd: It depends on where the tu­
mour is situated. It’s an almost im­
possible question to answer because one 
needs to know more details. Is it a 
proliferative lesion, is it a carpet type 
of lesion, does it extend over a major 
part of the circumference of the rec­
tum? One has seen some tumours that 
cover many square inches, just as a 
carpet. I think this is one situation 
where a transsphincteric operation has 
a place. The proliferative tumours 
sometimes may be dealt with by local 
excision. On occasions they can even 
be snared. Of course if the villous type 
of tumour becomes malignant it tends 
to be highly malignant and therefore 
these patients need to be watched ex­
tremely carfeully. My colleague, Mr. 
Parks, does sleeve resections for some 
of these, which he thinks is a safer 
procedure.
Dr. Tovee: Dr. Dionne, do you do 
local perfusion of the liver for meta- 
stases from carcinoma of the colon and 
rectum and what are the indications for
so doing?
Dr. Dionne: I treated some cases of 
liver metastases or perineal recurrences 
in this way with very poor results. Fol­
lowing the trend throughout the world, 
I abandoned the procedure completely. 
Dr. Tovee: Dr. Cummings, what hap­
pens to anal function after curative 
irradiation?
Dr. Cummings: After curative irradia­
tion for carcinoma of the rectum 
anal function will remain normal unless 
the tumour has already infiltrated the 
anal sphincter. If that has already hap­
pened you proceed to destroy the tu­
mour with radiation. Healing will be 
by fibrosis, as after any procedure, and 
if the patient initially was incontinent 
owing to this cause, then he is likely 
to remain so. There is no specific effect 
of the radiation as we deliver it that 
will destroy a normally functioning anal 
sphincter.
Dr. Tovee: Would you tell us a little 
more about the complication rate from 
radiation used in the treatment of carci­
noma of the rectum?
Dr. Cummings: With moderate-dose 
preoperative irradiation, as commonly 
used, complications are probably not 
significant. For postoperative irradia­
tion, the data are not yet available. 
From analogy with the treatment of 
other tumours and from reported 
studies, it is quite apparent that you 
should not give high-dose wide-field ir­
radiation to most of the pelvic and ab­
dominal contents. A total of about 70 
to 80 cases have been recorded in the 
literature where high doses, and by that 
I mean doses in excess of 5000 rads 
in 4 to 5 weeks, have been given to 
the whole of the pelvis and lower ab­
domen. Follow-up ranges from 12 
months to 7 or 8 years. Complications 
have developed and there have been 
radiation-induced deaths. What I call 
acceptable irradiation is a dose of 
4500 rads given over 4 weeks, and that 
can be given safely to the whole of 
the pelvis. In addition, one can give 
probably 2000 to 2500 rads to the 
whole of the upper abdomen including 
the liver, and that is quite tolerable. 
We have very wide experience with that 
sort of radiation in treating patients 
with carcinoma of the ovary and I 
think that, provided you control the 
dose, it is safe. Higher doses, I think, 
are dangerous. After radical irradiation 
such as we are using at Princess Mar­
garet Hospital for certain patients with 
carcinoma of the rectum, there has 
been moderate morbidity. I think every 
patient had troublesome diarrhea. If 
the tumour can be reached by the 
examining finger, we now deliberately 
irradiate the entire perineum to almost 
full dose because we found that 
otherwise these tumours recurred 
around the anal canal. Patients will 
have a moist reaction at the perineum 
and most will require bed rest for 
perhaps a week, although some of them 
in fact continue working. Healing takes 
place normally. A small proportion, 
about 3%, will have significant small- 
bowel morbidity. This figure is of the 
same order as after irradiation for car­
cinoma of the cervix. I can’t be more 
precise because a number of these pa­
tients die from uncontrolled tumour 
and it’s often impossible to distinguish 
side effects of irradiation from the ef­
fects of uncontrolled tumour. Provided 
the dose is controlled and the patient 
is watched carefully, the morbidity is 
acceptable.
Dr. Tovee: Dr. Peloquin, would you 
tell us what you do with the perineum 
that won’t heal after an abdomino­
perineal resection?
Dr. Peloquin: Usually it does heal, al­
though sometimes not very fast. You 
must be patient and wait. After a cer­
tain length of time one sometimes has 
to go back and try to do a second stage 
procedure.
Dr. Tovee: Mr. Todd, tell us, then, 
what you do for the perineum that 
fails to heal.
Mr. Todd: I think the most important 
thing is to have very good hemostasis 
or what you think is very good hemo­
stasis of the perineum before you close 
it, or whatever you do with it. Re­
cently we have closed the perineum in 
the male entirely and we have put in 
Shirley sump sucker drainage. I usually 
use only a single suction apparatus, but 
I have been very surprised that in the 
first 24 hours about 500 mL of what 
looks like pure blood collects in the 
sucker. Hence, no matter how dry you 
think you leave it, the perineum is 
actually not very dry. This is the first 
thing that matters. If you can’t obtain 
complete hemostasis, I certainly would 
not suture it completely, but would 
insert a small piece of corrugated drain 
and leave it in situ for 48 hours. I 
don’t believe in irrigating the wound 
unless a lot of blood collects; then I 
sometimes do irrigate it. Usually I do 
not use skin grafts for malignant cases. 
However, in cases of inflammatory 
bowel disease, which I find are prob­
ably more difficult to heal, I try to 
make the wound into an acceptable 
shape and then apply a xenograft and 
later a homograft.
Dr. Tovee: Have any of the panelists 
any thoughts about the value of the 
procedure of enclosing the suture line 
of an anterior resection with omentum? 
Is it worth while trying?
Mr. Todd: I bring down the omentum 
if it can be done easily, but I don’t 
make any special effort to mobilize it. 
One of the most important things in 
an anastomosis is a good blood supply. 
We acknowledge this, but a num­
ber of surgeons, I think, tie their su­
tures far too tightly and cut off the 
blood supply. A piece of omentum 
whose blood vessels you have tied in 
mobilizing it is not in the least helpful. 
If you can lay it easily in the neigh­
bourhood of the suture line, do so, 
otherwise forget it!
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Symposium on Pancreatitis
1. Conservative Management of Acute Pancreatitis*
Roger G. Keith, md, frcs[c], frcs, facs
Acute pancreatitis may present as the 
mild edematous type or the more rare 
and dangerous hemorrhagic form. The 
effects of the latter are believed 
to be due to the activation of pancreatic 
enzymes, notably trypsin. Therefore 
attempts are being directed towards 
suppression of pancreatic enzyme 
activation in the management of the 
condition. Aprotinin and glucagon are 
the agents for this purpose that have 
received most attention.
Patients with acute hemorrhagic 
pancreatitis are subject to respiratory 
failure, which is not detectable early 
by clinical evidence, so that early 
monitoring of pulmonary function by 
the determination of arterial blood-gas 
pressures is desirable. This is borne 
out by the findings in six fatal cases.
La pancreatite aigue peut etre du type 
oedemateux benin, ou prendre la forme 
hemorragique, dangereuse et plus 
rare. Dans ce dernier cas, les effets 
sont possiblement dus a I’activation des 
enzymes pancreatiques et, notamment, 
de la trypsine. Dans le traitement de 
cette affection, on essaie done de 
supprimer I'activation des enzymes 
pancreatiques. L'aprotinin et le glucagon 
sont les produits utilises a cette fin 
ayant recu le plus d’attention.
Les patients souffrant de pancreatite 
hemorragique sont sujets a une 
insuffisance respiratoire qui ne peut 
decelee tot a partir du tableau clinique. 
Une surveillance precoce de la 
fonction pulmonaire par la mesure des 
pressions gazeuses du sang arteriel 
est done souhaitable. Ceci est continue 
par les observations faites dans six 
cas mortels.
The Marseilles classification of pan-
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creatitis correlates the clinical and pa­
thological aspects of acute and chronic 
forms of the condition.1 Beyond that 
classification two forms of acute pan­
creatitis are recognized. Acute edemat­
ous pancreatitis, so called to indicate 
the pathologic state, is the mild form 
of the disease, which comprises about 
80% of all cases of acute pancreatitis.8,3 
Acute hemorrhagic pancreatitis, char­
acterized by parenchymal necrosis and 
hemorrhage, presents the risk of major 
complications and death.4-6 Clinical dif­
ferentiation between the two states at 
initial presentation is usually impos­
sible; the distinction is evident only in 
retrospect.
Acute hemorrhagic pancreatitis is a 
dynamic condition that may progress 
to a state of irreversible shock and 
organ failure through three major 
mechanisms. Hemorrhage occurs early 
and is usually restricted to the local 
peripancreatic tissues. Elastase plays a 
major role in the small vessel disrup­
tion implicated in this process. Retro- 
peritonitis with peritonitis and paralytic 
ileus also characterize the early phase 
of the disease. Subsequent third-space 
losses account for the extracellular fluid 
deficits, which range up to 10 L in the 
initial 24 to 36 hours. Pancreatic en­
zyme activation, absorption and disse­
mination account for additional micro- 
circulatory insufficiency and specific 
organ failure occurring from 48 hours 
onward. Current observations support 
the theories that trypsin activation pre­
cedes activation of other proteases and 
initiates activation of the kinin system, 
other vasoactive peptides, the coagula­
tion sequence and the platelet release 
phenomena.6'8 Using pH electrophoretic 
gel diffusion techniques, White has iso­
lated 22 pancreatic enzymes. In addi­
tion to lipase and phospholipase, there 
are 3 to 6 amylases and 15 proteases.® 
Trypsin is capable of activating the 
majority of the proteases as well as 
phospholipase and converts kallikreino- 
gen present in pancreatic tissue to kalli- 
krein, thereby activating the kinin sys­
tem.10 Thus, indirectly and directly,
through activation of the Hageman fac­
tor the coagulation cascade is initiated, 
as are platelet aggregation and release. 
It has been suggested that trypsin acting 
through phospholipase is capable of 
disrupting surfactant.11 The duration of 
free trypsin stability in the plasma is 
less than 30 seconds and measurement 
of circulating levels of this unbound 
enzyme in patients with pancreatitis is 
difficult. As well, two trypsin inhibitors 
have been identified. These are parti­
cularly potent in the intraductal inac­
tivation of trypsin.18,13
Recently Allan, Tournut and White13 
were able to obtain evidence of the con­
version of trypsinogen to trypsin in the 
intraductal secretions of the human 
pancreas during the spontaneous devel­
opment of pancreatitis. This is the first 
direct observation to support theories 
of the basic mechanism leading to the 
development of the proteolytic holo­
caust that results in the enzyme shock 
associated with acute hemorrhagic pan­
creatitis.
Current advances in conservative 
management of acute pancreatitis have 
been directed towards suppression of 
pancreatic secretory activity or inac­
tivation of pancreatic proteases. In 
1950 in Germany, Frey, Kraut and 
Werle14 isolated a trypsin and kallikrein 
inhibitor from beef salivary glands. 
Subsequent experimental and clinical 
trials using this trypsin inhibitor sug­
gested improved morbidity and mortal­
ity. However, controlled experimental 
trials with Trasylol (aprotinin) showed 
significant improvement from the use 
of this agent only when it was given 
prophylactically before the induction of 
pancreatitis in an experimental model. 
Many controlled clinical trials failed to 
show that Trasylol brought about sub­
stantial improvement when given in a 
dosage of 200 000 units/24 h.15'19 In 
1974 Trapnell and colleagues80 reported 
a controlled trial in which the patients 
treated with Trasylol received a dosage 
of 800 000 units/24 h; the mortality 
rate was substantially lower in the 
treated group. This report was criticized
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on the basis of the exclusion from the 
series of cases of alcoholic and post­
operative pancreatitis, and the control 
group may have been unduly weighted 
with cases of severe pancreatitis. The 
multicentre study conducted by the 
Medical Research Council in the 
United Kingdom prospectively com­
pared the effects of Trasylol and gluca­
gon in a controlled double-blind proto­
col; the mortality rate in patients treat­
ed with either agent was approximately 
the same as in the controls. Imrie (per­
sonal communication, 1977) prospec­
tively compared the outcome in pa­
tients treated with Trasylol in high 
dosage with that in controls in one 
institution over 2 years. In this series 
of 150 patients no significant difference 
in the mortality rate was noted between 
the two groups.
Glucagon, the hormone produced by 
the a  cells of the pancreatic islets, has 
primary glycogenolytic and gluconeo­
genic activity in the liver. Because of 
its positive inotropic and chronotropic 
action, glucagon has been used in the 
shock syndrome of myocardial dis­
ease.21 Pharmacologic doses of exo­
genous glucagon suppress pancreatic 
secretion.22,2'1 Hyperglucagonemia has 
been reported in bacterial infection,24 
shock25 and pancreatitis.26 Knight, Con­
don and Day26 observed a rapid fall of 
elevated plasma glucagon values, corre­
lating with onset of shock in a fatal 
experimental model of pancreatitis. Ex­
trapolating from this observation, they 
suggested that infusion of exogenous 
glucagon might further suppress pan­
creatic activity and reduce mortality. 
The animals treated with glucagon had 
a prolonged survival. Uncontrolled 
clinical experience has suggested that 
morbidity and mortality are reduced 
in patients with acute pancreatitis 
treated with glucagon.27
However, controlled studies using a 
number of pancreatitis models have 
failed to demonstrate prolonged surv­
ival in glucagon-treated animals.28 At 
the cellular level glucagon is believed 
to act at the cell membrane, activating 
adenyl cyclase at a specific receptor 
site with resultant subsequent cyclic 
AMP activity. Using histochemical 
techniques, Fodor and colleagues29 
were unable to identify glucagon re­
ceptor sites in pancreatic acinar tissue. 
Controlled clinical trials have failed to 
document improved survival in gluca­
gon-treated patients (Imrie CW: Per­
sonal communication, 1977).10
Recent reports that describe the 
mode of death in patients with acute 
hemorrhagic pancreatitis indicate a 
high incidence of respiratory failure.31 
This develops in the early phase of the 
disease, is usually unrecognized and 
may progress rapidly to sudden death.
Since 1974 we have assessed the res­
piratory function of 50 patients suf­
fering from acute pancreatitis. Arterial 
blood-gas measurements made 48 
hours after establishment of the diag­
nosis illustrated hypoxia in six cases 
that subsequently proved fatal. At this 
stage of disease the patients had limited 
clinical evidence of respiratory insuf­
ficiency. The chest roentgenograms 
were usually normal. None of the pa­
tients had persistent hypotension or 
shock. Coagulation studies showed 
thrombocytopenia but no evidence of 
disseminated intravascular coagulation 
(Table I). Minimal hypoxia is observed 
in some nonfatal cases of pancreatitis. 
Sustained hypoxia in the first 48 hours 
despite oxygen administration during 
spontaneous respiration should be con­
sidered to indicate a grave prognosis 
and should provoke consideration of 
early aggressive ventilatory support.
The respiratory failure of acute pan­
creatitis probably represents organ fail­
ure specifically related to an enzyme- 
mediated effect on pulmonary arte­
rioles and the alveolar capillary mem­
brane. Halmagyi and colleagues32 dem­
onstrated normal cardiac output and 
normal pulmonary wedge pressures, 
thus negating the theory of acute left 
heart failure. They also demonstrated 
increased pulmonary arteriolar pres­
sure. Warshaw and associates33 were 
unable to confirm pulmonary hyper­
tension and proposed as the site of 
injury the alveolar capillary mem­
brane. Imrie has shown a right-to- 
left cardiac shunt of up to 15%, a 
restricted ventilatory defect and evid­
ence of disseminated intravascular 
coagulation.8'34 Such changes in the 
lung are similar to those seen in the 
adult respiratory distress syndrome or 
shock lung; the term “pancreatitis 
lung” has been coined for this situa­
tion.
If we consider the principles for 
current management, it is possibly suf­
ficient in the majority of cases of acute 
edematous pancreatitis to replace fluid 
deficit, relieve pain with appropriate 
analgesics and treat the ileus as well as 
suppress pancreatic stimulation by 
means of nasogastric decompression. 
However, evidence of progressive clin­
ical deterioration with associated tissue 
hypoperfusion may indicate acute hem­
orrhagic pancreatitis. In such cases 
fluid losses will be more extensive and 
requirements may include albumin, 
plasma, or blood in addition to bal­
anced electrolyte solution. The role of 
glucagon and Trasylol is still in doubt. 
In early conservative management of 
acute pancreatitis attention must be di­
rected to the respiratory system. Early 
assessment of pulmonary function by 
determination of arterial blood—gas 
pressures is mandatory. Hypoxia, with 
failure of prompt response to oxygen 
administered by mask, should indicate 
the need for endotracheal intubation 
and positive-pressure ventilation. Im­
proved mortality rates in prospective 
trials support this therapeutic ap­
proach.20,33,35
Many problems exist in the overall 
management of acute pancreatitis. 
Awaiting definition through research 
are such tools as the biochemical char­
acteristics that will quickly distinguish 
edematous from hemorrhagic pancrea­
titis and the development of an effec­
tive protease inhibitor or blocker of 
vasoactive peptides. In spite of the ex­
cellence of conservative management, 
occasional patients fail to respond. In 
this situation, highly selective and well- 
defined surgical treatment will con­
tinue to have a place in the manage­
ment of acute pancreatitis.
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2. Surgical Management of Acute Pancreatitis*
P aul Po n celet , m d , fr c s[c ]
While there is general agreement on 
the indications for surgery in acute 
pancreatitis, the preferred operation is 
controversial and the approach ranges 
from one that is very conservative 
to one that is extremely aggressive.
The author believes that in all cases 
the gallbladder should be opened 
to permit exploration and that 
cholangiography should be performed.
If gallstones are discovered they should 
be removed and the organ drained; 
cholecystectomy is advised if the 
procedure is at all feasible. In a 
personal series of 50 cases of acute 
pancreatitis, 10 patients had early 
operation and 19 surgical procedures 
were performed.
* Presented at the inaugural meeting of 
the Canadian Association of General 
Surgeons, Toronto, Out., May 11 and 12, 
1977
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Alors qu'il y a generalement accord 
sur les indications de la chirurgie 
dans la pancreatite aigue, I'unanimite 
n’est pas faite sur I’operation de choix, 
I'abord etant ou bien tres conservateur 
ou extremement agressif. L'auteur croit 
pour sa part que la vesicule biliaire 
doit etre ouverte dans tous les cas 
pour en permettre I’exploration, et qu'on 
doit effectuer une cholangiographie.
Les calculs decouverts doivent etre 
enleves et I’organe draine; lorsqu'elle 
est possible, la cholecystectomie est 
recommandee. Dans une serie de 50 
cas de pancreatite aigue, 10 patients 
ont ete soumis a une operation precoce 
et 19 interventions chirurgicales ont 
ete realises.
Most cases of acute pancreatitis are 
best treated conservatively and only 
5% to 10% should be operated upon 
during the acute stage of the disease.1,2 
There is no consensus on the best tim­
ing for surgical exploration in these 
patients, but most surgeons3-5 agree that 
the indications for operation are:
1. When diagnosis is uncertain.
2. When persistent jaundice devel­
ops.
3. When the general condition of the 
patient deteriorates despite adequate 
medical treatment.
4. When a complication such as an 
abscess, pseudocyst, or hemorrhage 
supervenes.
What should be done at the time of 
operation is much more controversial.
Some surgeons close the abdomen 
without doing anything. In such cases 
the mortality remains the same; you do 
the patient no harm but you do not 
help him very much.
The most widely accepted practice 
today in North America is to drain 
widely the pancreatic area and to per­
form a cholecystostomy, gastrostomy 
and feeding jejunostomy.2,4,6 Some sur­
geons also establish a peritoneal 
dialysis around the pancreatic area1 or 
drain the thoracic duct.7 Cholecystos-
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tomy is probably unnecessary when the 
biliary tract is normal and some sur­
geons do not drain the gallbladder in 
such cases.6 The problem here is that, 
although the biliary tract may look 
normal, there can be small stones in 
the gallbladder or common bile duct. 
We strongly believe that in all cases 
the gallbladder should not only be pal­
pated but opened. Routine cholangio­
graphy should be performed and then 
the surgeon can decide whether or not 
to drain the biliary tree.
Other surgeons advocate a more ag­
gressive attitude.8'11 Hollender of Stras­
bourg performs pancreatectomy as 
early as 12 hours after the onset of 
the illness and sometimes removes as 
much as 95% of the pancreas.10,12 It is 
obvious that such an approach is too 
aggressive since at this stage necrosis 
is not always well defined and large 
parts of viable pancreas will be re­
moved, even if frozen sections are used 
to determine which portion should be 
left and which resected.
Still other surgeons, such as Edel- 
mann in Paris, are more conservative 
and wait 8 to 10 days. By this time 
necrosis is well defined and a subcap- 
sular sequestrectomy can be performed 
with surprisingly good results and few 
complications.6,13'15
What should be done with the gall­
bladder and common bile duct when 
pancreatitis is due to biliary tract dis­
ease? If there are gallstones, the least 
that should be done is to remove them 
and drain the gallbladder through a 
cholecystostomy after performing chol­
angiography to make sure there are no 
stones in the common bile duct. If 
technically feasible, a cholecystectomy 
should be done at this stage since no 
further operation would be needed.
If stones are demonstrated in the 
common bile duct, most authors agree 
they should be removed.5,16 Some sur­
geons perform a transduodenal sphinc­
terotomy if there is no other way to 
dislodge the stones, and their results 
are good;12’17 others claim that the 
sphincter should always be left alone 
at this stage and that drainage of the 
common bile duct is sufficient.5,16
We are able to report briefly our 
personal experience with such cases. 
Of 50 patients with acute pancreatitis, 
10 were operated upon early (12 hours 
to 10 days after onset). Nineteen opera­
tive procedures were performed at this 
stage: total pancreatectomy (1 case), 
left pancreatectomy (4 cases), seques­
trectomy (2 cases), cholecystectomy (7 
cases), sphincteroplasty (3 cases), and 
cystoduodenostomy with vagotomy and 
subtotal gastrectomy (1 case).
One patient died from acute myo­
cardial infarction with septic shock 12 
hours after the operation. Four patients 
had a minor pancreatic fistula that
closed spontaneously. One patient bled 
from an acute gastric erosion and was 
treated conservatively. Five patients be­
came infected and two of these had 
septic shock, but all recovered after 
treatment with antibiotics. One episode 
of minor pulmonary embolism was ob­
served.
In conclusion, we believe that two 
principles should govern our attitude 
to the surgical management of acute 
pancreatitis:
1. Necrotic tissue should be removed 
if possible or at least widely drained if 
resection is not technically feasible.
2. The primary cause of the disease 
should be treated at the same time 
whenever possible.
Bearing these principles in mind, 
early surgery is recommended in cases 
of gallstone pancreatitis—as soon as 
possible if diagnosis is established and 
the treatment should be definitive if 
possible.1,12,17,18 Early operation is ad­
vised also in severe cases of alcoholic 
pancreatitis when there has been im­
provement after 24 to 48 hours of 
intensive medical treatment.
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3. Diagnostic Tools in the Management of 
Chronic Pancreatitis*
J.E. Mullens, md, frcs[c] and S. Salem, md
The chief diagnostic tools used in 
planning the management of chronic 
pancreatitis require close collaboration 
of the surgeon and radiologist. Barium 
meal, endoscopic retrograde 
cholangiopancreatography (ERCP), 
ultrasonography and angiography are 
the most useful procedures. The barium 
meal is the initial screening procedure. 
Ultrasonography should follow if there 
is suspicion of a pseudocyst or 
pancreatic abscess. It also may be of 
value in demonstrating localized 
chronic pancreatitis. The most useful 
of all the tests is ERCP. This shows 
the pancreatic duct, the common bile 
duct, or both ducts, so that the surgeon 
may avoid operation where there is 
no defect to correct, or it may guide 
him in selecting an operation that is 
designed to correct the anatomical 
abnormalities of either duct. Angiography 
is occasionally of use when the 
foregoing procedures have not provided 
enough information. In over 80% of 
patients it is possible for the surgeon 
to undertake an operation with 
foreknowledge of the pancreas that 
will help him select the correct 
procedure to alleviate the patient's 
symptoms.
Les principaux moyens de diagnostic 
servant a planifier le traitement de la 
pancreatite chronique exigent la 
collaboration etroite du chirurgien et 
du radiologiste. La radiographie 
apres repas baryte, la cholangio- 
pancreatographie endoscopique 
retrograde (CPER), I’ultrasonographie 
et I’angiographie sont les techniques 
les plus utiles. Le repas baryte est la 
technique initiate de depistage. 
L’ultrasonographie vient en second 
lorsqu'il y a suspicion de pseudo-kyste 
ou d'abses pancreatiques. Elle peut
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egalement etre utile pour demontrer 
une pancreatite chronique localisee. 
L'epreuve la plus utile est la CPER. Elle 
met en evidence le canal pancreatique, 
le canal biliaire, ou les deux canaux, 
de sorte que le chirurgien peut eviter 
I'operation lorsqu'il n'y a pas de 
defaut a corriger, ou elle peut le 
guider dans le choix d’une operation 
destinee a corriger les anomalies 
anatomiques de I'un ou I’autre des 
deux canaux. A I'occasion, I'angiographie 
est utilisee quand les renseignements 
fournis par les methodes precedentes 
sont insuffisants. Chez plus de 80% 
des patients, le chirurgien peut 
entreprendre un operation avec une 
bonne connaissance du pancreas ce 
qui I'aidera a choisir le mode operatoire 
approprie pour soulager les symptomes 
du patient.
Until recently, dependable evaluation 
of the chronically inflamed pancreas 
was virtually impossible without resort­
ing to laparotomy. Now technologic 
advances in radiology have made 
it possible to assess the condition of 
the pancreas without operation in a 
large proportion of patients. In those 
patients with chronic pancreatitis one 
can distinguish abnormalities that can 
be corrected by operation from those 
that cannot.
There are four procedures that are
FIG. I—Pancreatic pscudocyst (p) dis­
placing stomach (s).
particularly helpful and complemen­
tary, and since more than one will be 
required to establish a diagnosis, the 
radiologist should be involved in the 
selection of the techniques. He will be 
able to choose the technique that is 
appropriate and he can give a reliable 
interpretation of the films if he is in­
formed of the patient’s history and of 
the presence or absence of pain, al­
coholism, diabetes mellitus, biochemical 
abnormalities such as an abnormal glu­
cose tolerance curve, pancreatic steator­
rhea and significant changes in urinary 
and serum amylase concentrations.
The four most useful procedures 
are:
1. Barium meal.
2. Endoscopic retrograde cholangio­
pancreatography (ERCP).
3. Grey-scale ultrasonography.
4. Angiography.
Barium Meal
A well-performed barium meal will 
often disclose swelling of the inflamed 
pancreas. Swelling is most easily de­
tected if the head of the pancreas is 
affected; in this case hypotonic duode­
nography may better demonstrate the 
swelling. Fig. 1 shows displacement 
of the stomach due to pancreatic 
swelling and Fig. 2 shows a swelling of
FIG. 2—Pancreatic pseudocyst (P) en­
croaching upon gastric antrum (ga).
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the head of the pancreas indenting 
the greater curve of the stomach. 
In both instances the lesions proved 
to be pancreatic pseudocysts. How­
ever, one cannot expect displace­
ment of the stomach or duodenum in 
all cases of enlargement of the pan­
creas, and this is especially true if the 
swelling lies in the tail of the pancreas.
ERCP
This is the most informative of the 
procedures available to assess the pan­
creas.1'9 The findings of critical im­
portance in planning the management 
of patients with pancreatitis are listed 
and illustrated as follows:
Z. The Normal Pancreas
Fig. 3 shows a normal pancreatic 
duct and common bile duct in a patient 
in whom the diagnosis was chronic pan­
creatitis. Clearly, it is important to the 
surgeon to know that the patient’s 
symptoms cannot be relieved by an 
operation on these normal ducts.
2. Papillary Stenosis
Fig. 4 shows a dilated common bile 
duct and dilated pancreatic duct. There 
is an organic or functional obstruction 
at the papilla, and a sphincteroplasty 
may relieve the patient’s symptoms.
3. Strictures of the Pancreatic Duct
Fig. 5 is the roentgenogram of a 
patient with chronic alcoholism and 
recurrent attacks of pancreatitis; there 
are multiple strictures of the pancreatic 
duct and irregular duct ectasia. The 
operative procedure selected to over­
come this problem must be one that 
drains the pancreas distal to the stric­
tures. This is the ideal type of case 
for retrograde drainage of the pancre­
atic duct into a Roux-en-Y loop anas­
tomosed to the opened pancreatic duct.
4. Obstruction of the Pancreatic
Duct
ERCP may show a complete obstruc-
FIG. 3—Normal pancreatic duct and 
bile ducts.
tion of the pancreatic duct. This find­
ing can be caused by carcinoma of the 
pancreas, but when there is a long 
history of attacks of pancreatitis one 
can usually be confident of relieving 
the condition by surgery. This type of 
abnormality usually can be managed 
by distal pancreatectomy.
5. Tortuous or Irregular Ducts
If there is a tortuous or irregular 
duct that extends from the head of the 
pancreas out to the tail it is difficult 
to provide adequate retrograde drain­
age. A subtotal pancreatectomy may be 
the best operation in this situation.
6. Small, Attenuated or Sclerotic
Ducts
If the pancreatic duct is thin and 
sclerotic there is no operation short of 
subtotal pancreatectomy or total pan­
createctomy that is likely to alleviate 
the patient’s symptoms.10
7. Stones in the Pancreatic Duct or
the Common Bile Duct
Fig. 6 shows stones in a dilated pan­
creatic duct. The operation selected for 
such a patient must be designed to 
remove the stones and provide drain­
age. Retrograde drainage with a Roux- 
en-Y loop to the opened pancreatic 
duct may suffice, but if the stones ex­
tend into the head of the pancreas it 
may be necessary to perform sphincte­
roplasty in addition.
One may find stones in the common 
bile duct in the absence of any ab­
normality in the pancreatic duct. Their 
removal may be sufficient to prevent 
further attacks of pancreatitis, but a 
sphincteroplasty may be required as 
well. An intravenous cholangiogram 
also may show stones in the common 
bile duct, but it does not give informa­
tion on the pancreatic duct, and it is 
a great advantage to possess this in-
FIG. 4— Papillary stenosis.
formation, if at all possible, before 
undertaking operation.
8. Stricture of the Lower End of the
Common Bile Duct
Chronic pancreatitis may cause a 
stricture of the retropancreatic portion 
of the common bile duct. The stricture 
may be of such a degree as to cause 
obstruction of the duct, and this prob­
lem should be anticipated before under­
taking operation to relieve chronic pan­
creatitis.11 Fig. 7 shows a stricture at 
the lower end of the common bile duct 
in a patient with pancreatitis. The su­
praduodenal portion of the duct should 
be anastomosed to the intestine in such 
cases, either by a choledochoduodenos- 
tomy or a choledochojejunostomy 
Roux-en-Y.
FIG. 5—Pancreatic duct ectasia with 
multiple strictures.
FIG. 6—Stones in pancreatic duct.
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FIG. 7—Stricture of pancreatic
9. Pseudocysts
In the opinion of some endoscopists 
it is unsafe to perform ERCP on pa­
tients with a pancreatic pseudocyst, but 
the hazards are not formidable if the 
pseudocyst is not overfilled with con­
trast medium. The pancreatic duct com­
municates with the pseudocyst in 60% 
of cases. Sometimes ERCP shows pseu­
docysts where none were suspected 
(Fig. 8). Ultrasonography is excellent 
for demonstrating pseudocysts, but it
FIG. 8— Pseudocyst of pancreas.
portion of common bile duct.
is not infallible. In particular, it has 
shown only one pseudocyst where more 
than one has actually been present.12
10. Carcinoma of the Pancreas
It is not always easy to distinguish 
carcinoma of the pancreas from chronic 
pancreatitis, especially if the history is 
atypical. If carcinoma is present ERCP 
will often demonstrate it, but the ap­
pearance is seldom pathognomonic and 
the diagnosis may have to be established
FIG. 9—Ultrasonogram showing pseu­
docyst (c) of pancreas: upper portion, 
transverse section; lower portion, sagittal 
section.
by operation or by external needle 
biopsy. If these examinations are not 
conclusive ERCP will provide the sur­
geon with additional evidence that may 
help him decide the management of the 
lesion.
Ultrasonography
Grey-scale ultrasonography demon­
strates the pancreas in 70% to 80% 
of patients and is particularly helpful 
in diagnosing pancreatic pseudocysts 
and abscesses (Fig. 9).13*15 It also may 
be of help in diagnosing carcinoma of 
the pancreas, but it cannot distinguish 
localized chronic pancreatitis from car­
cinoma because both lesions may pro­
duce a circumscribed solid-appearing 
mass on the ultrasonogram. Chronic 
pancreatitis may cause a uniform en­
largement of the pancreas, which is 
unusual in carcinoma. Ultrasonography 
cannot demonstrate atrophy of the 
pancreas.
Angiography
Fig. 10 is the arteriogram from a 
patient with two pseudocysts of the 
pancreas. Only one of these lesions had 
been disclosed by the other forms of 
radiologic examination. Angiography 
may also show obstruction of the 
splenic artery or the portal vein by 
pancreatic inflammation or neoplasm, 
but this may be of little help in plan­
ning management. Angiography cannot 
readily distinguish pancreatic inflam­
mation from neoplasia except in the 
presence of an endocrine neoplasm of 
the pancreas.
FIG. 10—Arteriogram outlining pan­
creatic pseudocyst.
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The procedure should be used selec­
tively on those patients in whom there 
is appreciable doubt about the patho­
logic process. In such patients it may 
provide additional information for 
planning the operation.
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4. Surgery in Chronic Pancreatitis*
Frank W. Turner, m b, ch b, m sc, frcs[c], facs
When the pain associated with 
chronic pancreatitis is due to ductal 
obstruction, it is logical that surgical 
management should be designed to 
relieve that obstruction while preserving 
as much of the functioning gland as 
possible. A number of cases are 
described to illustrate the various 
procedures available and to indicate 
the features that govern the selection 
of the one most appropriate for a 
particular patient. The operations include 
partial pancreatectomy, Roux-en-Y 
pancreaticojejunostomy and longitudinal 
pancreaticojejunostomy; these can be 
modified to suit the peculiar 
circumstances of a given case.
Quand la douleur associee a une 
pancreatite chronique est causee par 
une obstruction du canal pancreatique,
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il est logique de choisir un traitement 
chirurgical destine a soulager 
I’obstruction tout en conservant le plus 
possible de la glande. Un certain nombre 
de cas sont decrits afin d'illustrer les 
diverses interventions disponibles 
et pour indiquer les caracteristiques 
qui determinent le choix de I'operation 
la plus appropriee a un patient.
Les operations comprennent la 
pancreatectomie partielle, la pancreato- 
jejunostomie de Roux-en-Y et la 
pancreatojejunostomie longitudinale; 
celles-ci peuvent etre modifiees pour 
convenir aux circonstances particulieres 
d'un cas donne.
Despite the many studies of chronic 
pancreatitis, there has never been a 
controlled clinical trial to compare the 
results of one form of surgery with 
those of another or, indeed, to compare 
the results of surgery with those of 
nonoperative treatment. Therefore, the 
surgical management of this condition 
continues to be based on the opinions 
of individual surgeons, often supported 
at best by retrospective analyses of 
disparate series of patients. Having 
done nothing to improve this sad state 
of affairs, I can only present yet an­
other prejudiced opinion in the hope 
of stimulating debate.
By definition, this discussion will 
be concerned with the relief of symp­
toms resulting from permanent and 
progressive alteration in both structure 
and function of the pancreas.1 In fact, 
we are really discussing the manage­
ment of pain, because to restore lost 
endocrine and exocrine function is at 
present beyond our surgical capability. 
The exact cause of pain in chronic 
pancreatitis is unclear, but there can 
be little doubt that in most patients 
with ductal obstruction, relief of that 
obstruction brings about relief of pain. 
Unfortunately not all patients have 
major ductal obstruction, and in these 
it is postulated that a more diffuse 
obstruction in the smallest duct radicals 
is responsible.
Some advantage derives from the al­
tered nature of the chronically inflamed 
gland, in that it permits surgical assault 
in ways that would never be tolerated 
by the healthy gland with its propensity 
to acute inflammatory change on the 
least provocation. It is truly amazing 
how much battering the hard, fibrotic 
gland of chronic pancreatitis will with­
stand.
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University of Alberta Hospital
Experience, 1970 to 1976
A review of local experience served 
to indicate the scope of the subject 
and the relative uselessness of such re­
views. Endoscopic retrograde cholan­
giopancreatography (ERCP) was in­
troduced midway through the survey 
in mid-1973 and produced a notable 
improvement in the recognition and 
management of chronic pancreatitis, 
particularly in patients in whom radio- 
logic calcification of the gland was 
absent. Moreover, preoperative delinea­
tion of altered ductal morphology al­
lowed better selection of patients for 
surgery.
The causes of clinically recognized 
chronic pancreatitis in 53 patients are 
listed in Table I; not included in the 
analysis are the many cases of upper 
abdominal pain attributed to chronic 
pancreatitis but lacking documentation 
of pancreatic disease other than by 
exclusion. Radiologic evidence of calci­
fication was present in 28 (53%).
Of the total group, 28 eventually 
underwent surgery for relief of pain. 
Table II lists the 34 procedures per­
formed on these patients, the diversity 
illustrating a nice lack of rigidity among 
the operating surgeons. The term “duc- 
toplasty” is used to describe plastic pro­
T a b le  I— C a u s e s  of C h ro n ic  P a n c re a t it is  in
53 P a t ie n ts  T re a te d  a t  U n iv e r s ity  o f A lb e rta
H o s p ita l, 1970 to  1976
C a u s e N o . o f p a tie n ts
A lc o h o l 37
G a lls to n e s 3
F a m il ia l  fa c to rs 2
H y p e r lip id e m ia 1
T ra u m a 1
U n k n o w n 9
T a b le  I I — O p e ra tio n s  P e r fo rm e d  on 28 P a ­
t ie n ts  w ith  S ym p to m a tic  C h ro n ic  P a n c re a t it is
P ro c e d u re N u m b e r
“ D u c to p la s ty "
D is ta l p a n c re a te c to m y  w ith o u t
3
d r a in a g e
D is ta l p a n c re a te c to m y  w ith
3
d r a in a g e  (D u v a l)
S id e - to -s id e  p a n c re a t ic o je ju n o -
2
s to m y
L o n g itu d in a l p a n c re a t ic o je ju n o -
3
s to m y  (P u e s to w ) 8
N e a r - t o ta l  p a n c re a te c to m y  
P a n c re a tic o d u o d e n e c to m y
2
(W h ip p le ) 1
D ra in a g e  o f  re te n tio n  c y s t 4
B io p s y  a lo n e 1
P ro c e d u re s  on  com m on b ile  d u c t* 7
T o ta l 34
in c lu d e s  s p h in c te ro to m y , s p h in c te ro p la s ty  
an d  c h o le d o c h o d u o d e n o s to m y .
cedures on the pancreatic ducts them­
selves (either of Wirsung or Santorini) 
as differentiated from a sphinctero­
plasty, which only promotes drainage 
of the common bile duct. The one 
Whipple procedure was done in the 
belief that an occult malignant growth 
was responsible for the changes of 
chronic pancreatitis.
FIG. 1—Case 1. Distal pancreatic duct 
with cystic dilatation in tail.
The Logical Surgical Approach
In patients with demonstrable ductal 
abnormalities, the procedure selected 
must surely be that which will most 
easily overcome the problem while pre­
serving whatever pancreatic function 
remains. Assuming that ductal disten­
sion distal to a zone of obstruction is 
the major cause of pain in chronic 
pancreatitis,2 then relief of that obstruc­
tion by ductal decompression is all 
that is required. The logic of perform­
ing 95% resection of the gland as the 
initial procedure in such patients is 
hard to understand; not only is it tech­
nically more difficult, but it guarantees 
that those fortunate enough to survive 
the operation will suffer from both 
diarrhea and diabetes.
In patients in whom macroscopic 
ductal changes are absent and who, 
presumably, have diffuse disease, there 
may be no recourse other than per­
formance of a major resection, but, as 
illustrated below (case 8), ductal
FIG. 2—Case 2. Large cyst in cominu 
nication with distal pancreatic duct.
FIG. 3— Case 2. Normal pancreatic 
duct 1 year after resection of tail.
FIG. 4— Case 3. Narrowed supra-ampullary segment (arrows) with dilatation above.
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FIG. 5— Distal Roux-en-Y pancreatico- 
jejunostomy (Duval).
FIG. 7— Longitudinal pancreaticojeju- 
nostomy of Puestow. Incision into duct is 
usually carried further into head than 
illustrated here.
FIG. 8— Case 5. Multiple strictures with 
intervening areas of dilatation (“chain-of- 
lakes”).
FIG. 6— Case 4. Narrowed supra-ampullary segment with tortuous widely dilated 
duct above.
changes permitting a lesser procedure 
may eventually develop even in these 
patients.
The presence of retention cysts is 
readily recognized with ERCP. These 
vary in size from relatively small fusi­
form dilatations of the duct to large 
cysts frequently misinterpreted as post­
necrotic pseudocysts because, like pseu­
docysts, they may lack a recognizable 
lining epithelium. Retention cysts are 
always intrapancreatic and communi­
cate with a major duct. They represent 
cystic dilatation of the duct distal to 
a point of obstruction and usually de­
velop slowly without any precipitating 
episode of pancreatic necrosis. Their 
management depends upon their size 
and position, as illustrated below.
Finally, the surgeon must be con­
vinced that the patient’s symptoms are 
indeed attributable to pancreatitis; drug 
addiction is not uncommon in this dis­
ease and even the most skilful surgery
may fail to quench the demand for 
drugs.
Illustrative Cases
Case 1.—A 27-year-old alcoholic man 
had a 5-year history of recurrent chronic 
pancreatitis. ERCP demonstrated a norma1 
proximal duct but a 2 X 1 cm cys' .c 
dilatation in the tail (Fig. 1). Quite illogi- 
cally the procedure selected was sphinc­
teroplasty, from which no benefit was 
derived. A distal pancreatectomy would 
have been a better choice.
Case 2.—This 32-year-old woman had 
documented chronic pancreatitis of un­
known etiology. ERCP, 2 years after the 
diagnosis had been established, demon­
strated a 3 X 4 cm cavity in the tail of 
the pancreas associated with a normal 
proximal duct (Fig. 2). A distal pancrea­
tectomy completely relieved her symptoms 
and follow-up ERCP 1 year later (Fig. 3) 
confirmed the unchanged status of the 
remaining pancreas. It is of interest that
FIG. 9— Case 6. Operative pancreatogram demonstrating large cyst in head of 
pancreas associated with narrowing and elongation of proximal duct with distal 
dilatation.
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there was an unusual foreign-body giant 
cell reaction around eosinophilic foreign 
material in the wall of the cyst; the nature 
of this material was never determined.
Case 3.—In a 59-year-old alcoholic man 
with long-standing disease ERCP demon­
strated a narrowed, supra-ampullary seg­
ment (length, 6 cm) with dilatation beyond 
(Fig. 4). Multiple biopsies ruled out a 
malignant condition and a Roux-en-Y pan- 
creaticojejunostomy (Fig. 5) provided com­
plete relief of his symptoms.
Case 4 .—This 23-year-old alcoholic man 
was becoming dependent on narcotics. 
ERCP demonstrated a hugely dilated and 
tortuous duct with a narrowed supra- 
ampullary segment (Fig. 6). A longitudinal 
pancreaticojejunostomy (Fig. 7) provided 
dramatic relief of pain. At discharge 10 
days later he was not using any analgesics.
Case 5 .—This 36-year-old male alco­
holic was addicted to narcotics. Increasing 
severity of pain and a 20-kg weight loss 
over 3 months precipitated reinvestigation. 
ERCP revealed a characteristic “chain- 
of-lakes” deformity as well as narrowing 
of the distal common bile duct (Fig. 8); 
the pancreatic duct was packed full of 
calculi. A Puestow longitudinal pancreati-
FIG. 11— Case 7. Proximal stricture 
(arrow) with wide dilatation above.
cojejunostomy was performed together 
with a choledochoduodenostomy to relieve 
the common-duct obstruction. Postopera- 
tively, although readily admitting that his 
back pain had gone, his addiction to nar­
cotics continued.
Case 6.—A 41-year-old male alcoholic 
with increasing pain and a recent weight 
loss of 10 kg had a mass in the right 
upper abdominal quadrant. ERCP was 
unsuccessful. At exploration a large cystic 
mass was found in the posterior part of 
the head of the pancreas. A widely dilated 
duct was easily palpable in the body of 
the gland; after its injection with contrast 
medium a pancreatogram was obtained 
(Fig. 9). A Roux-en-Y loop was used to 
drain the cyst and was anastomosed side- 
to-side to the main pancreatic duct (Fig. 
10). The patient was completely relieved 
of his symptoms.
Case 7.—In a 46-year-old male alco­
holic with type IV hyperlipidemia sequen­
tial ERCPs 6 months apart demonstrated 
an increasingly narrow stricture of the 
duct (Fig. 11) with multiple calculi. A 
near-total pancreatectomy was followed by 
a difficult postoperative course during 
which the coexisting problems of diabetes, 
diarrhea, subnutrition, wound infection 
and pancreatic fistula were successfully 
managed.
Case 8.—This 32-year-old man, prob­
ably alcoholic, presented with a 3-year 
history of chronic pancreatitis. Initial 
ERCP demonstrated a normal duct (Fig. 
12). Near-total pancreatectomy was of­
fered at that time, but was refused. ERCP 
repeated 1 year later revealed a stricture 
of the main duct with cystic dilatation 
in the tail (Fig. 13). A Puestow procedure 
provided a good early result.
Longitudinal Pancreaticojejunostom y
This procedure was introduced by
FIG. 12— Case 8. Initial ERCP demonstrating normal duct.
FIG. 13— Case 8. Repeat ERCP, 1 year later. Stricture and dilatation are now 
evident.
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FIG. 14—Longitudinal pancreaticojeju- 
nostomy as modified by Thai.
Puestow and Gillesby in 1958s as a 
means of dividing all strictures and re­
moving calculi from the pancreatic 
duct. Because it can occasionally be 
difficult, modifications to avoid mobil­
izing the spleen and tail of the pancreas 
such as that suggested by Thai (Fig. 
14) have been widely adopted. How­
ever, it has been my experience that,
in all but the thinnest patients, it is 
necessary to mobilize the pancreas to 
be able to work comfortably upon the 
duct. Inserting the entire body and tail 
into the Roux-en-Y loop is also attrac­
tive, being much less likely to be fol­
lowed by fistula formation or loop 
separation. The latter has been de­
scribed as a late complication of the 
Thai operation (Trapnell JE: Personal 
communication, 1976).
Results and Conclusions
There is general agreement that ap­
propriate drainage procedures will pro­
vide good long-term relief of pain in 
75% of patients with ductal abnormali­
ties,4 an experience that is confirmed 
in our own series. In such patients 
immediate near-total pancreatectomy, 
which has a higher operative mortality 
rate and postoperative morbidity,5 is 
not justified. In patients with severe 
symptoms and normal major ducts, 
there may be no alternative to resection.
Occasionally a simple plastic proce­
dure carried out on the termination of 
the pancreatic duct (“ductoplasty”) will 
suffice if that is the only level of ob­
struction; the classic sphincteroplasty is 
of use only for stenosis of the sphincter 
of Oddi, which rarely is the obstructing 
lesion responsible for alcohol-related
chronic pancreatitis. It is generally ac­
cepted that attempts to relieve pain by 
splanchnicectomy or destruction of the 
celiac ganglia are of little or no value.6
Finally, the best results are obtained 
in patients who will abstain from al­
cohol. Resumption of drinking usually 
reactivates the disease, perhaps modi­
fied to consist of recurrent bouts of 
acute pancreatitis rather than the pre­
vious chronic form.
The help of Dr. Lambros Costopoulos 
in reviewing the roentgenograms and of 
Mr. Ralph McNabb in preparing the il­
lustrations is gratefully acknowledged.
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5. Panel Discussion on Pancreatitis*
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that the questioning of the panel mem­
bers be on a practical basis. We have 
listened to a number of presentations 
that have been both interesting and 
informative, but most of us would like 
to hear more about the actual details 
of treatment of patients with acute or 
chronic pancreatitis.
Most patients with acute pancreatitis 
suffer from the mild form of the dis­
ease and will recover on routine “suck 
and drip therapy” (i.e., nasogastric 
suction and intravenous fluids), to­
gether with suitable analgesia. How­
ever, approximately 20% of patients 
with severe pancreatitis require inten­
sive care and management, which call 
for the participation of various groups 
of specialists. It is in relation to this 
group of seriously ill patients that I 
would like to ask the panel for direc­
tion. Dr. Poncelet, in his presentation, 
briefly mentioned intravenous hyper­
alimentation (IVH) as an important 
part of the treatment of the patient 
with acute pancreatitis. Dr. Keith, do 
you think this is true? Do you use 
IVH?
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Dr. Keith: I agree and I disagree. I 
don’t think that in the first 48 to 72 
hours of the acute fulminant process 
IVH will do anything to reverse or 
reduce the severity of the disease. 
Later, when one is faced with com­
plications of the acute process, I cer­
tainly think it is of great value. I agree 
that both IVH and oral alimentation 
with elemental diets have little stimulat­
ing effect on the pancreas, which is 
in their favour for the management 
of this disease.
Dr. Thompson: Do any of you have 
strong beliefs on the use or the nonuse 
of antibiotics in the severe form of 
acute pancreatitis?
Dr. Poncelet: I use antibiotics in gall­
stone pancreatitis because most samples 
of bile from these cases show enteric 
bacteria. But antibiotics are only a 
part of the treatment. If there is pus 
in the gallbladder it is obvious that the 
organ should be removed as soon as 
possible; antibiotics alone are not going 
to cure this patient.
Dr. Mullens: I think that antibiotics 
should be reserved for the complica­
tions of pancreatitis. We don’t use them 
routinely.
Dr. Keith: I would like to remark that 
recently a report of a controlled clin­
ical trial was published demonstrating 
that antibiotics (1 think that ampicillin 
and cephalothin were used) had no 
effect whatever on the outcome of the 
acute form, so I do not use them.
Dr. Thompson: We would probably all 
agree, however, that in the complicated 
case, when the patient has infection or 
is suspected to have infection, anti­
biotics are indicated. Dr. Mullens, how 
do you diagnose a pancreatic abscess 
or an acute pseudocyst in these pa­
tients?
Dr. Mullens: I think that first of all 
radiology is a great help. The two 
initial procedures in the investigation 
of a pancreatic mass are ultrasono­
graphy and roentgenographic barium 
studies, followed when necessary by 
ERCP (endoscopic retrograde cholan­
giopancreatography).
Dr. Thompson: The patient in the in­
tensive care unit suffering from severe 
pancreatitis is extremely ill and prob­
ably can be subjected to no more than 
an ultrasonic B scan. This examination 
during the course of acute pancreatitis 
can be very helpful indeed.
Dr. Mullens: It is also very easy to do. 
Dr. Thompson: Agreed. It is noninva- 
sive and can help you diagnose the 
early abscess or acute pseudocyst. If 
repeated on a daily basis it can indicate 
whether the abscess or cyst is changing 
in size.
Is there any place for steroids in the 
treatment of acute pancreatitis? Dr. 
Keith?
Dr. Keith: No.
Dr. Thompson: Anybody else? Every­
one agrees that there is no place for 
steroids! How about the prevention and 
treatment of the respiratory complica­
tions that probably occur in most pa­
tients with severe pancreatitis, at least 
in most of the ones I see? Very many of 
them go into respiratory failure. Dr. 
Turner, have you any views on this 
subject?
Dr. Turner: The only comment I would 
make is that operating on patients with 
acute pancreatitis tends to increase the 
likelihood of respiratory complications. 
I would like to know what Dr. Keith 
thinks.
Dr. Thompson: Dr. Keith, are many of 
the respiratory complications iatro­
genic?
Dr. Keith: That’s an important ques­
tion. Are we overloading these patients? 
Are we projecting them into pulmo­
nary edema or is the pancreatitis the 
sole cause? Some reports suggest the 
former, since patients improve with 
massive doses of diuretics and albumin 
given in an attempt to draw fluid back 
into the intravascular compartment. 
The data available would indicate that 
there is a primary end-organ effect in 
this disease and that we must replace 
fluid losses. We have to use colloid for 
the purpose and must be careful not 
to overload the patient. But there is 
also an acute pulmonary problem for 
which the specific therapy is mechan­
ically assisted ventilation. By this I 
mean high-volume ventilation with posi­
tive end-expiratory pressure. Frequently 
respiratory failure is not recognized 
early enough and when it is, the revers­
ible stage of the disease has passed. The 
onus is on us to look for it earlier and 
to treat it aggressively. We will find, as 
Imrie in Scotland is finding, that the 
survival rate will be increased even in 
patients otherwise left untreated.
Dr. Mullens: I also firmly believe that 
the management of the pulmonary 
problem, as Dr. Keith has just said, 
should begin early in the course of 
the disease. I think it is very important 
to recognize the case of high-risk acute 
pancreatitis. This patient should also 
be treated with peritoneal dialysis; it 
is well established now that, when a 
patient has a low serum calcium value, 
a high leukocyte count, low Po2, high 
BUN concentration, reduced urinary 
output and is delirious, the institution 
of peritoneal dialysis can work miracles. 
Dr. Thompson: What fluid do you use 
for lavage?
Dr. Mullens: We use Ringer’s lactate 
solution, the same that the nephrol­
ogists use for peritoneal lavage except 
that we add a little potassium chloride 
to make it more efficient.
Dr. Thompson: One more word on
respiratory failure. Do any of the panel­
ists depend on pulmonary wedge pres­
sures in monitoring fluid therapy? Dr. 
Poncelet, do you feel these are superior 
to central venous pressures?
Dr. Poncelet: Yes. In most patients we 
use a Swan-Ganz catheter in the post­
operative period for 3 to 4 days.
Dr. Thompson: Is this a difficult pro­
cedure to carry out?
Dr. Poncelet: No, not for us because 
the anesthetist introduces them.
Dr. Thompson: I mean, can a measure­
ment of pulmonary wedge pressures by 
means of a Swan-Ganz catheter be car­
ried out only in a high-level university 
hospital or can this procedure be used 
by those of us who are working in 
smaller hospitals?
Dr. Poncelet: It should be available in 
any intensive care unit.
Dr. Thompson: We found pulmonary 
wedge pressures very useful to indicate 
whether the patient is being overloaded. 
The procedure is simple and it gives 
more reliable information than the cen­
tral venous pressure.
Would the panelists comment on the 
treatment of pancreatitis after biliary 
tract surgery or gastric surgery? Do any 
of you ever meet this postoperative 
complication?
Dr. Mullens: Postoperative pancreatitis 
is a serious condition associated with 
a high mortality rate. One must be 
aware of the possibility of its devel­
opment and institute early treatment. 
Not only can it follow biliary tract or 
pancreatic surgery but also operations 
on the bowel. These patients should 
have peritoneal lavage.
Dr. Thompson: Dr. Keith, should Tra- 
sylol (aprotinin) be used prophylacti- 
cally when there is a possibility of 
damage to the pancreas during, say, 
duodenal dissection or common-bile- 
duct exploration?
Dr. Keith: We haven’t used Trasylol 
but we have used glucagon. If glucagon 
has any place at all it is its prophylactic 
use when there has been dissection 
around the pancreas or biliary tract. 
Unfortunately, we have done no con­
trolled study so I cannot be specific 
about its value.
Dr. Thompson: Is glucagon available 
to the average surgeon?
Dr. Mullens: I am told its production 
is now limited. There has been such 
a demand for glucagon that I have had 
to stop using it in ERCP; the radiol­
ogists have a limited supply and they 
require it for hypotonic duodenography. 
Dr. Thompson: If it were readily avail­
able, is there any place for glucagon 
in the treatment of acute pancreatitis? 
Dr. Keith: Again, I can only refer back 
to what’s been reported. I think that 
once the disease is established this agent
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has little effect and that it probably 
has more value when given prophylac- 
tically.
Dr. Thompson: Could we consider the 
management of the patient with acute 
gallstone pancreatitis? By some means 
or other we have found out that a 
patient who is suffering from acute 
pancreatitis has gallstones. When should 
one operate to remove the gallstones? 
Dr. Poncelet, I believe it is your 
opinion that this should be done as 
soon as possible after the onset of the 
episode and as soon as the diagnosis 
has been made. If the patient has gall­
stone pancreatitis, should he be oper­
ated upon?
Dr. Turner: I don’t really have any 
strong views, but it would seem reason­
able if the patient is improving not to 
do anything about the gallstones at that 
time. I would allow the patient to re­
cover and bring him back in approxi­
mately 6 weeks for an elective chole­
cystectomy.
Dr. Keith: I think, Dr. Turner, you 
may find that in the 6 weeks the pa­
tient may have more attacks of pan­
creatitis? Have you not had this ex­
perience? I agree with Dr. Poncelet 
that early operation is indicated, but 
I would like him to tell us how he 
knows which patient has gallstones un­
less there has been a previous workup 
indicating their presence?
Dr. Poncelet: In most cases of gall­
stone pancreatitis my knowledge of the 
primary cause is based on a previous 
workup. Sometimes my diagnosis is on 
a clinical basis, for example, the patient 
does not drink alcohol or is a 40-year- 
old fat lady; in such instances one can 
be almost certain that the patient has 
gallstones.
Dr. Mullens: I would like to make a 
plea for ultrasonography — it will show 
gallstones in many cases.
Dr. Thompson: Sometimes the ultra- 
sonographer is a little overenthusiastic 
but usually he is pretty reliable.
In the case of a patient with acute 
pancreatitis as a result of gallstones, 
probably most of us would prefer to 
operate during the same admission. Per­
sonally I like to let the patient recover, 
but before he or she goes home 3 to 4 
weeks later to perform an elective chole­
cystectomy with operative cholangio­
graphy to make sure that there are no 
stones in the common duct.
Dr. Turner: I would ask the other 
panelists whether they believe that 
stones within the gallbladder or a stone 
passing into the common duct and 
through the sphincter causes the pan­
creatitis? It seems to me that if the 
stone that has caused the trouble has 
already passed, then there is not much 
urgency to take out the gallbladder.
Dr. Poncelet: How can you be sure that 
the stone has already passed?
Dr. Turner: I am not sure and that’s 
why I’m asking about it. There are 
reports that if the stools of such pa­
tients are filtered, a stone will be found 
in a very high percentage of them. 
Presumably it is the actual passage of 
the stone through the sphincter that 
causes the trouble rather than the mere 
presence of a stone in the common bile 
duct.
Dr. Poncelet: But sometimes there is 
just one big stone in the gallbladder 
and the patient has pancreatitis.
Dr. Turner: That just means that you 
have missed the one that has gone 
through.
Dr. Thompson: This is certainly a moot 
point. Perhaps we can move on to 
another area and I would like to pose 
the question, What should be done if 
one happens to operate on a patient 
with acute pancreatitis? Not all of us 
are as enthusiastic as Dr. Poncelet, but 
would somebody like to outline their 
indications for operation in the course 
of acute pancreatitis. Dr. Keith, you 
tend to treat these patients more con­
servatively than Dr. Poncelet. Do you 
believe there are indications for surgery 
during the course of acute pancreatitis? 
Dr. Keith: I think it will be simpler to 
discuss alcoholic pancreatitis and then 
we can set aside the question of what 
is to be done about gallstones. If a 
patient is not responding to conserva­
tive measures, are we going to con­
sider surgery? I believe the answer 
is yes. There are about 5% of patients 
whose condition, in spite of the most 
aggressive nonoperative management, 
excluding peritoneal lavage, will con­
tinue to deteriorate, and this is the 
patient who needs an operation. I have 
no personal experience with acute pan­
creatic debridement or sequestrectomy 
for a totally necrotic gland other than 
as an observer in France. I was im­
pressed at that time by the ease of 
removal of the dead black pancreas, but 
I was also impressed by the comments 
of the men who worked under Hol- 
lender that these patients had 100% 
mortality; about 5 days later they either 
bled to death or were overcome with 
sepsis.
Dr. Turner: I have tried this procedure 
in the acute stage and had great dif­
ficulty in recognizing whether the pan­
creas was actually necrotic or not.
Dr. Thompson: What might one do 
at the time of operation short of pan­
createctomy or sequestrectomy, if we 
accept the fact that most of us are a 
little hesitant about resecting the acute­
ly inflamed pancreas? What else can be 
done at the time of operation? Dr. 
Poncelet, you mentioned cholecystos- 
tomy or drainage of the biliary tract. 
Do you feel that this is important?
Dr. Poncelet: If there are gallstones
present, then I strongly believe that the 
biliary tract should be drained and, 
if possible, through the common bile 
duct. I think this is a better drainage 
procedure than a cholecystostomy. With 
respect to pancreatectomy, I disagree 
with Hollender, who proposes early 
operation within 12 hours, and I agree 
with Edelman that after 8 to 10 days 
is the optimal time to consider opera­
tion in these patients. Necrosis is then 
well defined and it is much easier to 
determine what part of the pancreas 
has to be resected and what can be 
left in place.
Dr. Thompson: Do you use drains in 
these patients?
Dr. Poncelet: Yes, the pancreatic area 
is widely drained and peritoneal lavage 
is carried out postoperatively.
Dr. Thompson: I think that many of 
these patients come to operation be­
cause of a misdiagnosis. We think 
we’re probably operating on a patient 
with acute cholecystitis and at opera­
tion, to our horror, we find the patient 
has active acute pancreatitis. What 
should one do then? Usually it is an 
acute, edematous type of pancreatitis 
and I believe that in such instances the 
less one does the better. These patients 
are going to recover as long as we 
don’t interfere with them too much, 
and I agree with Dr. Poncelet that if 
there is any evidence of biliary tract 
disease one should drain the biliary 
tract but not do much more than that.
Let us move on to a consideration 
of chronic pancreatic disease. Dr. 
Poncelet, would you like to comment 
on the easiest and best method of drain­
ing the average pseudocyst?
Dr. Poncelet: If possible, I drain them 
through the stomach after waiting 5 to 
6 weeks to be sure that there are good 
adhesions present. If one is forced to 
operate early during the acute phase 
of the cyst development, then external 
drainage is advisable. A pancreatic fis­
tula may follow but this can be dealt 
with at a later date. Sometimes a small 
cyst lying adjacent to the duodenum 
can be drained into this structure.
Dr. Turner: I would agree completely 
with Dr. Poncelet, although I am not 
sure what the average pseudocyst is. 
Dr. Thompson: The average pseudocyst 
is one that is well formed, easily identi­
fiable, has a thick fibrous wall and is 
not friable; in other words it can easily 
be sutured to stomach or bowel. Do 
complications ever follow drainage into 
the stomach?
Dr. Mullens: Not all pseudocysts re­
quire treatment; some of them subside 
spontaneously and we should not be 
too hasty in operating on these patients. 
Dr. Thompson: This is where ultrasonic 
B scanning has helped in allowing us 
to follow the course of the so-called
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acute pseudocyst, many of which do 
subside, as we now realize. In answer 
to the enquiry about complications 
from draining a pseudocyst into the 
stomach, I have encountered a few 
myself.
Dr. Mullens: What were they?
Dr. Thompson: Hemorrhage. If there 
is a highly alkaline fluid in the pseudo­
cyst and you drain it into the stomach, 
multiple bleeding ulcers can develop in 
the gastric mucosa and these can create 
quite a situation. I agree that this is a 
rare occurrence and that drainage into 
the stomach is the easiest and safest 
way of draining most cysts when they 
lie in the lesser sac. I, myself, prefer 
to drain them into the jejunum but 
most surgeons consider cyst-gastros­
tomy as the treatment of choice. How 
about the small pseudocyst in the tail 
of the pancreas?
Dr. Mullens: I was going to remark that 
there is sometimes more than one 
pseudocyst, and that these can be easi­
ly overlooked, especially one that is in 
the tail region of the pancreas.
Dr. Thompson: What would you do 
with such a one, Dr. Mullens?
Dr. Mullens: Excise the tail of the pan­
creas along with the spleen. With re­
gard to the stump of the pancreas, I 
would remind you of the little trick 
about the pancreatic duct that Sir Rod­
ney Smith taught. Sir Rodney advised 
that if you can see the duct in the 
stump of the pancreas, you should put 
a tube into the duct, attach the stump 
to the back of the stomach and bring 
the tube out through both walls of the 
stomach and the abdominal wall. This 
works very well.
Dr. Thompson: Dr. Turner, you have 
used the Puestow procedure in a num­
ber of patients with chronic pancrea­
titis. Were your results always good if 
ductal obstruction was present?
Dr. Turner: So far, yes, and this is in 
agreement with the reported results
of other surgeons. Several long-term 
studies have been recorded now. Jordan 
has 30 patients he has observed over 
15 years and White has patients who 
are doing well in the long term. Both 
of these investigators report good long­
term results, meaning freedom from 
pain, in 70% to 75% of patients.
Dr. Thompson: In performing a Pues­
tow or similar procedure, is a mucosa- 
to-mucosa apposition necessary?
Dr. Turner: I do not think so. Jordan 
doesn’t carry out such mucosa-to- 
mucosa apposition because he believes 
this may obstruct small radicles drain­
ing into the main duct. I don’t know 
how he avoids this because when you 
split the pancreas open it bleeds so 
much from the edges that, in my ex­
perience, the edges must be oversewn 
anyway. I have never carried out a 
formal mucosa-to-mucosa apposition in 
performing various pancreatic ductal 
drainage procedures.
Dr. Thompson: What suture material 
do you use when you are working on 
the pancreas?
Dr. Turner: I use silk routinely.
Dr. Thompson: Does anyone use ab­
sorbable sutures? No. How about the 
technique for closing the proximal 
stump after distal pancreatectomy?
Dr. Turner: I don’t think there is any­
thing special about this. I try to identify 
the duct and close it separately and 
then I simply use mattress sutures of 
silk for the end. Sometimes one can 
wedge the stump a little to get a better 
closure.
Dr. Mullens: You don’t need to do this 
if you use the Rodney Smith procedure 
I mentioned previously.
Dr. Keith: My only other comment is 
that if the stump is to be oversewn 
without draining it you must be sure 
that the sphincteric duodenal end is 
patent. This can easily be determined 
by sliding a small no. 5 esophageal 
feeding catheter along the pancreatic
duct; it should fall in the duodenum 
quite easily.
Dr. Thompson: Dr. Turner, you have 
mentioned a patient with chronic pan­
creatitis and a very normal-looking 
small duct; you stated there is no place 
for ductal drainage in this type of case. 
Then what would you do?
Dr. Turner: I am not altogether certain 
whether a patient with chronic pan­
creatitis but having a normal duct 
should actually have a pancreatectomy 
as the primary procedure. Perhaps it 
would be advisable to wait a few years 
and then operate on the duct after it 
has become dilated for then it will be 
more adaptable to a drainage proce­
dure.
Dr. Thompson: Dr. Mullens, should we 
all be doing ERCP? Are there any com­
plications from putting a little tube into 
the pancreatic and biliary duct systems? 
Dr. Mullens: It takes quite a time to 
develop the necessary skill and I think 
the performance of this procedure 
should be reserved for a few individuals 
so that they can get the practice neces­
sary to obtain dependable results con­
sistently. Our results are successful in 
approximately 90% of instances at the 
present time, but only after a great 
deal of practice on my part.
The complication I would like to 
mention first is the transmission of in­
fection when a patient with infectious 
hepatitis is being investigated. Obvious­
ly the instrument should be carefully 
sterilized before it is used in another 
patient. The practical rule is that if no 
cause for the patient’s jaundice is found 
at the time of ERCP, the scope should 
be sterilized in a gas autoclave. There 
is also the complication of sepsis, either 
cholangitis or pancreatic abscess, but 
as long as one is aware of the possibil­
ity, treatment with antibiotics can be 
instituted if these seem indicated. Third­
ly, pancreatitis can develop if one in­
jects the pancreatic duct at too high a 
pressure. Many patients do have a 
transient elevation of serum amylase. 
I have had two such cases but in both 
instances the disease process was short­
lived and of no great consequence.
Dr. Thompson: Do you find the so- 
called common channel in all patients 
whom you intubate?
Dr. Mullens: Oh no. In only about 
60%; in the other 40% the common 
bile duct and main pancreatic duct 
have to be cannulated separately. This 
means they have separate openings, but 
usually both are located in the same 
area.
Dr. Thompson: I would like to thank 
the members of the panel for their par­
ticipation and also the members of the 
audience who submitted many of the 
questions. It has been a most interest­
ing discussion.
Critique of Item 600 (SESAP II)
Pseudomonas aeruginosa grows very well under conditions of moisture 
and alkalinity. Urethral catheter drainage, when improperly managed, 
is an ideal situation for such infections since both conditions exist. The 
water trap used in mechanical ventilators to increase the water content 
of inspired gases provides the best environment for the growth of 
Pseudomonas. Although infection of the central venous catheters used 
either for recording of pressure or for hyperalimentation is an important 
complication, Candida albicans is the most frequent microorganism to 
appear in this situation; Pseudomonas aeruginosa is cultured infrequently.
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The skill and experience of the medical 
and nursing staff are the factors that 
have the greatest impact on the quality 
of monitoring and treatment of the 
critically ill surgical patient. Basic 
determinations at the bedside together 
with periodic evaluation of the whole 
patient by the medical staff may, in 
selected cases, be supplemented 
usefully by more invasive monitoring 
techniques. The specific complications 
and technical pitfalls of these techniques 
should be known, and caution should 
always be exercised that the values 
provided are not misinterpreted. A 
critical care area serving a major 
tertiary referral hospital should be able 
to measure pulmonary capillary wedge 
pressure and cardiac output. Mixed 
venous oxygen content and arterial 
lactate concentration, as indices of 
oxygen delivery, are also useful 
measures.
L'habilite et ('experience du personnel 
medical et infirmier sont les facteurs 
qui influencent le plus la qualite de la 
surveillance et du traitement du patient 
de chirurgie dont I'etat est critique.
Les principales determinations relevees 
au lit du malade associees a une 
evaluation periodique complete du 
patient par le personnel medical peut, 
dans des cas choisis, etre completees 
par des techniques de surveillance 
plus envahissantes. Les complications 
specifiques de ces techniques et leurs 
ecueils techniques doivent etre connus, 
et (’interpretation des valeurs obtenues 
doit toujours etre faite avec 
circonspection. Un poste de soins pour 
malades critiques attache a un grand
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hopital de consultation devrait pouvoir 
mesurer la pression capillaire 
pulmonaire et le debit cardiaque. La 
concentration veineuse mixte en oxygene 
et la concentration arterielle en lactate 
utilisees comme indices du transport 
d'oxygene sont aussi utiles.
Monitoring in its broadest sense refers 
to the surveillance, by whatever means, 
of either a static situation or an on­
going series of events, so as to detect 
change. When a patient is “monitored” 
this term is frequently interpreted as 
referring to various forms of electrical 
surveillance, but in this discussion the 
broader definition of the concept of 
monitoring will be used.
Many surgical patients require “in­
tensive” care, but are not critically ill. 
Individuals who have suffered major 
trauma or who have undergone a major 
surgical procedure require intensive 
monitoring, but this need not normally 
be carried out in a critical care unit. 
These patients can be cared for on a 
surgical ward where there is provision 
for continuous surveillance by experi­
enced nursing personnel. This need 
may usually be satisfied by a six- to 
eight-bed unit that is part of the surgi­
cal ward. As long as the individual 
sustains vital organ function, without 
need for major or continuous interven­
tion, while he remains a “major” sur­
gical case, he is not critically ill and 
does not require admission to a critical 
care unit.
Critical Care Units
Whether this is a medical, surgical, 
or combined unit, such an area should 
always be constructed in a manner that 
provides easy continuous observation 
by the nurses and physicians available.
The collection and recording of basic 
physiologic variables (such as tempera­
ture, pulse and blood pressure) by the 
nursing personnel, although important, 
serve the additional and perhaps more 
important function of bringing the 
nurse or physician to the patient’s bed­
side at regular and frequent intervals. 
A current and somewhat alarming trend 
is to provide a unit that is designed to 
remove the nurse from the bedside and 
to carry out multiple-patient, remote 
monitoring by television or digital dis­
play.1 Only the human mind has the 
capacity to recognize patterns in illness; 
there are many developments in the 
course of critical illness that are infre­
quent or unpredictable, and no trans­
ducer or electronic device has been yet 
devised that will warn of such events. 
The colour of the patient’s skin, an 
increase in his respiratory effort, a 
change in his pain pattern, impairment 
of cerebration, development of abdom­
inal distension, or discharge from a 
wound can only be observed, and their 
significance assessed, by an experienced 
nurse or physician.
Experienced nurses are a vital link 
in the monitoring of the critically ill 
patient. A critical care unit must have 
such a nursing staff, and must provide 
for their continuous instruction and 
updating of their knowledge and skills.
Nursing staff should be alert to, and 
recognize the significance of, trends 
in vital functions. They must recognize 
changes in respiratory parameters in 
ventilated patients and be able to iden­
tify important changes in cardiac 
rhythm. They must understand the sup­
portive or monitoring equipment and 
be capable of carrying out cardiopul­
monary resuscitation.
In order that the critical care unit 
may function well, there should be a 
full-time director who has responsibility 
for the performance and training of his 
nursing and medical staff, who also 
administers the unit and is responsible 
for the maintenance of instrumentation 
and other supportive equipment.
If the medical staff is composed par­
tially of residents, they should be of 
sufficient seniority (3rd or 4th year) to 
assure good management during the 
times when they are the only respon­
sible physicians present. Because res­
idents “rotate”, staggering of rotations 
is desirable, and the director of the
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unit must be sure that new staff are 
fully oriented to procedures and equip­
ment.
Although the construction of the unit 
and the skill and experience of the 
staff may seem rather basic considera­
tions, they are the factors in critical 
care that will have the greatest impact 
upon the quality of monitoring and 
treatment.
For the majority of patients, even in 
a critical care unit, sufficient monitor­
ing can be provided by an experienced 
nurse, who determines at frequent in­
tervals and records on an appropriate 
chart the blood pressure (taken with a 
cuff sphygmomanometer), pulse rate 
and urine volumes, together with a 
medical staff to carry out periodic 
evaluation of the patient, and supple­
mented by the necessary biochemical, 
hematologic and radiologic examina­
tions.
Failure of adequate oxygen delivery 
to the body cell mass must be detected 
and corrected as early as possible in 
order to prevent secondary deteriora­
tion of hepatic, renal and cerebral 
function; therefore, the adequacy of 
cardiac and respiratory function is the 
major priority in monitoring. Oxygen 
delivery may also be impaired at the 
microcirculatory or cellular level, but 
these problems are less common and 
their impact on oxygen delivery prob­
ably less significant than a serious 
deterioration of blood flow or arterial 
oxygen tension.
Monitoring Oxygen Transport
Pulse Rate and Electrical Activity
of the Heart
In a patient who has had a sufficient­
ly severe dislocation of his vital func­
tions to justify admission to a critical 
care unit, such a simple and useful 
device as a three-lead cardiac monitor 
should obviously be employed. In the 
management of myocardial infarction 
this form of inexpensive, noninvasive 
monitoring is extremely valuable, in 
that ventricular arrythmias are quickly 
detected and more serious problems 
thus averted. It should be recognized, 
however, that surgical patients, in 
whom myocardial disease is not the 
primary disorder, may have suffered 
cellular hypoxia for some time before 
cardiac arrythmias appear.
Radial Arterial Cannula
Insertion of a radial arterial cannula 
with continuous monitoring of blood 
pressure should be available in a critical 
care area but should seldom be re­
quired. This procedure is of low prior­
ity in initial management but is essen­
tial when drugs and anesthetic tech­
niques intended to lower peripheral
vascular resistance are used. It should 
be kept in mind that gangrene of the 
hand after such cannulation continues 
to be reported sporadically. Cannula­
tion of the radial or ulnar artery for 
the purpose of collecting arterial blood 
for blood-gas determinations is unnec­
essary, as multiple needle punctures 
are well tolerated.
Urine Volume
Insertion of a Foley catheter and 
recording of urine volume are a basic 
monitoring requirement not to be 
omitted in any critically ill patient. A 
falling hourly urine volume, showing a 
clear trend over a period of a few 
hours, warns of unfavourable changes 
in blood flow, usually on the basis of 
a contraction of blood volume, or a 
redistribution of flow in response to 
increasing metabolic demands (e.g., 
sepsis).
Central Venous Pressure
An adequate evaluation of the cen­
tral venous pressure (CVP) can some­
times be obtained by examination of 
the external jugular veins. In the crit­
ically ill patient it is seldom possible 
to base important therapeutic decisions 
on such an estimate of central venous 
pressures. For dependable CVP de­
terminations a catheter must be placed 
with its tip located in the superior 
vena cava. Respiratory fluctuation of 
the column must be evident, and the 
position of the catheter must be veri­
fied by roentgenography. The meas­
urement of CVP with a simple water 
manometer brings the technique within 
the scope of any small hospital. A CVP 
catheter also provides central venous 
access for the administration of drugs 
and fluids.
Central venous pressure does not 
measure blood volume but is an indi­
cator of the competence of the right 
ventricle in expelling the blood being 
returned to it. Venous tone and, parti­
cularly, intrathoracic pressures also af­
fect CVP levels. The CPV may be use­
ful in the diagnosis of a low-flow state, 
or, more importantly, a series of meas­
urements exhibiting a trend will act as 
a guide of blood volume expansion in 
the management of a low-flow state.
In most patients the CVP, as a meas­
ure of right heart filling pressures, may 
be titrated against hourly urine vol­
umes, and blood volume expansion be 
continued on the assumption that filling 
pressures in the right heart reflect those 
in the left heart.
Expansion of blood volume is the 
cornerstone of therapy in low-flow 
states, and can be most effectively and 
quickly accomplished by the infusion 
of a colloid; CVP will then be a re­
liable indicator of cardiac filling pres­
sures on both sides of the heart, and
ineffective and poorly sustained expan­
sion of blood volume with accumula­
tion of salt and water in the interstitium 
will be avoided.2
Therapeutic decisions based on a low 
CVP in an oliguric or hypotensive pa­
tient are usually correct, and the CVP 
is useful in diagnosis of hypovolemia 
and in guiding colloid infusion. In­
creased intrathoracic pressures, loss of 
right ventricular compliance, or outflow 
tract obstruction and increased pulmo­
nary vascular resistance can cause 
elevation of the initial CVP and may 
lead to erroneous conclusions and mis­
directed therapy.
Pulmonary Capillary Wedge
Pressures
Pulmonary hypertension, right ven­
tricular hypertrophy, or significant dis­
crepancies in function between the left 
and right ventricles are uncommon co­
existent problems in patients whose pri­
mary disease or injury is in another 
system. If they are present, however, 
it is not possible on the basis of CVP 
to make reliable estimates of, or to 
predict changes in, left atrial pressures.
These deficiencies have led to the 
development of flotation catheters and 
the measurement of pulmonary artery 
and pulmonary capillary wedge pres­
sures in selected patients. The indica­
tions for insertion of Swan-Ganz cath­
eters appear to be broadening as ex­
perience and confidence with the tech­
nique and instrumentation are gained. 
In our institution, at present, if the 
measured CVP is low and the clinical 
picture is compatible with hypovolemia, 
blood volume expansion can be carried 
out with the guidance of a CVP cath­
eter, and pulmonary capillary wedge 
pressures are not required.
In the event that the CVP is elevated 
or rises quickly with a volume chal­
lenge, without satisfactory evidence of 
improved cardiac output, subsequent 
therapy will have to be guided by 
knowledge of the left atrial pressures 
as indicated by pulmonary capillary 
wedge pressure.3 In these instances 
knowledge of the full clinical picture 
will usually suggest the factors that are 
making CVP an unreliable guide to 
volume expansion. In addition, some 
patients will be encountered where 
CVP is low, yet there are clinical or 
radiologic indications of cardiac failure. 
It is not possible to proceed with ex­
pansion of blood volume in these in­
dividuals without knowledge of left 
atrial pressures. It must be recalled, 
however, that monitoring of pulmonary 
capillary wedge pressure does not as­
sure that pulmonary edema will not 
develop or progress, because there are 
two other critical variables, plasma 
oncotic pressure and pulmonary capil­
lary permeability. There is no means
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of direct evaluation of pulmonary per­
meability.
Cardiac Output
The development of the triple-lumen 
balloon flotation catheter, incorporating 
a thermistor probe 4 cm from the cath­
eter tip, has greatly facilitated meas­
urement of cardiac output by the 
thermodilution technique. Electronic 
computation devices are required to 
allow the on-line determination of car­
diac output. Thermodilution now ap­
pears to be the method of choice for 
determining cardiac output. The in­
dicator (5% glucose) is inexpensive, no 
withdrawal of blood samples is re­
quired, and measurements can be ob­
tained at short intervals.
A unit that selectively employs pul­
monary capillary wedge pressure for 
diagnosis and monitoring should also 
be capable of determining cardiac out­
put. It is a major advantage in some 
cases to be able to construct a Starling 
curve for a patient on the basis of 
direct measurement of left atrial pres­
sures and cardiac output by thermo­
dilution.
The determination of cardiac output 
and derived values of ventricular func­
tion have found application in the diag­
nosis and management of patients with 
severe sepsis and septic shock, where 
physical examination may be mislead­
ing in so far as establishing a hemo­
dynamic diagnosis is concerned. In­
dividuals in respiratory failure and re­
quiring positive end-expiratory ventila­
tion may require cardiac output deter­
minations to assure that increases in 
positive end-expiratory pressure (PEEP) 
are not actually reducing oxygen de­
livery. Serial determinations of cardiac 
output may guide the use of vaso­
active or cardiotonic drugs when these 
are indicated.4
Mixed Venous Oxygen Content
A flow-directed catheter in the pul­
monary artery allows sampling of true 
mixed venous blood and the determina­
tion of mixed venous oxygen content. 
The gradient of arteriovenous oxygen 
content can be calculated. This value 
will normally approximate 4.1 vol%. 
Narrow differences will correlate rea­
sonably with high cardiac output, and 
wider differences with low-flow states. 
In a unit where flow-directed catheters 
are used but the instrumentation for 
cardiac output is not available, this 
value may indicate those individuals 
with high cardiac output and poor oxy­
gen extraction, a common development 
in sepsis, which may not be appreciated 
on the basis of bedside evaluation.
Arterial Lactate
Arterial lactate concentrations are 
still valuable as prognostic indicators,
and also serve as an additional detector 
of inadequate oxygen delivery or util­
ization. Microcirculatory or cellular 
disturbances associated with severe 
sepsis may be indicated by lactic acid­
osis, where cardiac output is normal or 
elevated and arterial oxygen tensions 
are in a satisfactory range. Bicarbonate 
concentrations are derived from direct 
measurements of pH and carbon di­
oxide pressure (Pco2), and may be de­
pressed by the accumulation of fixed 
acids other than lactate. Arterial lactate 
values therefore are a more direct 
measure of oxygen utilization at the 
cellular level than bicarbonate.
Severe lactic acidosis is not a con­
sistent finding in septic or hypovolemic 
shock, and bicarbonate should not be 
administered without the guidance of 
blood-gas determinations. Therapy 
should be directed towards correction 
of the primary disorder of oxygen de­
livery. One should be aware that transi­
ent increases in lactate concentra­
tion occur during resuscitation as a 
result of the “flush” phenomenon in 
hypoxic peripheral vascular beds.
Monitoring of Oxygenation
and Ventilation
In the unassisted patient, measure­
ment of Pco2 and arterial oxygen ten­
sion (Pao2), respiratory rate and vital 
capacity should assure that adequate 
arterial oxygenation and ventilation are 
possible, without undue elevation of 
respiratory rate and effort. Arterial 
oxygenation can be supported by in­
creasing the inspired oxygen concentra­
tion up to 60%. Respiratory rates 
greater than 35/min suggest that the 
effort of ventilation is excessive, and 
a vital capacity less than 15 mL/kg 
body weight suggests that the individ­
ual’s ventilatory reserves are limited. 
Where the full clinical picture indi­
cates that the disorder impairing 
oxygenation or ventilation will be pro­
gressive and not quickly reversible, 
endotracheal intubation and assisted 
ventilation will be required. No arbi­
trary figure can be the sole indication 
for ventilatory assistance; all the con­
tingencies of the case must be con­
sidered.
Once mechanical ventilation has been 
established, tidal volume, rate and min­
ute ventilation will be controlled, and 
can be adjusted and monitored with 
the volume-cycled respirator. Mon­
itoring of the inspired oxygen tension, 
Pao2 and Pco2 should continue at in­
tervals as frequent as other clinical 
factors indicate. In our experience, 
needle puncture of the radial artery 
may be repeated as often as necessary 
and insertion of a cannula is not in­
dicated solely for the purpose of 
sampling arterial blood.
Failure to maintain a Pao2 over 60 
mm Hg with an inspired oxygen 
concentration of 60% is usually an 
indication for PEEP. The response to 
PEEP is not always predictable, and 
estimations of arterial blood gases must 
be repeated as end-expiratory pressures 
are increased in small increments. With 
a PEEP, a fall in cardiac output should 
be anticipated.
A measure of compliance can be 
derived from peak inspiratory pressures 
and tidal volume. This value may assist 
in quantitating the course of the dis­
ease and predicting the response to 
increments of PEEP. During weaning 
from assisted ventilation, inspiratory 
force measurement may assist in pre­
dicting or monitoring progress.
Body Temperature
Monitoring of body temperature is 
of particular importance in the period 
immediately following major trauma 
or extended surgical intervention. The 
system utilized should be capable of 
detecting temperatures at the lowest 
range. Hypothermia is very common 
under these circumstances and may 
have a considerable effect on visceral 
function as well as on the interpretation 
of results (e.g., arterial blood gases).
Conclusions
Every critical care area servicing a 
major tertiary referral hospital should 
have the capacity to perform the in­
vasive monitoring techniques described 
above. Each of these techniques has 
specific complications and technical 
pitfalls. The worst complication of in­
vasive monitoring is misinterpretation 
of the results. Because such techniques 
provide figures, there is often an un­
fortunate tendency to attach undue im­
portance to a number, and to disregard 
or overlook important clinical observa­
tions.
Caution must be exercised at all 
times to be certain that the placement 
of invasive monitoring devices and the 
determination of baseline values do not 
delay urgent resuscitative measures. 
Frequently, simple bedside observations 
will indicate the appropriate therapy. 
It is wrong in these instances to delay 
such measures pending introduction of 
various monitoring devices and cath­
eters.
Once a monitoring catheter has been 
introduced and data are being obtained 
there is sometimes a reluctance to dis­
turb the collection of data by moving 
or examining the patient. Necessary 
examinations or treatment may thus 
be omitted in the interest of the mon­
itoring device.
An array of transducers and elec­
tronic devices may produce a mass of
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data, which is returned in a form that 
makes meaningful interpretation dif­
ficult. It is now possible to process 
the data and present the information 
as a “physiologic profile” on a pre­
printed format; the data are available 
within 1 hour and are presented in a 
way that facilitates interpretation and 
assists in therapeutic decision-making.5 
All techniques and devices used in criti­
cal care monitoring should be under 
continuous review to ensure that the 
risks and expense are justified by the 
collection of data that can be inter­
preted in time to be of value in making 
therapeutic decisions.
In the presence of good indications 
and an awareness of the hazards and 
pitfalls of interpretation, however, the 
advances in monitoring techniques will 
usefully supplement physical examina­
tion, laboratory and roentgenographic 
data and other components of the 
standard clinical record.
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2. Infection Control in the 
Surgical intensive Care Unit*
Jonathan L. M eakins, md, d sc, frcs[c]
Control of infection in the surgical 
intensive care unit demands unfailing 
attention to three distinct areas:
a) The bacteria responsible may be 
endogenous or exogenous. The effects 
of the former can be limited by careful 
surgical techniques and judicious use
of antibiotics, of the latter by the 
practice of asepsis and antisepsis, 
essentially of scrupulous cleanliness.
b) The environment of infection 
concerns the support of natural barriers 
to infection (notably the integrity of 
the skin and the adequate drainage of 
the pulmonary system), and the 
sterility and appropriate care and use 
of the many invasive devices currently 
available, c) The patient’s natural 
defence mechanisms show considerable
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variation, and those at increased risk 
can be detected by skin-testing with a 
number of antigens as well as by 
recognized clinical features. It is in 
these patients with anergy and abnormal 
natural defences that total parenteral 
nutrition can be of the greatest value.
Le controle des infections dans I'unite 
chirurgicale de soins intensifs exige une 
attention constante sur trois points 
precis: a) la bacterie responsable peut 
etre d'origine endogene ou exogene. 
Dans le premier cas, les effets peuvent 
etre circonscrits par des techniques 
chirurgicales soigneuses et une 
utilisation judicieuse des antibiotiques; 
dans le second cas, on recourra a la 
pratique de I'asepsie, de I'antisepsie 
et, essentieilement, d’une proprete 
absolue. b) L’envirormement, ou le 
milieu responsable de Tinfection, 
suppose le maintien des barrieres 
naturelles (particulierement, I'integrite 
de la peau et un drainage adequat du 
systeme pulmonaire) et la sterilite 
ainsi que la manipulation et I’usage 
appropries des divers dispositifs 
d'utilisation courante destines a penetrer 
I'organisme. c) Les mecanismes naturels 
de defense des patients montrent des 
variations considerables. Ceux qui
presentent un risque augmente peuvent 
etre identifies par cutireaction avec 
un certain nombres d'antigenes ainsi 
que par des caracteristiques cliniques. 
La nutrition parenterale totale s'avere 
tres benefique chez les patients 
anergiques.
Infection control in a surgical intensive 
care unit (SICU) is an ongoing and 
difficult job. In this population sepsis 
continues to be either the major cause 
of death or a major contributing factor 
to organ failure and subsequent mor­
tality. Control of infection is directed 
practically and philosophically against 
the three determinants that are inti­
mately involved with the development 
and evolution of each septic process. 
These are: bacteria, which cause the 
infection; the environment or local 
area, where the infection develops; and 
host defence mechanisms, which are 
systemic reactions to the developing in­
fectious process, that are to contain and 
ultimately resolve the infection.
The SICU patient is at particular 
risk in all of these areas. There is 
exposure to bacterial flora, which has 
usually demonstrated pathogenicity and 
increased resistance to antibiotics. These 
are patients in whom the environment
78 VOLUME 21, NO. 1, JANUARY 1978 /  THE CANADIAN JOURNAL OF SURGERY
of potential infection is altered by their 
disease or by their treatment; specif­
ically, invasive devices, inability to 
clear secretions, the presence of wounds 
and fistulas, and previous surgery all 
contribute to potential infection. Lastly, 
host defence mechanisms can be dem­
onstrated to be altered in the majority 
of these patients.1
Bacteria
The infecting organisms to which the 
SICU patient is exposed are endo­
genous or exogenous. Endogenous or­
ganisms are the patient’s normal flora, 
that is, commensal flora of the skin, 
mouth and nasopharynx and gastro­
intestinal tract. These organisms are 
usually susceptible to antibiotics and 
have modest pathogenicity, and their 
identity may to some extent be pre­
dicted by site. The normal flora does 
change in hospital so that autochthon­
ous organisms are replaced by hospital 
flora, making infections caused by en­
dogenous bacteria more difficult to 
treat. In time, endogenous flora becomes 
exogenous. Exogenous flora comprises 
those organisms that flourish in the area 
where the patient is being treated. In 
an intensive care unit these organisms 
tend to have considerable pathogenicity 
and resistance to antibiotics.
Control of endogenous and exogen­
ous bacteria is different. The removal 
of endogenous flora is clearly impos­
sible. There have been attempts, par­
ticularly in burn centres and centres 
administering the chemotherapy of ad­
vanced neoplasia with associated com­
plications of bone marrow aplasia, to 
use life islands and intensive antibiotic 
treatment to alter or obliterate the pa­
tient’s normal flora and isolate the 
patient from contact with the outside 
world. These attempts have been suc­
cessful on occasion but are, however, 
extraordinarily expensive and not justi­
fied in the SICU. The exposure of the 
patient to his or her own endogenous 
flora is usually greatest at the time of 
surgery, and control of infection relates 
particularly to surgical technique, to the 
judicious use of preoperative antibio­
tics, and to subsequent careful wound 
and dressing management with optimal 
technique. Critical selection of anti­
biotics in the SICU, that is, prescription 
only for demonstrable infection, as dis­
tinct from colonization, can prevent 
overgrowth of normal flora with re­
sistant bacteria and fungi.
Control of exogenous bacteria pre­
sents different issues. The development 
of resistant flora in any area, but par­
ticularly in an ICU, is frequently the 
product of antibiotic pressures, and 
therefore judicious use of antibiotics is 
critical. The second feature, perhaps 
the most important and certainly the
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simplest factor in the control of in­
fection in an ICU area, is a zeal for 
cleanliness and good technique on the 
part of personnel in their approach to 
the patient. The approach to control 
of exogenous bacteria is in many ways 
similar to control of the environment 
of infection and reflects attitudes and 
techniques that date back to Semmel- 
weiss, Lister and Halsted and were 
designed to keep bacteria from the 
locale of potential infection: lungs, 
wounds, venepuncture sites, etc. Asep­
sis and antisepsis are the keystone of 
control.
Environment of Infection
(Local Factors)
The environment relates to the area 
of the patient that is to become in­
fected, or that is indeed infected. Fea­
tures of control are maximization of 
the local factors to prevent lodgement 
of bacteria in a potentially infected 
focus. In the SICU the support of these 
natural barriers is largely attitudinal 
and technical. Specifically there are 
mechanical, chemical and bacteriologic 
barriers to colonization, lodgement and 
subsequent development of bacteria.2
Maintenance of the integrity of the 
skin is perhaps a simple example but 
nevertheless makes the point. The skin 
is an obvious mechanical barrier to 
the invasion of bacteria and in addition 
its fatty acids have major chemical 
bactericidal properties. With normal 
cutaneous integrity, bacteria that are 
potentially invasive are in these settings 
kept on the outside. The problems in 
infection control in thermal injuries 
bear this out. More pertinent is the 
development of a decubitus ulcer (a 
problem for which SICU patients are 
at risk), presenting an environment for 
the growth of bacteria that is most 
appealing and therefore representing a 
very real risk of systemic sepsis to the 
patient. Prevention is the key to con­
trol. The pulmonary system, another 
area in which infection is common in 
the surgical intensive care patient, re­
quires constant attention. In uncon­
scious patients control of bronchopul­
monary secretions is difficult and naso­
tracheal or oral-tracheal suction and 
promotion of drainage are critical. In 
those patients who are able to cough, 
the clearing of their own secretions is 
equally important and the patients 
must continually be urged to do so.
While these two examples may ap­
pear somewhat simple they make the 
point that constant vigilance and atten­
tion to the minutiae of care are critical 
in order that infection may be pre­
vented and thereby controlled. In both, 
it is the control of the environment of 
potential infection that reduces in­
fection.
Invasive devices, some of which are 
listed in Table I, present the other large 
area of environmental control. Intra­
venous catheters both central and peri­
pheral, bladder catheters, endotracheal 
tubes and arterial lines have all been 
a major source of local infection as 
well as systemic sepsis in this patient 
population. In addition, the equipment 
associated with these devices, such as 
transducers, respirators and nebulizers, 
is a documented source of potential in­
fection. Care must be taken to ensure 
that these items do not become con­
taminated and a source of sepsis. The 
control of infection from these devices 
is largely a function of attention to 
detail and the belief on the part of 
personnel responsible for their use that 
these devices upon which we have come 
to depend so greatly for their monitor­
ing and therapeutic benefits must also 
be controlled to cause a minimal 
amount of harm. It is my belief that 
we have too many invasive lines, which 
not only detract from our willingness 
to examine the patient but which also 
remain in place overlong and are prone 
to infection. The technology for the 
management of intravascular, intra­
vesical and endotracheal intubation is 
well known. The problem in reality is 
the difficulty of maintaining constant 
vigilance. It is never adequate to have 
solved the problem once. These devices 
remain an issue that is a constant 
thorn in the side of managing physi­
cians in intensive care and if they are 
not attended to in a meticulous manner, 
major infectious complications inev­
itably follow.
The most obvious example is the 
sepsis that is associated with hyper­
alimentation or total parenteral nutri­
tion and central lines. Depending on 
the studies reported it is clear that the 
infection rate can range from 5% to 
33%. The major difference in the in­
cidence of sepsis in these patient popu­
lations and the type of organisms that
Table 1— In v as ive  Devices
V ascu lar
Peripheral venous catheter 
Central venous catheter 
m onitoring  
nutrition  
Arterial line s  
Sw an-G anz catheter
Respiratory
Endotracheal tube 
nasal 
oral
Chest tube
U rinary
Bladder catheter 
urethral 
suprapubic  
Nephrostom y
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are responsible stems from the attitude 
of the personnel looking after these 
lines and the technical attention paid to 
their management. In control of both 
the bacteria and the patient’s envir­
onment or local areas of infection, atti­
tudes, techniques and attention to detail 
are more important than any other 
factors.3
Host Defence Mechanisms
(Systemic Factors)
Surgeons have long believed that in 
spite of good surgical technique and ex­
cellent pre- and postoperative care, some 
patients have major septic complica­
tions that can only be ascribed to some 
intrinsic host defect. The demonstration 
of such defects in general surgical pa­
tients has been very difficult. However, 
in the case of burn injury, consistently 
the most severe form of trauma, it has 
been shown that major abnormalities 
of neutrophil function, cell-mediated 
immunity, and complement and hu­
moral responses develop, and that these 
abnormalities are associated with septic 
episodes.4,5 Other forms of trauma have 
been shown periodically to be accom­
panied by defects in some aspects of 
host defence, but none that could be 
related to clinical course or outcome. 
In other branches of surgery, investiga­
tions have been less informative. 
Identification of the patient at risk for 
sepsis because of abnormal host defence 
mechanisms has been an elusive goal.
There are now data to show that the 
results of a procedure as simple as skin 
testing with five antigens — mumps, 
varidase, Candida, purified protein 
derivative and trichophyton — can 
identify those patients at increased risk 
for sepsis and mortality.1'6,7 In 320 
patients skin-tested prior to surgery, 42 
had abnormal responses with 21.4% 
demonstrating sepsis and a 33.3% post­
operative mortality rate compared with
4.6% and 4.3%, respectively, in those 
who reacted normally. In the context 
of the intensive care unit, 115 have 
been studied and results are shown in 
Table II. There was no difference be­
tween those who were anergic and 
those who were relatively anergic. As ex­
pected, in the SICU there was an in­
creased number of patients with altered 
skin tests. The sepsis rate in all groups 
was increased, consistent with the 
severity of the disease processes for 
which patients were admitted to the 
SICU, but it was significantly greater 
in those with altered responses. It is of 
interest that the mortality rates in ICU 
patients with altered or normal re­
sponses were identical to those in pa­
tients with similar responses studied 
preoperatively.
Skin-test responses are related to the 
process of delayed hypersensitivity and 
as such are thought to be a reflection 
of cell-mediated immunity, that branch 
of the immune response associated with 
reaction to tumours, organ transplants 
and infections from a variety of viruses, 
fungi and other intracellular parasites 
such as Salmonella, Listeria monocyto­
genes and Mycobacterium tuberculosis. 
None of these organisms are common 
pathogens in the SICU. In a study we 
conducted of this subject, all the infec­
tions were caused by common gram­
positive cocci or gram-negative rods.7 
This indicates that if there were de­
fects in host defence, they were not 
cell-mediated. Extensive in vitro studies 
of lymphocytes in mixed leukocyte 
culture from anergic patients, cell- 
mediated lympholysis, ability to gen­
erate blastogenic factor and response 
to various mitogens were all normal. 
There were some lymphocyte abnor­
malities; resetting of lymphocytes with 
sheep erythrocytes was abnormal and 
was associated with a serum factor 
that inhibited resetting of normal lym­
phocytes, indicating a change in cell 
surface characteristics. The resetting 
abnormality and normal lymphocyte 
function were not associated with the 
demonstrated increase in sepsis in the 
anergic patients.
Neutrophil function was also as­
sessed. We found that neutrophil pha­
gocytic and bactericidal function was 
often abnormal6 but did not correlate 
with sepsis in the SICU patient as has 
been shown for the burn injury.4 
Neutrophil chemotaxis was examined 
and found to be abnormal in patients 
with altered skin-test responses. This 
abnormality was no longer evident 
when cutaneous responses were re­
stored, an indication that host defences 
could improve. Similarly anergic serum 
contained a factor that inhibited chem­
otaxis in normal neutrophils as well as 
in anergic neutrophils. This factor 
disappeared if the anergic state re­
turned to normal cutaneous reactivity.
This improvement correlates clinic­
ally with skin testing as a measure of 
host defence (Table III). The mortality 
rate in those patients whose skin-test 
responses improved was much lower 
than in those whose responses and pre­
sumably host defence remained ab­
normal.
Skin testing identifies those patients 
who are at increased risk for sepsis 
and mortality, whether they are studied 
preoperatively or seen in the SICU. 
We have identified a number of clinical 
features commonly associated with 
anergy. These are age over 80 years, 
major trauma, sepsis, shock related to 
hemorrhage and malnutrition. Surgical 
principles, well founded in practice, 
address themselves to resolution of 
trauma, drainage of infected sites and 
restoration of blood volume. None of 
these measures can be considered as 
immunotherapy, nevertheless they ap­
pear to be so. Shizgal and his group, 
using body composition studies, have 
clearly demonstrated that in anergic 
patients there is an erosion of body 
cell mass and that restoration of the 
body cell mass is associated with return 
to normal of cutaneous responses.8
However, in many patients total 
parenteral nutrition given over periods 
of between 2 and 3 weeks does not 
correct the contraction of body cell 
mass or the abnormal ratio of total 
exchangeable sodium to total exchange­
able potassium. In these particular cases 
skin reactivity also remains abnormal 
and the prognosis is poor. Correction 
of protein-calorie malnutrition by total 
parenteral nutrition is likely to fail if 
this treatment is delayed until after a 
septic complication has developed. 
Anergy is often a reversible state, but 
the aggressive early use of total parent­
eral nutrition is essential in the treat­
ment of these patients.
Table I I— Outcome in 115 Patients in an Intensive Care U nit after Operation or Trauma, According
to Response to Skin Testing
Outcome, % *
Response to skin testing Sepsis Death
Anergy or relative anergy, n =  96 61.5 31.3
Norm al, n =  19 26.3 5.3
•D ifferences in outcome according to response to skin testing are significant a t P <  0.001.
Table I I I—Outcome in 178 Patients According to Results of Serial Skin Testing
Outcome, %
R esult of skin testing Sepsis Death
Norm al, n =  76 6.6 0
Im proved, n =  59 42.4 5.1
Fa ilu re  to improve, n =  43 65.0 74.4
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In practical terms the presence of 
anergy alerts the surgeon to the ac­
quired defects in host defence in a 
patient who requires alert anticipatory 
care, possibly drainage of an infection 
and certainly total parenteral nutrition. 
The restoration of cutaneous responses 
allows some relaxation of vigilance as 
the patient is then usually on his way 
to recovery.
Conclusion
Control of infection is a reasonable 
goal in the SICU and should be di­
rected at the three determinants of 
infection: bacteria, environment and 
host defence. The first two are ap­
proached through attitudes and tech­
niques of asepsis and antisepsis. Host 
defence may be bolstered by resolution 
of those factors that are responsible 
for its diminution, particularly by the 
early use of total parenteral or enteric 
nutrition.
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3. Upper Gastrointestinal Bleeding in 
the Intensive Care Unit*
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Bleeding from hemorrhagic erosions in 
the stomach or duodenum of seriously 
ill patients is associated with a high 
mortality. While the pathogenesis of 
such lesions is by no means certain, 
it is known that they are universal 
after shock, sepsis or severe burns. 
Fiberoptic endoscopy has become the 
most valuable means of diagnosis. This 
should be preceded by gastric irrigation, 
which usually suffices to control 
bleeding caused by acetylsalicylic acid 
or alcohol, or both. Neutralization of 
gastric acidity is essential. The 
histamine H2-receptor antagonist, 
cimetidine, was used in 27 patients 
with erosive gastritis, and bleeding 
ceased in 24. There is a prospect that
*From the departments of surgery and 
medicine, Dalhousie University, Victoria 
General Hospital, Halifax, NS
I’resented at the inaugural meeting of the 
Canadian Association of General Surgeons, 
Toronto, Ont., May 11 and 12, 1977
Reprint requests to: Dr. Allan S. 
MacDonald, Clinical Research Centre, 
5849 University Ave., Halifax, NS 
B3H 1W2
such agents will obviate the necessity  
of total gastrectomy in the occasional 
resistant cases in favour of conservative 
surgery.
Chez les patients gravement malades, 
le saignement provoque par I'erosion 
hemorragique de I’estomac et du 
duodenum est associe a un taux de 
mortality eleve. Bien que la pathogenie 
de ces lesions demeure inconnue, on 
les retrouve de faqon constante apres 
un choc, une septicemie ou des brulures 
graves. La fibroscopie est devenue 
une methode diagnostique des plus 
precieuses. Elle devrait etre precedee 
d'une irrigation gastrique qui suffit 
habituellement a controler le 
saignement cause par I'acide 
acetylsalicylique ou I'alcool. La 
neutralisation de I'acidite gastrique est 
essentielle. La cimetidine, un antagoniste 
des recepteurs histaminiques H2, a 
ete utilisee chez 27 patients souffrant 
de gastrite erosive et le saignement 
a cesse chez 24. On peut entrevoir 
que de tels agents therapeutiques 
puissent obvier a la necessity d'une
gastrectomie totale dans les cas 
resistants occasionnels, laissant la 
place a une chirurgie conservatrice.
It is unfortunate but true that in those 
seriously ill patients who can withstand 
them least, hemorrhagic erosions are 
most likely to develop in the stomach 
or duodenum. It is therefore not sur­
prising that the mortality rate from this 
condition is distressingly high, from 
20% to 60% in reported series.1’6 At 
the Victoria General Hospital, Halifax, 
in only 15% of cases of hemorrhagic 
gastritis induced by alcohol or acetyl­
salicylic acid in otherwise fit individuals 
does the bleeding fail to stop spon­
taneously and in those few requiring 
operation the mortality rate is less than 
3%. But in patients who require ad­
mission into an intensive care unit 
(ICU), bleeding erosions are often the 
final straw that determines a fatal 
outcome.
Pathogenesis
There has not been a single report 
of bleeding erosions of the stomach or
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duodenum in an achlorhydric patient. 
Therefore it appears that acid is essen­
tial for the production of such ulcers. 
In experimental animals acid is re­
quired, indeed the erosions are difficult 
to produce if the gastric luminal pH 
is much above 3. On the other hand, 
it is also true that there is no increase 
in acid production in response to 
serious illness; in fact, it often falls.7,8 
Although disputed,9 many believe that 
an increase in back diffusion of acid 
across the gastric mucosa produces the 
observed mucosal damage. This implies 
a breakdown in mucosal resistance to 
acid and an alteration in mucosal per­
meability. Agents such as acetylsalicylic 
acid,10 bile acids7 and alcohol11 have 
been shown to have this effect. The 
mechanism by which this occurs in 
seriously ill patients is not understood. 
Hypovolemic shock is accompanied by 
gastrointestinal ischemia and it is not 
difficult to visualize how this might 
cause focal ischemic necrosis of the 
mucosa.12 However, in our experience 
most patients in whom these erosions 
develop in the intensive care unit have 
not experienced hypotensive shock. In 
fact, in some groups (e.g., patients in 
renal failure) hypervolemia is often 
present. The majority of patients who 
bleed have sepsis, frequently caused by 
gram-negative organisms, but often they 
are not in shock. Clinical observations 
of alterations in gastric blood flow are 
not very convincing. Yet it has been 
demonstrated that the appearance of 
mucosal ulcerations is almost universal 
after shock, sepsis, or severe burns13,14 
and the incidence is probably much 
higher than suspected in other stressful 
conditions. While the ulcerations may 
occur universally, bleeding does not. 
This is probably due to the tremendous 
regenerative capacity of the gastro­
intestinal mucosa. Mucosal ulcerations 
often disappear within 24 hours or less 
despite massive involvement of gastric 
fundus and duodenum initially. It is our 
belief that what distinguishes the bleed­
ers from the nonbleeders or transient 
bleeders is continuation of the stressful 
situation that led to the erosions.
It is tempting to think that all the 
common situations that lead to stress 
ulcers have a common pathogenesis. 
Yet there are factors that are obviously 
more important in one disease than in 
another. The common clinical condi­
tions we have found to precede erosive 
gastritis in our ICU are shock, sepsis, 
organ failure (kidney, liver and lung), 
drug ingestion (acetylsalicylic acid, al­
cohol and corticosteroids) and elevated 
intracranial pressure. In the majority 
of patients more than one factor has 
been implicated. The mechanism by 
which sepsis, in the absence of overt 
shock, causes erosions in stomach and 
duodenum is still a matter of specula­
tion. In some patients alterations in 
liver function are apparent, whereas in 
others the lung is affected and hypoxia 
is present. Usually there is a high car­
diac output. In some patients prolonged 
clotting times or depressed platelet 
counts are present. In uremic individ­
uals there is often interference with nor­
mal coagulation as well, as an effect 
of uremia on the mucosal barrier. The 
incidence of bleeding is exceptionally 
high in patients in whom uremia devel­
ops as a complication of some other 
surgical problem and in our hands the 
mortality in those who bleed has been 
50%.15 In liver failure bleeding is also 
frequent, probably because of the asso­
ciated coagulation defects and the ac­
companying hyperacidity; an incidence 
higher than 50% has been reported and 
the mortality is forbidding.' The role 
of acetylsalicylic acid or alcohol, or 
both, in precipitating erosions is well 
recognized. In our experience, in almost 
all these patients the bleeding will stop 
with very little treatment, unless it has 
precipitated other problems such as 
liver failure, heart failure etc. The ef­
fect of steroids is much less clear cut 
and the previously accepted connection 
has been challenged.16 The doses of 
corticosteroids now used in the treat­
ment of shock, adult respiratory distress 
syndrome and renal transplant rejection 
are much higher than those used for 
chronic conditions. However, the very 
conditions for which the steroids are 
given are those in which bleeding gas­
tric erosions are common. The role of 
steroids is therefore unproven.
Raised intracranial pressure is asso­
ciated with increased vagal tone and 
hyperacidity. Frequently in such pa­
tients deep penetrating ulcers develop 
rather than superficial erosions, al­
though the latter do occur.
There are a variety of other condi­
tions seen frequently in the intensive 
care unit that are associated with bleed­
ing erosions. Pancreatic disorders, par­
ticularly postoperative resections, are 
not rare causes of massive bleeding 
from acute erosive gastritis. Here the 
concomitants of liver pathology, hypo­
volemia and sepsis are presumed to be 
responsible. Not infrequently patients 
are seen with rebleeding from erosive 
gastritis after operations for control of 
bleeding duodenal or gastric ulcer, or 
even for erosions themselves.
Diagnosis
The hallmark of erosive gastritis is 
bleeding, and the mainstay of diagnosis 
is fiberoptic endoscopy. Barium con­
trast roentgenographic examination is 
not helpful because, although it may 
show varices or an ulcer, neither one 
may cause the bleeding. The superficial 
erosions are not deep enough to be
seen by roentgenography and the bari­
um may interfere with subsequent 
endoscopy or angiography. Endoscopy 
should be done first and the roent­
genographic examination reserved for 
those patients who stabilize or those 
who are being considered for surgery.
Pripr to endoscopy, gastric irrigation 
is required, first to confirm that the 
origin of the bleeding is indeed prox­
imal to the ligament of Treitz, second 
to indicate the rate of blood loss, and 
third, therapeutically to reduce or stop 
the bleeding by the use of iced glucose 
or saline solution. This procedure may 
be sufficient to stop the bleeding, or at 
least to slow it to the point where en­
doscopy is feasible. Even if the bleeding 
is torrential, endoscopy should be per­
formed at least to rule out esophageal 
varices as the source.
At endoscopy, early in the course of 
illness, one finds numerous punctate 
areas of hemorrhage, typically most in­
tense along the lesser curvature and 
over the posterior wall of the fundus. 
The antrum is often spared. The duo­
denum may show only erythema al­
though often it too has multiple small 
bleeding areas. Occasionally only the 
duodenum is involved. As the duration 
of the illness lengthens, the erosions 
tend to enlarge and coalesce, often 
forming a long serpiginous shallow ul­
cer several centimetres long, which 
can be mistaken for a Mallory-Weiss 
tear. If the process is allowed to con­
tinue, the ulcers begin to deepen, but 
reactive granulations are still absent. 
This sequence is most likely in those 
patients who have irreversible organ 
failure with an inevitably fatal out­
come. In patients in whom the primary 
stress that has produced disease is re­
lieved, for example, by surgical drain­
age of an intra-abdominal abscess, 
the erosions can disappear incredibly 
rapidly.
Treatment
Acute hemorrhagic erosive gastritis 
as a single disease entity, usually pre­
cipitated by acetylsalicylic acid or al­
cohol, or both, almost always resolves 
with simple lavage of the stomach with 
ice water followed by oral antacids. 
The same condition occurring in an 
otherwise severely ill patient is an­
other matter. Results have improved 
with the demonstration by Skillman 
and Silen17,18 and others19'20 of the bene­
ficial effect of neutralizing gastric acid­
ity by the use of antacids. A whole 
variety of other techniques have been 
tried with occasional success, including 
intragastric instillation of viper venom 
or epinephrine, or both,21 endoscopic 
electrocoagulation,22 laser-induced co­
agulation,23 selective embolization of 
the gastric arteries,24 and percutaneous
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transarterial celiac artery catheteriza­
tion and infusion of vasopressin.25 In 
our hands the mainstays of therapy 
have been ice water lavage, neutraliza­
tion of gastric acidity and infusion of 
vasopressin by way of the celiac artery. 
Where we have differed from others is 
in our use of histamine H2-receptor an­
tagonists instead of, or in addition to, 
intragastric instillation of antacids.26 
These new agents are potent inhibitors 
of gastric acid secretion,27,28 and have 
the advantage of inhibiting histamine 
release from mast cells29 and its dam­
aging effect on gastric mucosa. In our 
first series of patients we used meti- 
amide to treat 17 episodes of bleeding 
from erosive gastritis in severely ill 
patients. Because of occasional agranu­
locytosis metiamide was withdrawn, but 
cimetidine, an equally effective agent, 
is now available. We have used it in 
27 patients with erosive gastritis (Table 
I); bleeding ceased in 24. These were 
uncontrolled trials and we do not 
know if the results represent any im­
provement over what could have been 
achieved by standard therapy alone. 
However, in the majority of instances 
we were asked to see the patients after 
conventional treatment had failed, 
when blood loss had been substantial 
and when continued bleeding was an 
immediate fatal threat in patients who 
were believed to have relative or ab­
solute contraindications to surgery. Of 
the four in whom bleeding recurred, 
all were operated on and three died in 
the immediate postoperative period.
Similar good results have been re­
ported with antacids only.20 The only 
advantage of the H2 blockers, in our 
opinion, is the ease and completeness 
with which they prevent hydrogen-ion 
release and thus elevate the pH to 
neutrality. That this will not be suf­
ficient for all patients is illustrated by 
the report from Dudley, Fielding and 
Glazer30 of four consecutive failures 
with cimetidine used to manage upper 
gastrointestinal bleeding; one of the 
cases was certainly, and one probably, 
due to stress erosions.
In all four failures in our practice
endoscopic examination had confirmed 
the presence of diffuse punctate ero­
sions in the gastric fundus. As the con­
dition progressed some of these co­
alesced into larger erosions. When 
cimetidine was started the small ero­
sions promptly disappeared, leaving one 
to three erosions that continued to 
bleed. To one of these patients cime­
tidine was given prophylactically fol­
lowing a Whipple pancreatectomy, yet 
the erosions caused bleeding that ul­
timately required total gastrectomy. It 
is not clear whether the erosions de­
veloped prior to the patient’s Whipple 
operation, or while he was on cime­
tidine. In this patient, as in many 
others, we have been struck by the 
marked bile reflux that is apparent at 
endoscopy.
We have been most impressed by 
the results of controlled trials of his­
tamine H2-receptor antagonists for the 
prevention of upper gastrointestinal 
bleeding in patients in hepatic coma, as 
reported by MacDougall, Bailey and 
Williams.31,32 Only 1 of 26 patients re­
ceiving H2 blockers bled, while 54% 
of their controls did so. The drug ap­
pears to be almost completely free of 
side effects during short-term usage and 
it is our prediction that its routine 
prophylactic use in intensive care pa­
tients who are at risk will greatly 
reduce the problem of erosive gastritis.
There will, however, always be some 
patients who fail to stop bleeding de­
spite all conservative measures and who 
will require operation. The selection of 
the procedure to be adopted is a vexing 
question. One is equally reluctant to 
remove the stomach in a patient who 
does not have a long-standing ulcer 
diathesis, or to do a lesser procedure 
and leave bleeding mucosa behind. A 
recent review of the literature by 
Moody and Cheung33 shows that only 
total gastrectomy, as advocated by 
Menguy, Gadacz and Zajtchuk34 is not 
associated with substantial rebleeding. 
The rebleeding rate for subtotal 
gastrectomy is 51%. Using vagotomy 
and drainage with suture ligation Men­
guy and colleagues had only a 9.5%
rebleeding rate, although 24% of their 
patients died.
Based on our experiences with meti­
amide and cimetidine, we would ad­
vocate conservative surgery. In those 
who continue to bleed despite the ad­
ministration of H2 blockers, discrete 
ulcers are present which can be han­
dled by suture ligation or excision, 
followed by vagotomy and drainage 
and continuous cimetidine therapy un­
til the stressful situation has passed. 
Only time will tell if this is the correct 
recommendation.
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and renal function must receive 
attention. Open lung biopsy is of the 
greatest value when the diagnosis 
is open to question. Resort to a 
membrane oxygenator to provide 
extracorporeal oxygenation of blood 
can sustain for a time the patient in 
whom hypoxia is critical in degree.
Les patients necessitant une respiration 
assistee peuvent avoir des poumons 
normaux mais une ventilation inadequate, 
ou ils peuvent souffrir d’une anomalie 
de I'echange gazeux pulmonaire en 
depit d'une ventilation adequate. Dans 
le premier groupe, on doit recourir 
a une forme quelconque d'assistance 
ventilatoire mecanique, a cycle de 
pression ou a cycle de volume, par 
intubation endotracheale au debut et, 
par la suite seulement, a I'aide d'une 
tracheotomie. II faut des soins speciaux 
pour debrancher le patient de I'appareil.
Dans les cas d'insuffisance 
pulmonaire, I'utilisation d'une pression 
positive en fin d'expiration a constitue 
une amelioration majeure. On doit
porter attention a I'hemoglobinemie, au 
debit cardiaque et a la fonction renale. 
Quand le diagnostic est incertain, la 
biopsie a poumon ouvert est de premiere 
importance. L'emploi d’un oxygenateur 
a membrane pour assurer une 
oxygenation extracorporelle du sang 
peut maintenir, pour un certain temps, 
le patient dont le degre d'hypoxie est 
devenu critique.
While acute respiratory failure may be 
variously defined, it can be considered 
the inability to maintain spontaneously 
normal arterial oxygen and carbon di­
oxide concentrations by an individual 
breathing room air and who has not 
previously had lung impairment.
Patients requiring respiratory support 
fall roughly into two categories: those 
with fairly normal lungs but with ina­
dequate ventilation, and those in whom 
pulmonary gas exchange is defective 
even with adequate ventilation. The 
management of these two problems is 
quite different. Patients suffering from 
sedative overdose or from neurologic
i <
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disease by and large require primarily 
mechanical ventilatory support and do 
not have gas-exchange difficulties. 
These patients fall into the first cate­
gory. Patients with cardiac and renal 
failure, and those with primary pul­
monary abnormalities that bring about 
defective pulmonary gas exchange be­
long to the second category. Patients 
with chest injuries and some postopera­
tive patients may have features in 
common with both groups.
Respiratory units were first devel­
oped for the management of patients 
primarily requiring mechanical ventila­
tory support. The Copenhagen experi­
ence with poliomyelitis, in 1952, pro­
vided the opportunity for first wide­
spread use of positive-pressure ventila­
tion, and demonstrated its advantages 
over negative-pressure ventilation with 
an iron lung or a cuirass. Poliomyelitis 
patients and patients with other neuro­
muscular disorders such as myotonia, 
myasthenia, muscle wasting diseases 
and injuries to the central nervous sys­
tem provided the stimulus for the devel­
opment of specialized respiratory units.
Tracheostomy
Over the years important lessons 
have been learned regarding the logis­
tics and mechanics of delivering safe 
positive-pressure ventilation. In the 
early days of such care, emergency 
tracheostomies were common and so 
were their related problems. These in­
cluded local hemorrhage, displacement 
or obstruction of the tube, incorrect 
placement of the tracheostomy stoma 
and difficulties with the management 
of secretions. Today there is almost 
no place for emergency tracheostomy 
other than for acute upper airway ob­
struction. Respiratory support is begun 
with an endotracheal tube and trache­
ostomy is subsequently done on an elec­
tive basis, usually 4 to 7 days later.
Elective tracheostomy has not solved 
all problems relating to the use of 
cuffed tracheostomy tubes. We recently 
had experience with three tracheo- 
innominate fistulas, which were suc­
cessfully managed by partial sternotomy 
and resection of the innominate artery. 
Control of the hemorrhage was by 
hyperinflation of the balloon cuff and 
forward leverage on the tracheostomy 
tube, or, failing this, by endotracheal 
intubation, removal of the tracheostomy 
tube and digital compression through 
the tracheostomy site, by pressing the 
innominate artery forward against the 
back of the sternum. In two of these 
cases the tracheostomy had obviously 
been placed much too low, causing the 
elbow of the tube to rest against the 
back of the innominate artery. In one 
case the tracheostomy was situated as 
low as the 7th tracheal ring. While it
may be comforting to know that this 
complication can be successfully man­
aged, it is far better to avoid the com­
plication by placing the tracheostomy at 
the 2nd or 3rd tracheal ring. Even so, a 
high-riding innominate artery can still 
occasionally be eroded by the elbow of 
the tube.
We now know that old fashioned, 
high pressure endotracheal and trache­
ostomy cuffs can cause considerable 
tracheal damage in a short period of 
time, due to pressure necrosis at the 
cuff site. This causes necrosis and 
eventual dissolution of cartilaginous 
rings. Healing may be by scar forma­
tion with resultant tracheal stenosis. 
Pressure necrosis by the cuff can also 
lead to erosion through the posterior 
wall of the trachea into the esophagus, 
or through the anterior wall into the 
innominate artery. With the advent of 
tracheostomy tubes and endotracheal 
tubes fitted with high volume, com­
pliant, low pressure cuffs, the problems 
of the cuff stenosis and cuff fistula have 
been virtually eliminated in those hos­
pitals where such cuffs are routinely 
used.
Ventilators
Ventilators are available in various 
sizes, shapes and complexities. Their 
source of power may be electricity or 
compressed gas. A cycling mechanism 
determines the magnitude of the breath, 
a system is provided for determining 
the rate of inspiration and the inspired 
gas is properly humidified. Based upon 
the cycling system, ventilators can be 
roughly divided into two groups — the 
pressure-cycled ventilators such as the 
Bird, and the volume-cycled ventilators 
such as the Bennett, Ohio, or Emerson.
The Bird ventilator delivers gas at a 
preset flow rate until a predetermined 
peak airway pressure is reached, at 
which point the ventilator shuts off. 
Since the airway pressure depends on 
many factors including the patient’s 
cooperation, chest wall and pulmonary 
compliance, the pressure-cycled venti­
lators do not deliver a given vol­
ume. The tidal volume must be meas­
ured periodically to ensure that the 
patient is receiving the desired ventila­
tion. Also, the concentration of in­
spired oxygen is not accurately con­
trolled by the Bird ventilator. A mix­
ture of compressed air and oxygen may 
be required to give the desired concen­
tration of inspired oxygen, and the 
oxygen concentration must be frequent­
ly checked with an oxygen analyzer.
Volume-cycled ventilators deliver a 
preset volume and an accurate concen­
tration of inspired oxygen. With the 
use of such ventilators these parameters 
do not have to be monitored as fre­
quently.
Whatever the type of ventilator, it 
must be monitored, including the vol­
ume and peak of the gas mixture de­
livered, the inspired oxygen concentra­
tion, and the effects on the patient’s 
cardiovascular system and on arterial 
blood gases. One of the most important 
ventilator safeguards is an alarm system 
that sounds in case of a disconnection 
or mechanical failure. This may seem 
obvious today, but many of us who 
have been associated with respiratory 
care for a period of time can re­
member patients who have been lost in 
the past because ventilator disconnec­
tions were not discovered in time, in 
the absence of an alarm system.
Weaning
Just as there are problems associated 
with the use of a ventilator, there are 
others posed by weaning a patient from 
the ventilator. In this regard, the use 
of intermittent mandatory ventilation 
(IMV) has been an important recent 
advance. Traditionally the patient was 
weaned from the ventilator by intermit­
tently removing him completely from a 
ventilator for progressively longer 
periods. With an IMV circuit the 
patient can breathe spontaneously 
at any rate he wishes and in addition 
he receives a fixed number of mech­
anical breaths from the ventilator. The 
gas inspired in the spontaneous breaths 
has the same oxygen concentration as 
the gas provided by the ventilator 
breaths. Over a period of hours or 
days the number of assisted breaths is 
gradually reduced, for example from 
15/min, to 14/rnin, to 13/min, and so 
on, so that the patient is always receiv­
ing some assistance and increasingly 
does more of the work himself. This 
type of weaning is much smoother and 
easier for the patient and is useful in 
some of the more difficult problems. 
Early use of such a circuit, even before 
the patient is ready to be weaned, may 
be of value in preserving the strength 
and coordination of the patient’s res­
piratory muscles.
An understanding and familiarity 
with the mechanics of ventilatory tech­
niques help the surgeon to use ration­
ally a form of ventilatory support for 
his patients. Certainly some patients 
undergoing major surgery appear to do 
much better when routinely ventilated 
overnight. Thereby some of the com­
plications of marginal ventilation in the 
early postoperative period are avoided. 
As well, the patient may be provided 
with needed rest for the first night fol­
lowing operation. The surgeon familiar 
with ventilator support will consider 
its postoperative use, when indicated, 
as an important part of his therapy and 
not as an undesirable, and all too ob­
vious, result of the operation.
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Another example of ventilatory sup­
port as an adjunct to surgery is the 
case of the patient with an acute gen­
eralized empyema such as might result 
from a ruptured esophagus. Following 
thoracotomy to close the perforation 
and to drain the chest, the routine use 
of ventilatory support and positive end- 
expiratory pressure for several days will 
maintain a high lung volume, quickly 
obliterate the pleural space and avoid 
subsequent development of loculated 
pleural infection.
Ventilatory Support for Pulmonary
Insufficiency
The second group of patients re­
quiring respiratory support, those with 
basic pulmonary dysfunction, are far 
more difficult to manage. In patients 
with pneumonia, chronic lung disease, 
aspiration pneumonia, pulmonary ede­
ma or one of a host of inflammatory 
conditions of the lung, mechanical 
ventilatory support may not be enough 
and one must try to improve the im­
paired pulmonary gas exchange. It is 
now known that the pattern of ventila­
tion in such patients may be as im­
portant as the amount of ventilation 
in improving gas exchange. These pa­
tients almost always require a volume 
ventilator. A ventilator that operates 
on a sine wave, such as the Engstrom, 
may give better gas exchange than one 
operating on square wave cycle. An 
inspiratory hold or plateau in the cycle 
may also improve gas exchange.
The use of positive end-expiratory 
pressure (PEEP) has been a major ad­
vance. Its use can be traced back at 
least to 1943 when Barach used such a 
system for spontaneous ventilation. 
With the use of end-expiratory pressure 
the lungs are maintained at a higher 
volume than otherwise, and in certain 
conditions this markedly improves oxy­
genation. Usually a pressure of 5 to 15 
cm HzO achieves maximum effect. In 
some patients, however, even higher 
levels, or “super PEEP” may produce 
further improvement. In one case, a 
patient receiving 100% oxygen had a 
partial pressure of oxygen (Po2) of 50 
mm Hg when the PEEP was 15 cm 
H 20 . The Po2 rose immediately to 150 
mm Hg when the PEEP was increased 
to 25 cm H 2O. When the PEEP was 
raised to 30 cm H 2O no further rise 
in P0 2  was achieved and the cardiac 
output began to fall, so the PEEP was 
reduced to 25 cm H20 , which was well 
tolerated.
When faced with severe hypoxia and 
acute respiratory failure, one mani­
pulates the entire patient to improve 
the oxygen delivery to tissues. Careful 
monitoring is important during this 
period of active intervention. Pulmon­
ary gas exchange is rendered optimal
86
with the use of PEEP and an ap- 
propiate ventilatory pattern. The use of 
bronchodilators and sedation or bring­
ing about paralysis of the patient, when 
required, may improve ventilation.
Oxygen delivery to the tissues is a 
product of the cardiac output and the 
oxygen content of the blood. Hence 
maintaining an adequate hemoglobin 
concentration and a satisfactory cardiac 
output is important. Digitalis, albumin, 
inotropic agents and calcium may be 
required to maintain adequate cardiac 
output in the case of hypoxia. Oxygen 
consumption can be reduced by cooling 
the patient to as low as 32°C and by 
sedating or paralysing the patient to 
reduce or eliminate muscle activity.
Increased pulmonary extravascular 
water is inevitably present in almost all 
patients with acute respiratory failure, 
regardless of its cause. Maximum de­
hydration by diuretics and correction 
of left ventricular failure, when present, 
are of the greatest importance. The use 
of peritoneal or hemodialysis should be 
considered if renal function is impaired, 
since reduction of excess body water 
is essential.
Emergency Open Lung Biopsy
In cases of acute respiratory failure 
if the cause is at all in doubt, a specific 
tissue diagnosis is required. Under these 
circumstances emergency open lung 
biopsy is most helpful. When we re­
cently reviewed 28 cases in which 
emergency open lung biopsy had been 
performed we found that a correct 
diagnosis had been made possible in 
27 (96%) cases. The clinical diagnosis 
prior to biopsy was confirmed in 12 
cases but was in error or incomplete 
in 15 cases.
The procedure is usually done in the 
operating room but can be done at 
the bedside. Since a specific diagnosis 
in such cases is so important we con­
sider there to be very few contraindica­
tions to emergency open lung biopsy. 
It can be done when the patient is on 
a ventilator and even when very high 
volumes of PEEP are being used. 
Thrombocytopenia is not a contraindi­
cation, as a platelet transfusion at the 
time of biopsy has, in our experience, 
prevented problems of bleeding.
One dramatic example of the 
importance of open lung biopsy was 
the case of a young woman presenting 
with rapidly developing pulmonary in­
filtrates and fulminant respiratory fail­
ure, several days after a normal de­
livery. The clinical diagnosis was amni- 
otic fluid embolism. Emergency open 
lung biopsy revealed fulminant tuber­
culous pneumonitis. Treatment with 
antituberculous drugs in combination 
with steroids led to prompt resolution 
and complete recovery.
Controversies in Respiratory Care
Many controversies remain regarding 
the management of acute respiratory 
failure. For example, how long should 
an endotracheal tube be left before 
changing over to tracheostomy? The 
correct answer is probably 5 to 7 days, 
but there are great differences of 
opinion. There is a question as to the 
significance of pulmonary oxygen toxi­
city in humans. If it does exist as a 
primary entity, what is the safe con­
centration for inspired oxygen? I per­
sonally doubt whether oxygen toxicity 
is an important clinical problem if 
blood gases are monitored, and if one 
does not allow arterial oxygen concen­
trations to become excessive. Basically, 
hypoxia is bad, oxygen is good — but 
one should not use more oxygen than 
necessary. If there is an alternative to 
the use of high oxygen concentrations, 
such as the use of PEEP to improve 
oxygenation, this should be the first 
resort. However, one should not hesi­
tate to use even 100% oxygen for 
days if required to prevent critical hy­
poxia. A number of patients so treated 
at high ventilatory pressures continu­
ously for 4 and 5 days have made a 
complete recovery.
The debate as to whether colloid or 
crystalloid should be used for volume 
replacement is a continuing one, as 
is the use of massive doses of steroids 
for specific and nonspecific inflamma­
tory conditions of the lung.
Use of Membrane Oxygenator
If all else fails, one can buy addi­
tional time with the use of a membrane 
oxygenator, a device for extracorporeal 
oxygenation of the blood. This device 
exchanges gas across a thin silicone 
rubber membrane separating the blood 
and gas phases. This avoids direct 
blood-gas contact and prevents most 
of the harmful effects on red cells, 
proteins and platelets, which occur after 
several hours on a bubble oxygenator. 
The membrane oxygenator can be used 
for days or even weeks. The longest 
documented successful perfusion was 
for 10 days and ended with the pa­
tient’s complete recovery.
The membrane oxygenator can be 
used for acute respiratory failure when 
a patient with critical hypoxia has a 
disease process presumed reversible; by 
this means the physician can sustain 
the patient for a few extra days while 
waiting for recovery to occur. The per­
fusion catheters are inserted up the 
femoral vein and artery into the inferior 
vena cava and aortic arch, respectively. 
A ventilator is still required for part of 
the gas exchange requirements. We have 
used a membrane oxygenator on six
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patients. One of the patients was re­
moved successfully from it after 3 days 
of perfusion, but died several weeks 
later of bone marrow insufficiency due 
to underlying leukemia. Our one long­
term success was a 19-year-old girl with 
a 3-week history of progressive dyspnea 
and cyanosis, and multiple small pul­
monary emboli confirmed by lung scan­
ning and pulmonary angiography. In­
creasing pulmonary edema and respira­
tory failure developed and the patient 
went into shock with a high pulmonary 
artery pressure, a low cardiac output
and anuria. Pulmonary embolectomy 
was not believed to be indicated be­
cause no central major clots were 
identifiable on the pulmonary angio­
gram and the patient’s history suggested 
that the small peripheral emboli were 
up to 3 weeks old. As a last desperate 
effort she was connected to a mem­
brane oxygenator with a bypass flow 
of 3.5 L/min. This promptly reversed 
the shock, the anuria, the hypoxia and 
the pulmonary edema. After 35 hours 
of perfusion, however, the patient was 
still totally dependent on the oxygen­
ator and continued to have elevated 
pulmonary artery pressures and a low 
cardiac output. Selective pulmonary 
angiography through a Swan-Ganz 
catheter revealed a clot obstructing the 
major branch to the right lower lobe. 
Peripheral embolectomy of this and 
several other smaller vessels was per­
formed through a median sternotomy. 
There was no immediate improvement 
and she required another 35 hours of 
membrane oxygenator support before 
she could manage without it. She had 
an uneventful recovery thereafter.
5. Panel Discussion on Intensive Care*
Chairman: John H. Du ff , md, FRCs[c]f 
Panelists: D.B. Allardyce, J.D. Cooper, A.S. MacDonald and J.L. Meakins
Dr. Duff: A number of questions have 
been supplied by the audience and I 
will assign these to the member of the 
panel for whom they seem appropriate. 
How do you administer the H2 blockers 
metiamide and cimetidine? Dr. Mac­
Donald.
Dr. MacDonald: We routinely use 
intravenous cimetidine. Metiamide is no 
longer available, and at first we used 
to give 300 mg q6h. Now we tend to 
give it by continuous infusion at the 
rate of 300 mg over 6 hours. The ob­
jective is to eliminate production of 
acid and one can determine one’s suc­
cess by measuring intragastric pH. With 
cimetidine one can almost invariably 
bring the pH to 7.
Dr. Duff: Do you employ the exchange­
able sodium to exchangeable potassium 
ratio to indicate anergy or do you 
routinely do the skin tests to confirm 
your diagnosis of anergy and its cor­
rection by parenteral nutrition? Dr. 
Meakins.
*'Conducted at the inaugural meeting 
of the Canadian Association of General 
Surgeons, Toronto, Ont., May 11 and 12, 
1977
1 Chief of general surgery, University 
Hospital, University of Western Ontario, 
London, Ont.
Reprint requests to: Dr. J.H. Duff, 
Department of surgery, University 
Hospital, 339 Windermere Rd., London, 
Ont. N6A 5A5
Dr. Meakins: We just use serial skin 
testing. Body composition studies do 
not rapidly supply the data necessary 
and so we use them in clinical practice 
only occasionally. As a general rule 
skin testing for anergy is done serially 
once a week on all patients in the 
intensive care unit.
Dr. Duff: Is this your present method 
of determining whether or not your 
parenteral nutrition is effective?
Dr. Meakins: Yes. And we have no 
better method of finding out how the 
patient is doing immunologically. 
Chemotaxis is accurate but skin testing 
is easier.
Dr. Duff: A question on which all the 
members of the panel might express an 
opinion. When do you decide on hyper­
alimentation for patients in the inten­
sive care unit?
Dr. Allardyce: We believe that in the 
acute situation, for example during the 
period of resuscitation from shock, 
whether of the septic or hemorrhagic 
type, or when major surgery has just 
been carried out, total parenteral nutri­
tion (TPN) probably complicates the 
issue and is not of much value. But as 
soon as the patient is stable from a 
cardiovascular standpoint, we institute 
intravenous feeding. We decide on the 
central or peripheral route on the basis 
of the expected duration of TPN. If it 
is to continue for 3 weeks or longer, 
we use the central route. If we think it
will be for only 2 to 3 weeks we choose 
the peripheral route.
Dr. Duff: When do you start TPN and 
what solution do you give?
Dr. Cooper: When I go 12 hours with­
out eating, I get rather hungry and by 
the time I have gone 24 hours without 
food I am feeling rather weak. It is 
definitely my opinion that it is unfair 
to put a patient on a ventilator in the 
intensive care unit and make him fight 
his way without giving him any nutri­
tional support. To do so is to add 
starvation to his illness. I think nutri­
tion is often neglected because we are 
so busy taking care of everything else. 
Often 5 or 6 days have passed when 
we suddenly remember even to do 
something so simple as putting in a 
nasogastric tube for feeding. By all 
means if you anticipate a long course 
for the disease you should start feeding 
the patient right away. My personal 
feeling is that feeding should be given 
during the first few days via a stomach 
tube if possible, otherwise by the par­
enteral route. It should be part of the 
early treatment plan to identify the 
patient who is likely to require either 
TPN or enteric nutritional supplemen­
tation. In 1977, this part of surgical 
treatment is to be considered, if not 
in the emergency room, certainly pretty 
soon afterwards.
Dr. Duff: Dr. MacDonald, have you 
anything to add?
Dr. MacDonald: Yes, two points. We
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discourage the use of peripheral veins 
for TPN. If the patient is going to be 
ill and in an intensive care situation for 
a long time, you want to have every 
peripheral vein available for as long as 
possible. The more you spare, the 
better. We use central veins early. The 
second point is that patients in an in­
tensive care unit often have caloric 
requirements that are much higher than 
can be supplied by peripheral TPN 
systems.
Dr. Duff: Dr. MacDonald, one mem­
ber of the audience believes your results 
with cimetidine are not good because 
the patients who received it were 
treated with the agent for quite a long 
time despite continued bleeding. In 
other words, surgery was delayed, and 
the questions are, Was surgery delayed 
too long in the patients to whom you 
gave cimetidine? and, Would an earlier 
operation have resulted in a better 
salvage rate?
Dr. MacDonald: Those are fair ques­
tions. The figures reported here are for 
patients from whom surgery was with­
held because of prohibitive operative 
risk. These patients received cimetidine. 
The study showed that those with ero­
sive gastritis did well, those with duo­
denal or gastric ulcer did not do well. 
But they did not die because surgery 
was delayed; they died because they 
were in severe pulmonary failure, renal 
failure, or liver failure.
Dr. Duff: What is your opinion of phy­
siologic gastrectomy for acute erosive 
gastritis rather than a total gastrectomy 
in an old, medically unfit patient?
Dr. MacDonald: Physiologic gastrec­
tomy is performed when you give cime­
tidine. This drug completely abolishes 
gastric acid production and decreases 
acid output from pentagastrin stimula­
tion by 85%. But in our experience, 
patients will still bleed despite complete 
inhibition of gastric acid production. 
From our gastroscopy findings, I sus­
pect that many of these individuals have 
a bile gastritis. We have tried cimetidine 
in patients who have postgastrectomy 
bile gastritis and they obtained no bene­
fit. Bile can produce erosions in pa­
tients who have a compromised 
mucosa.
Dr. Duff: Some surgeons like to have 
their patients extubated quickly, others 
believe extubation should be delayed. 
How do you tell when to extubate a 
patient who, say, had been ventilated 
overnight?
Dr. Meakins: Adequate oxygenation 
must be proven prior to extubation — 
a Po2 in the range of 80 to 100 mm Hg, 
a normal Pco2 and normal pH. The 
breathing should be easy without strain­
ing or tachypnea. In the case of a pa­
tient who has been on a respirator for 
several days, if he is extubated too 
quickly he is likely to tire, go into
respiratory failure and require reintuba­
tion. It is much more difficult to get 
a patient off the respirator the second 
time.
Dr. Duff: Is there a Po2 value that you 
will tolerate or below which you will 
not extubate?
Dr. Meakins: In a patient without 
chronic chest disease who has been on 
a respirator, I am very reluctant to ex­
tubate that patient if the Po2 is much 
under 75 mm Hg.
Dr. Duff: Dr. Cooper, have you any­
thing to add on that point?
Dr. Cooper: An endotracheal tube does 
prevent coughing, and the normal 
negative-pressure inflation of the lungs 
is better than positive-pressure infla­
tion. Therefore there is reason to ex­
tubate the patient as soon as possible. 
However, having said that, I would 
emphasize that there are very few ha­
zards present in well-managed units and 
the benefits of that extra time of rest 
and adequate mechanical ventilation 
may be very important.
Dr. Duff: If a patient has had emer­
gency thoracentesis in the emergency 
room and then requires positive end- 
expiratory pressure (PEEP) or mech­
anical ventilation, there is the risk of 
a sudden pneumothorax. Should such 
a patient have a chest tube inserted 
prophylactically?
Dr. Allardyce: We have had bad ex­
periences with the sudden development 
of a tension pneumothorax in the situa­
tion you have described. I think you 
have to balance the risk of a sudden 
pneumothorax and your ability to de­
tect it in time against the need for 
PEEP.
Dr. Cooper: Yes, the likelihood of 
spontaneous pneumothorax is probably 
high, so keep the chest tube near the 
bedside if you have tapped the patient 
with multiple injuries in the emergency 
ward. I very often insert a chest tube 
as a prophylactic measure in a patient 
going to the operating room for an 
abdominal procedure who has had mul­
tiple injuries and pleural effusions or 
rib fractures, even though he has no 
pneumothorax.
Dr. Meakins: I really do not like the 
concept of a prophylactic chest tube. 
All volume-cycle respirators have a 
gauge that indicates the pressure re­
quired to achieve adequate inspiration. 
As a pneumothorax develops, that pres­
sure is going to increase. Careful mon­
itoring can identify this problem so that 
the needless insertion of chest tubes is 
avoided.
Dr. Duff: Dr. Meakins, does splenec­
tomy affect the cutaneous anergic re­
sponse?
Dr. Meakins: Not as far as we know. 
Patients who have had splenectomy for 
isolated splenic injury have not become 
anergic.
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